<SEC-DOCUMENT>0001193125-24-127601.txt : 20240501
<SEC-HEADER>0001193125-24-127601.hdr.sgml : 20240501
<ACCEPTANCE-DATETIME>20240501170040
ACCESSION NUMBER:		0001193125-24-127601
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20240501
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240501
DATE AS OF CHANGE:		20240501

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Walgreens Boots Alliance, Inc.
		CENTRAL INDEX KEY:			0001618921
		STANDARD INDUSTRIAL CLASSIFICATION:	RETAIL-DRUG STORES AND PROPRIETARY STORES [5912]
		ORGANIZATION NAME:           	07 Trade & Services
		IRS NUMBER:				471758322
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36759
		FILM NUMBER:		24903913

	BUSINESS ADDRESS:	
		STREET 1:		108 WILMOT ROAD
		CITY:			DEERFIELD
		STATE:			IL
		ZIP:			60015
		BUSINESS PHONE:		(847) 315-2500

	MAIL ADDRESS:	
		STREET 1:		108 WILMOT ROAD
		CITY:			DEERFIELD
		STATE:			IL
		ZIP:			60015
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d821017d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:wba="http://walgreensbootsalliance.com/20240501" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2024-05-01_to_2024-05-01" id="ixv-283">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2024-05-01_to_2024-05-01">0001618921</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="wba-20240501.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2024-05-01_to_2024-05-01"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001618921</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-05-01</xbrli:startDate> <xbrli:endDate>2024-05-01</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2024-05-01_to_2024-05-01_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001618921</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-05-01</xbrli:startDate> <xbrli:endDate>2024-05-01</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2024-05-01_to_2024-05-01_us-gaap-StatementClassOfStockAxis_wba-M3.600WalgreensBootsAllianceInc.NotesDue2025Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001618921</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">wba:M3.600WalgreensBootsAllianceInc.NotesDue2025Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-05-01</xbrli:startDate> <xbrli:endDate>2024-05-01</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2024-05-01_to_2024-05-01_us-gaap-StatementClassOfStockAxis_wba-M2.125WalgreensBootsAllianceInc.NotesDue2026Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001618921</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">wba:M2.125WalgreensBootsAllianceInc.NotesDue2026Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-05-01</xbrli:startDate> <xbrli:endDate>2024-05-01</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2024-05-01_to_2024-05-01" id="ixv-318">8-K</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2024-05-01_to_2024-05-01" format="ixt:datemonthdayyearen" id="ixv-319">May 1, 2024</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2024-05-01_to_2024-05-01" id="ixv-320">WALGREENS BOOTS ALLIANCE, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2024-05-01_to_2024-05-01" format="ixt-sec:stateprovnameen" id="ixv-321">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2024-05-01_to_2024-05-01" id="ixv-322">001-36759</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2024-05-01_to_2024-05-01" id="ixv-323">47-1758322</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission File</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification Number)</p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2024-05-01_to_2024-05-01" id="ixv-324">108 Wilmot Road</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2024-05-01_to_2024-05-01" id="ixv-325">Deerfield</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2024-05-01_to_2024-05-01" format="ixt-sec:stateprovnameen" id="ixv-326">Illinois</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2024-05-01_to_2024-05-01" id="ixv-327">60015</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2024-05-01_to_2024-05-01" id="ixv-328">(847)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2024-05-01_to_2024-05-01" id="ixv-329">315-2500</ix:nonNumeric></span></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2024-05-01_to_2024-05-01" format="ixt-sec:boolballotbox" id="ixv-330">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2024-05-01_to_2024-05-01" format="ixt-sec:boolballotbox" id="ixv-331">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2024-05-01_to_2024-05-01" format="ixt-sec:boolballotbox" id="ixv-332">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2024-05-01_to_2024-05-01" format="ixt-sec:boolballotbox" id="ixv-333">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:43%"/>
<td style="vertical-align:bottom"/>
<td style="width:12%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:43%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2024-05-01_to_2024-05-01_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" id="ixv-334">Common Stock, $0.01 par value</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2024-05-01_to_2024-05-01_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" id="ixv-335">WBA</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2024-05-01_to_2024-05-01_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" format="ixt-sec:exchnameen" id="ixv-336">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2024-05-01_to_2024-05-01_us-gaap-StatementClassOfStockAxis_wba-M3.600WalgreensBootsAllianceInc.NotesDue2025Member" id="ixv-337">3.600% Walgreens Boots Alliance, Inc. notes due 2025</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2024-05-01_to_2024-05-01_us-gaap-StatementClassOfStockAxis_wba-M3.600WalgreensBootsAllianceInc.NotesDue2025Member" id="ixv-338">WBA25</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2024-05-01_to_2024-05-01_us-gaap-StatementClassOfStockAxis_wba-M3.600WalgreensBootsAllianceInc.NotesDue2025Member" format="ixt-sec:exchnameen" id="ixv-339">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2024-05-01_to_2024-05-01_us-gaap-StatementClassOfStockAxis_wba-M2.125WalgreensBootsAllianceInc.NotesDue2026Member" id="ixv-340">2.125% Walgreens Boots Alliance, Inc. notes due 2026</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2024-05-01_to_2024-05-01_us-gaap-StatementClassOfStockAxis_wba-M2.125WalgreensBootsAllianceInc.NotesDue2026Member" id="ixv-341">WBA26</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2024-05-01_to_2024-05-01_us-gaap-StatementClassOfStockAxis_wba-M2.125WalgreensBootsAllianceInc.NotesDue2026Member" format="ixt-sec:exchnameen" id="ixv-342">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2024-05-01_to_2024-05-01" format="ixt-sec:boolballotbox" id="ixv-343">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:22%;vertical-align:top" align="left"><span style="font-weight:bold"><span style="text-decoration:underline">Item&#8201;7.01</span>.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left"><span style="text-decoration:underline">Regulation FD Disclosure</span>. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously disclosed, on November&#160;14, 2023, the putative shareholder derivative suit <span style="font-style:italic">Vladimir Gusinsky Revocable Trust v. Pessina et al.</span>, No. <span style="white-space:nowrap"><span style="white-space:nowrap">23-cv-15654</span></span> (N.D. Ill.) was stayed to permit the parties to explore the possibility of settlement. On April&#160;10, 2024, the putative shareholder filed a motion for preliminary approval of a settlement resolving the litigation. On April&#160;17, 2024, the court entered an order preliminarily approving the settlement. Pursuant to that preliminary approval order, Walgreens Boots Alliance, Inc. is attaching hereto as Exhibits 99.1 and 99.2, respectively, and incorporating by reference herein, (i)&#160;the Stipulation and Agreement of Settlement, dated April&#160;10, 2024, and (ii)&#160;Notice of Pendency and Proposed Settlement of Shareholder Derivative Action and of Settlement Hearing, in the form preliminarily approved by the court on April&#160;17, 2024. </p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this Item 7.01 of this Current Report on Form <span style="white-space:nowrap">8-K</span> and Exhibits 99.1 and 99.2 shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section. This information shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference to such disclosure in this Form <span style="white-space:nowrap">8-K</span> in such filing. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:22%;vertical-align:top" align="left"><span style="font-weight:bold"><span style="text-decoration:underline">Item&#8201;9.01</span>.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left"><span style="text-decoration:underline">Financial Statements and Exhibits</span>. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following exhibits are included herewith: </p> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:5%"/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d821017dex991.htm">Stipulation and Agreement of Settlement, dated April&#160;10, 2024 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"/>
<td style="height:1.5pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.2</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d821017dex992.htm">Notice of Pendency and Proposed Settlement of Shareholder Derivative Action and of Settlement Hearing, preliminarily approved April&#160;17, 2024 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:1.5pt"/>
<td style="height:1.5pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">104</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="text-decoration:underline">SIGNATURE </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:44%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:5%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:44%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3">WALGREENS BOOTS ALLIANCE, INC.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: May&#160;1, 2024</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Joseph B. Amsbary, Jr.</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Joseph B. Amsbary, Jr.</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Vice President and</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Corporate Secretary</p></td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d821017dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 1
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES DISTRICT COURT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>NORTHERN DISTRICT OF ILLINOIS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>EASTERN DIVISION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="19" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="19" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">VLADIMIR GUSINSKY REVOCABLE TRUST, Derivatively on Behalf of WALGREENS BOOTS ALLIANCE, INC.,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Case No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">23-cv-15654</FONT></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; font-size:12pt; font-family:Times New Roman">Plaintiff,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; font-size:12pt; font-family:Times New Roman">v.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt"><FONT STYLE="font-size:12pt">STEFANO PESSINA, JOSE E. ALMEIDA, JANICE M. BABIAK, DAVID J. BRAILER, WILLIAM C. FOOTE, GINGER L. GRAHAM, JOHN A. LEDERER, DOMINIC MURPHY, LEONARD
D. SCHAEFFER, NANCY M. SCHLICHTING, and JAMES A. SKINNER,</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; font-size:12pt; font-family:Times New Roman">Defendants,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; font-size:12pt; font-family:Times New Roman">and</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt"><FONT STYLE="font-size:12pt">WALGREENS BOOTS ALLIANCE, INC., a Delaware Corporation,</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:14pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; font-size:12pt; font-family:Times New Roman">Nominal
Defendant.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #cdd4e9">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #cdd4e9">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 2
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>STIPULATION AND AGREEMENT OF SETTLEMENT</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">This Stipulation and Agreement of Settlement, dated April&nbsp;10, 2024 (the &#147;Stipulation&#148;), is made and entered
into by and among the following parties (the &#147;Parties&#148;) through their respective counsel: (i)&nbsp;the Vladimir Gusinsky Revocable Trust (&#147;Plaintiff&#148;); (ii) Stefano Pessina, Jos&eacute; E. Almeida, Janice M. Babiak, David J.
Brailer, William C. Foote, Ginger L. Graham, John A. Lederer, Dominic Murphy, Leonard D. Schaeffer, Nancy M. Schlichting, and James A. Skinner (the &#147;Individual Defendants&#148;); and (iii)&nbsp;nominal defendant Walgreens Boots Alliance, Inc.
(&#147;Walgreens&#148; or the &#147;Company,&#148; and together with the Individual Defendants, &#147;Defendants&#148;). This Stipulation is intended by the Parties to fully, finally, and forever resolve, discharge, and settle the Released Claims as
to the Released Persons upon Court approval and subject to the terms and conditions herein.<SUP STYLE="font-size:75%; vertical-align:top">1</SUP><B> </B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>I.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>BACKGROUND AND PROCEDURAL HISTORY </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The above-captioned action (&#147;Action&#148;) is a shareholder derivative action brought for the benefit of Walgreens. The
Action alleges that certain current and former officers and directors of Walgreens breached their fiduciary duties to the Company by failing to adequately oversee opioids-related matters, including compliance with the Controlled Substances Act
(&#147;CSA&#148;). Specifically, the Action alleges that the Board failed to adequately oversee the Company&#146;s compliance with a 2013 settlement agreement with the Drug Enforcement Administration and with the CSA, which harmed the Company by
exposing it to liability, including in expansive multi-district litigation and other opioids-related litigation and proceedings. On September&nbsp;23, 2022, Plaintiff filed a shareholder derivative action on behalf of Walgreens in the United States
District Court for the Northern District of Ohio (the &#147;N.D. Ohio Action&#148;), asserting claims for breach of fiduciary duty, unjust enrichment, and violations of Section&nbsp;14(a) of the Securities Exchange Act of 1934. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:24%">&nbsp;</P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><SUP
STYLE="font-size:75%; vertical-align:top">1</SUP> Capitalized terms are defined on first use or in Section IV. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 3
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">One year later, on September&nbsp;22, 2023, the court in that case ruled that the Northern District of Ohio was an improper
venue for the litigation, and thus dismissed the N.D. Ohio Action without prejudice for refiling in a proper venue. Plaintiff selected the Northern District of Illinois as the venue for the refiling of its claims. Accordingly, it filed the Complaint
in the above-captioned action on November&nbsp;4, 2023, raising the same allegations and claims as it had previously asserted in the N.D. Ohio Action. <I>See</I> Dkt. 1. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>II.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>SETTLEMENT NEGOTIATIONS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">On September&nbsp;21, 2023, Plaintiff served a settlement demand on the Individual Defendants. The demand called for a
material monetary payment to be made to the Company by its and/or the Individual Defendants&#146; directors and officers insurance carriers (the &#147;D&amp;O Insurers&#148;), as well as detailed corporate governance reforms to be implemented at the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">To facilitate their settlement discussions, the Parties retained the Hon. Layn R. Phillips (Ret.) of Phillips
ADR Enterprises, an experienced and respected mediator. Under the guidance of Judge Phillips and Michelle Yoshida, Esq., also of Phillips ADR Enterprises, the Parties exchanged counteroffers in January 2024, and convened for a <FONT
STYLE="white-space:nowrap">two-day,</FONT> <FONT STYLE="white-space:nowrap">in-person</FONT> mediation on February&nbsp;10 and 11, 2024, in New York City. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Although no settlement was reached by the end of the <FONT STYLE="white-space:nowrap">in-person</FONT> mediation on
February&nbsp;10 and 11, settlement negotiations continued under Judge Phillips&#146;s supervision. Ultimately, the Parties agreed to the Settlement and executed a term sheet on February&nbsp;23, 2024. The agreed-upon terms include the
implementation by Walgreens of robust corporate governance changes and a monetary payment of $36,000,000.00 to the Company by the D&amp;O Insurers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 4
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Thereafter, the Parties negotiated the formal operative terms of the Settlement as set forth in this Stipulation, and commenced
negotiations regarding an appropriate amount of attorneys&#146; fees and expenses to be paid to Plaintiff&#146;s Counsel in recognition of the benefits conferred by this Settlement on the Company, again with the assistance of Judge Phillips.
Ultimately, in recognition of Plaintiff&#146;s Counsel&#146;s role in initiating, prosecuting, and settling the Action and the substantial benefits those efforts have conferred upon Walgreens and its shareholders, Walgreens agreed to a fee and
expense amount of $8,000,000.00, subject to Court approval. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>III.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>CLAIMS OF PLAINTIFF AND THE BENEFITS OF SETTLEMENT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Plaintiff and Plaintiff&#146;s Counsel believed at all times and continue to believe that the claims asserted in the Action
have merit. Plaintiff and Plaintiff&#146;s Counsel also recognize the substantial time, expense, and uncertainty inherent in the continued prosecution of the claims through trial and any subsequent appeal, including problems of proof, overcoming the
available defenses, the difficulties of proving and measuring damages, and the challenges of collecting on any damages awarded at trial. Based on their thorough investigation and evaluation, Plaintiff and Plaintiff&#146;s Counsel have determined
that the Settlement set forth in this Stipulation is appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Plaintiff&#146;s Counsel&#146;s conclusion is based on
their extensive and thorough investigation and evaluation of information, which included, <I>inter alia</I>: (i)&nbsp;reviewing Walgreens<B> </B>press releases, public statements, SEC filings, and securities analysts&#146; reports and advisories
about the Company; (ii)&nbsp;reviewing media reports about the Company; (iii)&nbsp;researching the applicable law with respect to the claims alleged in the Action and potential defenses thereto; (iv)&nbsp;preparation and filing of the Action as well
as litigation of the N.D. Ohio Action; (v)&nbsp;reviewing and analyzing relevant pleadings, exhibits, and other documents from the national opioids multi-district litigation captioned <I>In re National Prescription Opiate Litigation</I>, No. <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1:17-md-2804</FONT></FONT> (N.D. Ohio); (vi) reviewing the Company&#146;s existing corporate governance policies and preparing a settlement
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 5
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">demand detailing proposed corporate governance reforms to strengthen the Company&#146;s governance; (vii)&nbsp;participating in mediation
sessions and extensive settlement discussions with Defendants&#146; Counsel; and (viii)&nbsp;negotiating the term sheet executed by the Parties on February&nbsp;23, 2024 (the &#147;Term Sheet&#148;) and this Stipulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Plaintiff&#146;s Counsel&#146;s assessment of the facts and legal issues material to their recommendation in favor of the
Settlement was honed and refined over the course of months of substantive written and verbal exchanges with counsel for Defendants and Judge Phillips in the context of mediation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Based on Plaintiff&#146;s Counsel&#146;s thorough review and analysis of the relevant facts, allegations, defenses, and
controlling legal principles, Plaintiff and Plaintiff&#146;s Counsel have concluded that the Settlement set forth in this Stipulation is fair, reasonable, and adequate, and that the Settlement confers substantial benefits upon and is in the best
interests of Walgreens and its shareholders, including through the substantial financial component to be paid to the Company and the adoption and/or implementation of the corporate governance changes reflected in Exhibit A hereto (the
&#147;Reforms&#148;). Accordingly, Plaintiff has agreed to settle the Action upon the terms and subject to the conditions set forth herein. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>IV.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>THE INDIVIDUAL DEFENDANTS&#146; DENIALS OF WRONGDOING AND LIABILITY </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Individual Defendants have denied and continue to deny each and all of the claims alleged by Plaintiff in this Action. In
particular, the Individual Defendants have expressly denied and continue to deny each and all charges of wrongdoing or liability against them relating to opioids, arising out of any of the conduct, statements, acts, inaction, or omissions alleged in
the Action, or arising out of any claim related to opioids that could have been alleged in the Action. Without limiting the foregoing, the Individual Defendants have denied, and continue to deny, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 6
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">among other things, that they breached their fiduciary duties or any other duty owed to Walgreens or its shareholders, or that they or the
Company committed or engaged in any violation of law or improper action. The Individual Defendants have further asserted, and continue to assert, that at all relevant times, they acted in good faith and in a manner they reasonably believed to be in
the best interests of Walgreens and its shareholders. In addition, the Individual Defendants maintain that they have meritorious defenses to all claims alleged in the Action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Nonetheless, Defendants have concluded that further litigation could cause burden, inconvenience, expense, uncertainty, and
distraction, and that it is desirable and beneficial to finally put to rest and terminate all of the claims that have been, or could have been, asserted in the Action. Defendants have therefore determined that the Settlement confers a substantial
benefit upon Walgreens and its shareholders, and the Settlement, and each of its terms, is in all respects fair, reasonable, and in the best interests of Walgreens and its shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Nothing in this Stipulation, the Judgment, any document or exhibit referred or attached to this Stipulation, or any action
taken to carry out this Stipulation is, may be construed as, or may be used as evidence of the validity of any of the Released Claims or an admission or concession by or against any Defendant with respect to any claim of fault, wrongdoing,
liability, or damage whatsoever or any infirmity in the defenses that could have been asserted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Walgreens&#146;s current
Board of Directors acknowledges, in an exercise of its independent business judgment, that the initiation, prosecution, and settlement of the Action was the cause of consideration for this Settlement, and that the Settlement is fair, reasonable, and
adequate, and confers substantial benefits to Walgreens and its shareholders. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>V.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>TERMS OF STIPULATION AND AGREEMENT OF SETTLEMENT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">NOW, THEREFORE, IT IS HEREBY STIPULATED AND AGREED by and among the Parties, through their respective counsel, that in
consideration of the benefits flowing to the Parties </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 7
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">from the Settlement, and subject to the approval of the Court, the Released Claims shall be fully, finally, and forever compromised, settled,
discharged, relinquished, and released, and the Action shall be dismissed with prejudice and with full preclusive effect, upon and subject to the terms and conditions of this Stipulation, as set forth below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>1. &#8195;Definitions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">As used in this Stipulation, the following terms have the meanings specified below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.1&#8195; &#147;Action&#148; means the derivative action captioned <I>Vladimir Gusinsky Revocable Trust v. Pessina et
al.</I>, originally filed as Case No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1:22-cv-01717</FONT></FONT> on September&nbsp;23, 2022, in the Northern District of Ohio, and subsequently filed as Case No. <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1:23-cv-15654</FONT></FONT> on November&nbsp;4, 2023, in the Northern District of Illinois. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.2&#8195; &#147;Court&#148; means U.S. District Court for the Northern District of Illinois. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.3&#8195; &#147;Defendants&#148; means the Individual Defendants and Walgreens. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.4&#8195; &#147;Defendants&#146; Counsel&#148; means Sidley Austin LLP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.5&#8195; &#147;Effective Date&#148; means the first date by which all of the events and conditions specified in
Section&nbsp;6.1 of this Stipulation have all been met and/or have occurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.6&#8195; &#147;Fee and Expense
Amount&#148; shall have the meaning defined in Section&nbsp;4.1 of this Stipulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.7&#8195; &#147;Final&#148; means
the date upon which the last of the following shall occur with respect to the Judgment approving this Stipulation, substantially in the form of Exhibit E attached hereto: (1)&nbsp;the expiration of the time to file a notice of appeal from the
Judgment; or (2)&nbsp;if an appeal has been filed or if an appeal is taken, the United States Court of Appeals for the Seventh Circuit has either affirmed the Judgment or dismissed that appeal, and the time for any reconsideration or further
appellate review has passed; or (3)&nbsp;if the Supreme Court of the United States has granted further appellate review, that Court has either affirmed the underlying Judgment or affirmed the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 8
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Seventh Circuit&#146;s decision affirming the Judgment or dismissing the appeal. For purposes of this paragraph, an &#147;appeal&#148; shall
not include any appeal that concerns only the issue of attorneys&#146; fees and expenses or the payment of a service award. Any proceeding or order, or any appeal or petition for a writ of certiorari pertaining solely to the application for
attorneys&#146; fees, costs, or expenses, or the payment of a service award, shall not in any way delay or preclude the Judgment from becoming Final. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.8&#8195; &#147;Individual Defendants&#148; means Stefano Pessina, Jos&eacute; E. Almeida, Janice M. Babiak, David J.
Brailer, William C. Foote, Ginger L. Graham, John A. Lederer, Dominic Murphy, Leonard D. Schaeffer, Nancy M. Schlichting, and James A. Skinner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.9&#8195; &#147;Judgment&#148; means the Order and Final Judgment to be entered by the Court, substantially in the form
attached hereto as Exhibit E. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.10&#8195; &#147;Notice&#148; means the Notice of Pendency and Proposed Settlement of
Shareholder Derivative Action and of Settlement Hearing, substantially in the form attached hereto as Exhibit C. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.11&#8195; &#147;Parties&#148; means, collectively, Plaintiff and Defendants. &#147;Party&#148; means, individually, any of
the Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.12&#8195; &#147;Person&#148; means an individual or legal entity, including any corporation, limited
liability corporation, professional corporation, partnership, limited partnership, limited liability partnership, association, joint venture, joint stock company, estate, legal representative, trust, unincorporated association, government or any
political subdivision or agency thereof, or business or legal entity, and each of their spouses, heirs, predecessors, successors, representatives, or assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.13&#8195; &#147;Plaintiff&#148; means the Vladimir Gusinsky Revocable Trust. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 9
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.14&#8195; &#147;Plaintiff&#146;s Counsel&#148; means The Weiser Law Firm, P.C., Heffner Hurst, and any other law firm that
appears for Plaintiff in the Action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.15&#8195; &#147;Preliminary Approval Order&#148; means the order to be submitted
to the Court granting preliminary approval of the Settlement substantially in the form attached hereto as Exhibit B. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.16&#8195; &#147;Related Persons&#148; means: (i)&nbsp;with regard to any individual, the individual&#146;s spouses, marital
communities, immediate family members, heirs, executors, personal representatives, estates, administrators, trusts, beneficiaries, distributees, foundations, agents, employees, fiduciaries, partners, partnerships, general or limited partners of
partnerships, joint ventures, member firms, limited liability companies, corporations, predecessors, successors, and assigns or other individual or entity in which such individual has a controlling interest, and each and all of their respective past
and present officers, directors, employees, agents, affiliates, parents, subsidiaries, divisions, attorneys, accountants, auditors, advisors, insurers, <FONT STYLE="white-space:nowrap">co-insurers,</FONT>
<FONT STYLE="white-space:nowrap">re-insurers,</FONT> heirs, executors, personal representatives, estates, administrators, trusts, predecessors, successors, assigns, financial or investment advisors, advisors, consultants, investment bankers,
entities providing any fairness opinion, underwriters, brokers, dealers, lenders, and commercial bankers; and (ii)&nbsp;with regard to any entity (i.e., <FONT STYLE="white-space:nowrap">non-individual),</FONT> including Walgreens, the entity&#146;s
past or present agents, officers, directors, attorneys, accountants, auditors, advisors, insurers, <FONT STYLE="white-space:nowrap">co-insurers,</FONT> <FONT STYLE="white-space:nowrap">re-insurers,</FONT> consultants, partners, controlling
shareholders, joint venturers, fiduciaries, partners, partnerships, general or limited partners of partnerships, joint ventures, member firms, limited liability companies, corporations, related or affiliated entities, employees, affiliates,
predecessors, successors, parents, subsidiaries, and assigns. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 10
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.17&#8195;&#147;Reforms&#148; means the corporate governance changes set forth in Exhibit A attached hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.18&#8195;&#147;Released Claims&#148; means any and all actions, demands, suits, claims, debts, fees, rights, liabilities,
and causes of action of any nature, including both known and Unknown Claims (as defined in Section&nbsp;1.26 below), existing derivatively on behalf of Walgreens or by Walgreens, that were asserted in this Action, could have been asserted in this
Action, or in the future are asserted derivatively on behalf of Walgreens or by Walgreens,<B> </B>that arise out of, are based on, or relate to in any way, in whole or in part: (i)&nbsp;any Relevant Period Opioids-Related Matters; (ii)&nbsp;any
other actions, omissions, conduct, facts, events, or matters referenced in this Action, including any actions, omissions, conduct, facts, events, or matters referenced in any pleading or other document filed in this Action; (iii)&nbsp;any
opioids-related matters that have been publicly disclosed by Walgreens, whether completed or ongoing; or (iv)&nbsp;the Settlement, except for any claims to enforce the Settlement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.19&#8195;&#147;Released Persons&#148; means, collectively, Walgreens, the Individual Defendants and their Related Persons,
and any and all current or former directors, officers, or employees of Walgreens. &#147;Released Person&#148; means, individually, any of the Released Persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.20&#8195;&#147;Releasing Parties&#148; means Plaintiff, all other Walgreens<B> </B>Shareholders, Plaintiff&#146;s Counsel,
and Walgreens. &#147;Releasing Party&#148; means, individually, any of the Releasing Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.21&#8195;&#147;Relevant
Period Opioids-Related Matters&#148; means any actions, omissions, conduct, facts, events, or other matters related to, resulting from, or in connection with compliance with the Controlled Substances Act or related or similar regulations, or
otherwise relating to opioids in any way, directly or indirectly, occurring at any time prior to the date of entry of the Final Judgment and Order, including without limitation any opioids-related matter that has been publicly disclosed by Walgreens
prior to such date regardless of whether that matter remains ongoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 11
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.22&#8195;&#147;Settlement&#148; means the resolution of the Action and Released Claims in accordance with the terms and
conditions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.23&#8195;&#147;Settlement Hearing&#148; means any hearing or hearings at which the Court
will determine whether the Settlement should be approved and the Judgment entered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.24&#8195;&#147;Settlement Monetary
Amount&#148; means $36,000,000.00. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.25&#8195;&#147;Summary Notice&#148; means the Summary Notice of Pendency and
Proposed Settlement, substantially in the form attached hereto as Exhibit D. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.26&#8195;&#147;Unknown Claims&#148; means
any and all actions, demands, suits, claims, debts, fees, rights, liabilities, and causes of action of any nature that Plaintiff, Walgreens, any Walgreens Shareholder, or any Individual Defendant does not know of or suspect to exist in their favor
or in favor of Walgreens, whether derivatively on behalf of Walgreens or by Walgreens, at the time of the release of such claims, including claims that, if known, would have affected this Settlement, release of the Released Claims, or a decision not
to object to this Settlement. With respect to any and all Released Claims, the Parties stipulate and agree that, upon the Effective Date, each Party expressly waives, and each Walgreens Shareholder shall be deemed to have waived, and by operation of
the Judgment shall have expressly waived, any and all provisions, rights and benefits conferred by or under California Civil Code section 1542, or any other law of the United States or any state or territory of the United States, or principle of
common law, which is similar, comparable, or equivalent to section 1542, which provides: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; margin-right:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">A GENERAL
RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT
WITH THE DEBTOR OR RELEASED PARTY. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 12
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">The Parties acknowledge that they may hereafter discover facts in addition to or different from those now known or believed to
be true by them, with respect to the Released Claims, but it is the intention of the Parties to completely, fully, finally, and forever compromise, settle, release, discharge, and extinguish any and all Released Claims, known or unknown, suspected
or unsuspected, contingent or absolute, accrued or unaccrued, apparent or unapparent, which do now exist, heretofore existed, or may hereafter exist, and without regard to the subsequent discovery of additional or different facts or subsequent
developments. Each Party and each Walgreens Shareholder shall be deemed by operation of the Judgment to have acknowledged that the foregoing waiver and release of Unknown Claims was separately bargained for and is a key element of the Settlement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.27&#8195;&#147;Walgreens<B> </B>Shareholders&#148; means any Person or Persons who owned Walgreens common stock as of
the date of the execution of this Stipulation and continues to hold their Walgreens<B> </B>common stock as of the date of the Settlement Hearing, excluding the Individual Defendants, the officers and directors of Walgreens, and their Related
Persons. &#147;Walgreens Shareholder&#148; means, individually, each of the Walgreens Shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.28&#8195;&#147;Walgreens&#148; or the &#147;Company&#148; means nominal defendant Walgreens Boots Alliance, Inc., a
Delaware<B> </B>corporation, and any of its current or former predecessors, successors, parents, subsidiaries, affiliates, joint venturers, and assigns, including Walgreen Co. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 13
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>Settlement Consideration </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.1&#8195;In consideration for the full and final release, settlement, and discharge of any and all Released Claims and the
dismissal with prejudice of the Action on the terms and conditions set forth in this Stipulation: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:12%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(a) Defendants shall
cause the D&amp;O Insurers to pay the Settlement Monetary Amount to the Company on behalf of their insureds, by wire transfer or check at the option of the D&amp;O Insurers, no later than 20 business days after the later of: (i)&nbsp;the D&amp;O
Insurers&#146; receipt of an order from the Court preliminarily approving the Settlement, and (ii)&nbsp;the D&amp;O Insurers&#146; receipt of the necessary payment and delivery details, including specific bank identification and wiring information
and a duly executed Form <FONT STYLE="white-space:nowrap">W-9;</FONT> and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:12%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;Walgreens and its Board of
Directors<B> </B>shall, within 90<B> </B>days of the Effective Date, adopt, implement, and/or initiate, as appropriate in their business judgment, the Reforms identified in Exhibit A attached hereto, for a period of not less than 5<B> </B>years
following the Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:12%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(c) Walgreens&#146;s current Board of Directors, in an exercise of its independent
business judgment, has determined that the Settlement Monetary Amount shall be used by the Company solely for the purposes of funding: (i)&nbsp;controls, programs, salaries, and other efforts relating to adoption, implementation, and/or initiation
of Reforms; (ii)&nbsp;the Company&#146;s compliance with the terms of injunctions and settlement agreements from other matters relating to opioids and compliance with the Controlled Substances Act or related regulations, including, but without
limitation, compliance with injunctive relief provisions in the injunction order entered in the national opioids multi-district litigation captioned <I>In re National Prescription Opiate Litigation</I>, No. <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">1:17-md-2804</FONT></FONT> (N.D. Ohio), and in other opioids-related settlements reached to date or future opioids-related settlements that may contain such provisions; (iii)&nbsp;the Company&#146;s and its Board of
Directors&#146; oversight of and responses to compliance-related risks; and (iv)&nbsp;the Fee and Expense Amount. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 14
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.2&#8195;To the extent the Settlement is terminated or cancelled pursuant to any of the conditions set forth in Sections 6.2
and 6.3, the Company shall make a full refund to the D&amp;O Insurers of the payment the Company received under Section&nbsp;2.1(a), no later than 20 business days after the Settlement has been so terminated or cancelled, and such refund will be
distributed to the D&amp;O Insurers in accordance with the provisions of separate agreements between Walgreens and the D&amp;O Insurers entered into in connection with the Settlement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.3&#8195;The D&amp;O Insurers&#146; payment of the Settlement Monetary Amount and the entry of the Judgment shall constitute
full and final satisfaction of all of the Released Claims. The Individual Defendants&#146; sole monetary obligation under the Settlement shall be the D&amp;O Insurers&#146; payment of the Settlement Monetary Amount, and no Individual Defendant shall
be liable for any other amounts, including any Court-awarded attorneys&#146; fees or litigation expenses to Plaintiff&#146;s Counsel, which shall be paid, if awarded, by the Company out of the Settlement Monetary Amount. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>Notice and Approval </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">3.1&#8195;After execution of this Stipulation, Plaintiff shall file a motion for preliminary approval accompanied by this
Stipulation, and all other documents necessary to ultimately effectuate Court approval of the proposed Settlement, and will apply for entry of the Preliminary Approval Order. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">3.2&#8195;After the Settlement is preliminarily approved by the Court, Walgreens shall provide notice to Walgreens
Shareholders pursuant to Rule 23.1 of the Federal Rules of Civil Procedure. Notice to Walgreens Shareholders shall consist of the Notice, which includes the general terms of the Settlement set forth in this Stipulation and the date of the Settlement
Hearing, substantially in the form attached hereto as Exhibit C. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">3.3&#8195;Walgreens shall undertake the administrative
responsibility for giving notice to Walgreens Shareholders and shall be solely responsible for paying the costs and expenses related </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 15
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">to providing such notice to its shareholders. Within ten (10)&nbsp;business days after the entry of the Preliminary Approval Order, Walgreens
shall: (i)&nbsp;cause the Stipulation and the Notice to be included in a Form <FONT STYLE="white-space:nowrap">8-K</FONT> furnished to the SEC, (ii)&nbsp;Walgreen shall publish or cause to be published the Summary Notice, substantially in the form
attached hereto as Exhibit D, once in <I>Investor&#146;s Business Daily</I> or a similar online publication; and (iii)&nbsp;Walgreens shall post a link to the Stipulation and the Notice on the &#147;Investor Relations&#148; page of Walgreens&#146;
website, and shall maintain that link through the date of the hearing for the Court to determine whether to finally approve the Settlement. If additional notice is required by the Court, then the cost and administration of such additional notice
will be borne by Walgreens. The Parties believe the content and manner of notice, as set forth in this paragraph, constitutes adequate and reasonable notice to Walgreens Shareholders pursuant to applicable law and due process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">3.4&#8195;Following the passage of the applicable notice period, Plaintiff shall promptly request that the Court enter an
order and final judgment, substantially in the form attached hereto as Exhibit E, providing final approval of the Settlement and dismissal of the Action with prejudice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">3.5&#8195;Pending the Effective Date, the Parties agree that: (i)&nbsp;all proceedings and discovery in the Action should
continue to be stayed (with the exception of the proceedings necessary to effectuate the consummation and final approval of the Settlement); and (ii)&nbsp;Plaintiff and Plaintiff&#146;s Counsel are barred and enjoined from commencing, prosecuting,
instigating, or in any way participating in the commencement or prosecution of any action, including this Action, asserting any Released Claim. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>Plaintiff&#146;s Counsel&#146;s Separately Negotiated Fee and Expense Amount </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.1&#8195;In recognition of Plaintiff&#146;s Counsel&#146;s role in prosecuting and settling the Action and the substantial
benefits conferred upon the Company as a result of the Settlement, Walgreens agrees that Plaintiff&#146;s Counsel&#146;s should receive a fee and expense amount of $8,000,000.00 (the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 16
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;Fee and Expense Amount&#148;).<B> </B>Plaintiff and Plaintiff&#146;s Counsel agree not to request that any greater amount be awarded to
Plaintiff&#146;s Counsel by the Court and not to seek the payment of attorneys&#146; fees and expenses from any person or entity other than Walgreens. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.2 &#8195;The Fee and Expense Amount or such other amount as may be awarded by the Court shall constitute final and complete
payment for Plaintiff&#146;s Counsel&#146;s fees and expenses that have been incurred or will be incurred in connection with the Action. Defendants and Defendants&#146; Counsel shall have no responsibility for the allocation or distribution of the
Fee and Expense Amount among Plaintiff&#146;s Counsel. Defendants shall have no obligation to cause payment to be made to any of Plaintiff&#146;s Counsel other than as provided in Section&nbsp;4.3 herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.3 &#8195;The Parties acknowledge and agree that any Fee and Expense Amount in connection with the Settlement shall be paid
by Walgreens to an escrow account created by Plaintiff&#146;s Counsel (the &#147;Escrow Account&#148;), via wire transfer or check at the option of Walgreens, from the Settlement Monetary Amount, no later than 15 business days after the later of:
(i)&nbsp;Walgreens&#146;s receipt of payee information, wire instructions, and tax identification information for the payment from Plaintiff&#146;s Counsel; and (ii)&nbsp;Walgreens&#146;s receipt of the entirety of the Settlement Monetary Amount
from the D&amp;O Insurers. For the avoidance of doubt, any Fee and Expense Amount shall be paid out of, and not be in addition to, the Settlement Monetary Amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.4 &#8195;The Fee and Expense Amount shall remain in the Escrow Account until the entry of an order by the Court finally
approving the Settlement, at which time the Fee and Expense Amount shall be immediately releasable to Plaintiff&#146;s Counsel, notwithstanding the existence of any timely filed objections thereto or potential for appeal therefrom, or collateral
attack on the Settlement or any part thereof. Should the Court order the payment of attorneys&#146; fees and expenses to Plaintiff&#146;s Counsel in an amount less than the agreed Fee and Expense Amount prior to, or at
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 17
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">the time of, entry of the Judgment, then only the Court-approved amount shall be released to Plaintiff&#146;s Counsel. Any amounts remaining in
the Escrow Account shall be returned to Walgreens within 20 calendar days of entry of the Judgment or a final judgment after any appeal is concluded. For the avoidance of doubt, no fees or expenses shall be paid to Plaintiff&#146;s Counsel pursuant
to this Stipulation absent approval by the Court of a complete release of all Released Parties and their Related Persons, in the form provided herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.5 &#8195;The payment of any Fee and Expense Amount to Plaintiff&#146;s Counsel shall be subject to the obligation of
Plaintiff&#146;s Counsel to: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:12%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(a) &#8195;in the event the Settlement is terminated or cancelled pursuant to any of the
conditions set forth in Sections 6.2 and 6.3, make a full refund of any such payment to Walgreens in accordance with instructions to be provided by Defendants&#146; Counsel; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:12%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(b) &#8195;in the event the Fee and Expense Amount is reduced or reversed as a result of any appeal or further proceedings on
remand or successful collateral attack and such order reducing or reversing the award has become final, pay to Walgreens, in accordance with instructions to be provided by Defendants&#146; Counsel, the portion of any such reduction or reversal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.6 &#8195;Except as otherwise provided herein or except as provided pursuant to indemnification or insurance rights, each of
the Parties shall bear their own costs, expenses, and attorneys&#146; fees. Plaintiff&#146;s Counsel shall be solely responsible for any administrative costs associated with the Escrow Account as well as the filing of any and all informational and
other tax returns with the Internal Revenue Service, or any other state or local taxing authority, as may be necessary or appropriate. Neither Defendants nor Defendants&#146; Counsel shall have responsibility for, nor bear any risk or liability with
respect to, the Escrow Account, its operation, or any taxes or expenses incurred in connection with the Escrow Account. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 18
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.7 &#8195;The amount of any Fee and Expense Amount shall be subject to Court approval, which shall not be a precondition to
the Court&#146;s approval of the Settlement. The Court may consider and rule upon the fairness, reasonableness, and adequacy of the Settlement independently of the consideration of any Fee and Expense Amount. Any changes by any court, including this
Court, to the negotiated amount of any Fee and Expense Amount, or to any service award, will not otherwise affect the finality of the Judgment or the validity of the Settlement, and the Parties&#146; obligations under the Settlement (except with
respect to the payment of attorneys&#146; fees and expenses) shall not be conditioned on the resolution of, nor any ruling regarding, any Fee and Expense Amount, including any service award. Any orders or proceedings relating to any request for a
Fee and Expense Amount or service award, or any appeal from any orders or proceedings relating thereto, shall not affect the validity of the Settlement, operate to terminate or cancel the Stipulation, and/or affect or delay either the Effective Date
or the finality of the Judgment approving the Settlement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.8 &#8195;Plaintiff may apply to the Court for a service award
of up to $2,500.00<B> </B>for Plaintiff (the &#147;Service Award&#148;), only to be paid upon Court approval. Any Service Award shall be funded exclusively from the Fee and Expense Amount. The failure of the Court to approve any requested Service
Award, in whole or in part, shall have no effect on the Settlement set forth in this Stipulation. Defendants shall take no position on whether the Court should approve the Service Award, and no Defendant shall have any obligation to pay any such
Service Award or any portion thereof. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>Release of Claims and Dismissal of Action </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.1 &#8195;This Settlement is conditioned on the dismissal with prejudice of the Action at the time of final approval by the
Court. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 19
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.2 &#8195;Upon the Effective Date, each of the Releasing Parties shall be deemed to have fully, finally, and forever released,
relinquished, and discharged the Released Claims (including Unknown Claims), including against the Released Persons, as well as any and all claims arising out of, relating to, or in connection with the defense, settlement, or resolution of the
Action, including against the Released Persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.3 &#8195;Upon the Effective Date, each of the Defendants shall be
deemed to have fully, finally, and forever released, relinquished, and discharged Plaintiff and Plaintiff&#146;s Counsel from all claims (including Unknown Claims) arising out of, relating to, or in connection with the institution, prosecution,
assertion, settlement, or resolution of the Action or the Released Claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.4 &#8195;Nothing herein shall in any way
impair or restrict the rights of any Party to enforce the terms of this Stipulation. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>Conditions of Settlement; Effect of Disapproval, Cancellation, or Termination </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">6.1 &#8195;The Effective Date of this Stipulation shall be conditioned on the occurrence of all of the following events: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:12%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(a) &#8195;Court approval of the Settlement in all material respects; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:12%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(b) &#8195;Court entry of the Judgment in all material respects; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:12%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">(c) &#8195;the passing of the date upon which the Judgment becomes Final. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">6.2 &#8195;If any of the conditions specified above in Section&nbsp;6.1 are not met, then this Stipulation shall be canceled
and terminated subject to Section&nbsp;6.3, unless counsel for the Parties mutually agree in writing to proceed with this Stipulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">6.3 &#8195;If for any reason the Effective Date of this Stipulation does not occur, or if this Stipulation is in any way
cancelled or terminated, or otherwise fails to become Final in accordance with its terms: (a)&nbsp;all Parties and Released Persons shall be restored to their respective positions in the Action as existed immediately prior to the date of execution
of this Stipulation; (b)&nbsp;all releases </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 20
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">delivered in connection with this Stipulation shall be null and void, except as otherwise provided for in this Stipulation;
(c)&nbsp;Plaintiff&#146;s Counsel, including their law firms, partners, and/or shareholders, and Plaintiff, to the extent they have received any amount of the Fee and Expense Amount, shall within 20 business days after written notification from
Walgreens&#146;s counsel or from a court of appropriate jurisdiction refund to Walgreens the entirety of such amount, including any service awards, according to written instructions from Walgreens&#146;s counsel consistent with such cancellation or
termination; (d)&nbsp;Walgreens shall refund to the D&amp;O Insurers the payment the Company received under Section&nbsp;2.1(a) within 20 business days of receiving from Plaintiff&#146;s Counsel the refund of the Fee and Expense Amount; (e)&nbsp;the
terms and provisions of this Stipulation (other than those set forth in Sections 4.2, 6.2, 6.3, 7.4, 7.5 hereof) shall have no further force or effect with respect to the Parties and shall not be used in the Action or in any other proceeding for any
purpose; and (f)&nbsp;all negotiations, proceedings, documents prepared, and statements made in connection herewith shall be without prejudice to the Parties, shall not be deemed or construed to be an admission by a Party of any act, matter, or
proposition, and shall not be used in any manner for any purpose in any subsequent proceeding in the Action or in any other action or proceeding (other than to enforce the terms remaining in effect). In such event, the terms and provisions of this
Stipulation shall have no further force and effect with respect to the Parties and shall not be used in the Action or in any other proceeding for any purpose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">6.4 &#8195;No order of the Court concerning the Fee and Expense Amount or the Service Award that awards amounts at or below
those stated in Sections 4.1 and 4.8 (and no modification, or reversal on appeal of any order concerning the Fee and Expense Amount or the Service Award) shall constitute grounds for cancellation or termination of the Stipulation, affect the
enforceability of the Stipulation, or delay or preclude the Judgment from becoming Final. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 21
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>Miscellaneous Provisions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">7.1 &#8195;The Parties: (a)&nbsp;acknowledge that it is their intent to consummate this Stipulation; and (b)&nbsp;agree to
cooperate to the extent reasonably necessary to effectuate and implement all terms and conditions of the Stipulation and to exercise good-faith efforts to accomplish the foregoing terms and conditions of the Stipulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">7.2 &#8195;The Parties intend this Settlement to be a final and complete resolution of all disputes with respect to the
Action. The Settlement compromises claims that are contested and shall not be deemed an admission by any Party or Releasing Person as to the merits of any claim, allegation, or defense. The Defendants acknowledge that the Action was filed in good
faith, was not frivolous, and is being settled voluntarily by the Defendants. The Parties agree that throughout the course of the litigation, all parties and their counsel complied with the provisions of Federal Rule of Civil Procedure 11 and all
similar state law provisions. The Judgment shall contain a finding that, during the course of the litigation, each Party and their respective counsel at all times has complied with the requirements of Rule 11 and all other similar laws and/or rules
governing professional conduct. The Settling Parties agree that the Released Claims are being settled voluntarily after consultation with legal counsel who could assess the strengths and weaknesses of their respective clients&#146; claims or
defenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">7.3 &#8195;Pending the Effective Date, the Parties agree not to initiate any proceedings concerning the
Released Claims other than those incident to the Settlement itself; provided, however, that Walgreens, the Individual Defendants, and any Releasing Party may seek to prevent, dismiss, or stay any other action or claims brought seeking to assert any
Released Claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">7.4 &#8195;Each of the Defendants expressly denies and continues to deny all allegations of wrongdoing
or liability against themselves arising out of any conduct, statements, acts, or omissions alleged, or which could have been alleged, in the Action. The existence of the provisions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 22
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">contained in this Stipulation shall not be deemed to prejudice in any way the respective positions of the Parties with respect to the Action,
shall not be deemed a presumption, a concession, or admission by any of the Parties of any fault, liability, or wrongdoing as to any facts, claims, or defenses that have been or might have been alleged or asserted in the Action or with respect to
any of the claims settled in the Action, or any other action or proceeding, and shall not be interpreted, construed, deemed, invoked, offered, or received in evidence or otherwise used by any person in the Action, or in any other action or
proceeding, except for any litigation or judicial proceeding arising out of or relating to this Stipulation or the Settlement whether civil, criminal, or administrative, for any purpose other than as provided expressly herein. For the avoidance of
doubt, any Party may file this Stipulation and any related documents to enforce the provisions of this Stipulation, including the releases provided for herein. This provision shall remain in force in the event that the Term Sheet or Settlement is
terminated for any reason whatsoever, in accordance with its terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">7.5 &#8195;All confidentiality designations and
agreements made between or amongst any or all of the Parties, including the confidentiality agreement governing the Parties&#146; mediation and any orders entered during the course of the Action relating to the confidentiality of documents or
information, shall continue in force and are not superseded or altered by the Settlement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">7.6 &#8195;This Stipulation may
be modified or amended only by a writing signed by, or on behalf of, all Parties or their respective <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest.</FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">7.7 &#8195;This Stipulation shall be deemed drafted equally by all Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">7.8 &#8195;No representations, warranties, or inducements have been made to any of the Parties concerning this Stipulation or
its exhibits other than the representations, warranties, and covenants contained and memorialized in such documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 23
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">7.9 &#8195;Each counsel or other Person executing this Stipulation or its exhibits on behalf of any of the Parties hereby
warrants that such Person has the full authority to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">7.10 &#8195;The exhibits to this Stipulation are material and
integral parts hereof and are fully incorporated herein by this reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">7.11 &#8195;This Stipulation and the exhibits
attached hereto constitute the entire agreement among the Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">7.12 &#8195;The Stipulation supersedes and replaces
any prior or contemporaneous writing, statement, or understanding pertaining to the Action (including, without limitation, the Term Sheet), and no parole or other evidence may be offered to explain, construe, contradict, or clarify its terms, the
intent of the Settling Parties or their counsel, or the circumstances under which the Stipulation was made or executed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">7.13 &#8195;In the event that there exists a conflict or inconsistency between the terms of this Stipulation and the terms of
any exhibit hereto, the terms of this Stipulation shall prevail. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">7.14 &#8195;Counsel for the Parties are expressly
authorized by their respective clients to take all appropriate actions required or permitted to be taken pursuant to the Stipulation to effectuate its terms and conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">7.15 &#8195;Plaintiff represents and warrants it has not assigned or transferred, or attempted to assign or transfer, to any
Person any Released Claim or any portion thereof or interest therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">7.16 &#8195;This Stipulation shall be binding upon,
and inure to the benefit of, the Parties and the Released Persons, and their respective successors, assigns, heirs, spouses, marital communities, executors, administrators, trustees in bankruptcy, legal representatives, and any corporation or other
entity into or with which any Party merges, consolidates, or reorganizes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 24
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">7.17 &#8195;Any failure by any party to this Stipulation to insist upon the strict performance by any other party of any of the
provisions of the Stipulation shall not be deemed a waiver of any of the provisions, and such party, notwithstanding such failure, shall have the right thereafter to insist upon the strict performance of any and all of the provisions of the
Stipulation to be performed by such other party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">7.18 &#8195;This Stipulation shall be considered to have been
negotiated, executed, and delivered, and to be wholly performed, in the State of Illinois, and the rights and obligations of the parties to this Stipulation shall be construed and enforced in accordance with, and governed by, the internal,
substantive laws of the State of Illinois without giving effect to Illinois&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">choice-of-law</FONT></FONT> principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">7.19 &#8195;The headings herein are used for the purpose of convenience only and are not meant to have legal effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">7.20 &#8195;Without further order of the Court, the Settling Parties may agree to the reasonable extensions of time to carry
out any of provisions in this Stipulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">7.21 &#8195;This Stipulation may be executed in one or more counterparts,
including by electronic signature. Each counterpart, when so executed, shall be deemed to be an original, and all such counterparts together shall constitute the same instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">7.22 &#8195;Any dispute between the Parties arising out of or relating to the Settlement shall be resolved by a mediator from
Phillips ADR, first by way of mediation and, if unsuccessful, then by way of final, binding, <FONT STYLE="white-space:nowrap">non-appealable</FONT> resolution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">7.23 &#8195;The Court shall retain jurisdiction to implement and enforce the terms of the Stipulation and the Court&#146;s
Judgment, and the Parties submit to the jurisdiction of the Court for purposes of implementing and enforcing the Settlement embodied in the Stipulation and Judgment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 25
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">7.24 &#8195;Nothing in this Stipulation and, or the negotiations relating thereto, is intended to or shall be deemed to
constitute a waiver of any applicable privilege or immunity, including, without limitation, the attorney-client privilege, the joint defense privilege, or work product protection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, the Parties have caused this Stipulation to be executed by their duly authorized attorneys. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 26
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">Dated: April&nbsp;10, 2024</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><B>THE WEISER LAW FIRM. P.C.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>SIDLEY AUSTIN LLP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><U>/s/ James M. Ficaro&#8195;&#8195;&#8195;&#8195;&#8194;&#8195;&#8195;&#8195;&#8195;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>/s/ Kristen R. Seeger&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">James M. Ficaro (admitted <I>pro hac vice</I>)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">The Weiser Law Firm, P.C.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Four Tower Bridge</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">200 Barr Harbor Drive, Suite 400</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">West Conshohocken, PA 19428</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">(610) <FONT STYLE="white-space:nowrap">225-0206</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">jficaro@weiserlawfirm.com</P> <P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>HEFFNER HURST</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Matthew T. Heffner</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Matthew T. Hurst</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">30 North LaSalle, Suite 1210</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Chicago, Illinois 60602</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Telephone: (312) <FONT
STYLE="white-space:nowrap">346-3466</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">mheffner@heffnerhurst.com</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">mhurst@heffnerhurst.com</P> <P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman"><I>Counsel for Plaintiff</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Kristen R. Seeger (No. 6278416)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">John M. Skakun
III (No. 6297636)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Caroline A. Wong (No. 6324863)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">One South
Dearborn</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Chicago, IL 60603</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Telephone: (312) <FONT
STYLE="white-space:nowrap">853-7000</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">kseeger@sidley.com</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">jskakun@sidley.com</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">caroline.wong@sidley.com</P>
<P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman"><I>Counsel for Defendants</I></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 27
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:50pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 28
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>CORPORATE
GOVERNANCE REFORMS</U> </B></P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman">Unless another timeframe is specifically outlined herein, within ninety (90)&nbsp;days of issuance of a final
order approving the settlement, Walgreens Boots Alliance, Inc. (the &#147;Company&#148;) and its Board of Directors (&#147;Board&#148;), as appropriate, shall take actions to adopt, implement, and/or initiate the following corporate governance
changes for a period of not less than 5 years following the effective date of the settlement. </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>I.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B><U>Creation of Board Committee</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman">The Board shall create a Compliance, Safety, and Quality Committee, which shall be dedicated to the oversight of compliance, safety, and
quality risks and comprised of independent directors. The Board shall adopt the charter attached as Exhibit 1 for this Committee. </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>II.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B><U>Appointment of Additional Independent Directors</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman">With the assistance of the Nominating and Governance Committee, the Board shall appoint 2 new independent directors satisfying the
independence standards set forth in the Company&#146;s bylaws. The appointment of new independent directors at any point since January&nbsp;1, 2024, shall satisfy this requirement. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman">When appointing new directors: </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">Following an initial background and suitability review, the Nominating and Governance Committee shall conduct a
thorough review of each candidate (including commissioning customary background checks and interviews). The review shall have as one of its goals identifying candidates whose membership on the Board will create more diversity of gender, ethnicity,
experience, and perspective. </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">Once suitable candidates are identified by the Nominating and Governance Committee, the Board shall, in the
exercise of its business judgment and subject to its fiduciary duties, nominate for election or appoint the candidates for election to the Board. </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>III.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B><U>Creation of Management-Level Governance, Risk, and Compliance Committee</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman">The Company shall create a U.S. Retail Pharmacy Governance, Risk, and Compliance Committee. The Company shall adopt the charter attached as
Exhibit 2 for this Committee. </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>IV.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B><U>Controlled Substance Compliance</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>A.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>Changes to Chief Controlled Substance Compliance Officer Responsibilities </B></P></TD></TR></TABLE>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman">The following duties and responsibilities shall be added to the position of Chief Controlled Substance Compliance Officer: </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">All quarterly reports provided by the Chief Controlled Substance Compliance Officer regarding the Controlled
Substance Compliance Program (&#147;CSCP&#148;) shall also be provided to the Compliance, Safety, and Quality Committee. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 29
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">Annually, the Chief Controlled Substance Compliance Officer shall present to the Board an overview of the
previous year&#146;s quarterly reports regarding the CSCP, and shall provide information to the Board regarding whether the Company&#146;s governance obligations relating to controlled substance compliance are satisfied consistent with the
Company&#146;s previous agreements. </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>B.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>Changes to the Controlled Substance Compliance Committee Duties </B></P></TD></TR></TABLE>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman">The following duties and responsibilities shall be added to the Controlled Substance Compliance Committee: </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">The most recent annual written report prepared by the Controlled Substance Compliance Committee shall
immediately be made available to the Compliance, Safety, and Quality Committee. </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">All changes to the Company&#146;s CSCP policies adopted by the Controlled Substance Compliance Committee shall
be conveyed to the Compliance, Safety, and Quality Committee. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 30
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:55pt; font-family:Times New Roman" ALIGN="center">EXHIBIT 1 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 31
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial" ALIGN="center"><B>Walgreens Boots Alliance, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial" ALIGN="center"><B><U>Compliance, Safety, and Quality Committee Charter</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:arial"><B><U>Purpose</U> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:11pt; font-family:arial" ALIGN="justify">The Board of Directors (the
&#147;Board&#148;) of Walgreens Boots Alliance, Inc. (the &#147;Company&#148;) has established the Compliance, Safety, and Quality Committee (the &#147;Committee&#148;) to assist the Board in its oversight of (1)&nbsp;the Company&#146;s global legal
and regulatory compliance, including with regard to pharmacy, healthcare, and retail laws and regulations to which the Company is subject, (2)&nbsp;the Company&#146;s advancement of patient and team member safety, and (3)&nbsp;the Company&#146;s
advancement of pharmacy and healthcare delivery quality. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:11pt; font-family:arial" ALIGN="justify">In addition to the powers and responsibilities expressly delegated to the
Committee in this Charter, the Committee may exercise any other powers and carry out any other responsibilities delegated to it by the Board. To the fullest extent permitted by law, the Committee shall have the power to determine which matters are
within the scope of the powers and responsibilities delegated to it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:arial"><B><U>Composition</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:11pt; font-family:arial" ALIGN="justify">The Committee will consist of no fewer than three directors. Each member of the Committee must meet the independence requirements of the
Nasdaq Stock Market and the Company&#146;s categorical independence standards. At least one member of the Committee shall, in the judgment of the Board, have a background in healthcare that includes oversight or responsibility for safety,
compliance, and/or quality. At least one member of the Committee, and no more than half of the members of the Committee, shall serve concurrently on the Audit Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:11pt; font-family:arial" ALIGN="justify">The members of the Committee are appointed by the Board upon recommendation of the Nominating and Governance Committee, and serve at the
discretion of the Board. One member of the Committee will be appointed by the Board as Chair, upon recommendation of the Nominating and Governance Committee. The Board may remove Committee members with or without cause, including upon the
recommendation of the Nominating and Governance Committee. Any action duly taken by the Committee shall be valid and effective, whether or not the members of the Committee at the time of such action are later determined not to have satisfied the
requirements for membership provided herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:11pt; font-family:arial" ALIGN="justify">Determinations of whether a particular director satisfies the requirements for
membership on the Committee will be made by the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:arial"><B><U>Authority and Delegation</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:11pt; font-family:arial" ALIGN="justify">The Committee has the authority to review any activity of the Company in order to adequately discharge its responsibilities. The
Committee shall have direct access to the Company&#146;s Global Chief Compliance and Ethics Officer, Global Chief Legal Officer, Chief Pharmacy Officer, Chief Controlled Substance Compliance Officer, head of Patient Safety for Pharmacy, Chief
Information Officer, head of Internal Audit, Chief Medical Officer 1 and other senior medical personnel, any other executive or manager of the Company, and the records of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:11pt; font-family:arial" ALIGN="justify">The Committee has the authority to retain consultants, outside counsel, and other advisors as the Committee deems appropriate in its
sole discretion to assist the Committee in the performance of its </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP> If any title referenced in this charter is changed, the reference shall be to the functionally equivalent
position(s). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 32
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial" ALIGN="justify">duties. The Committee is authorized to approve related fees and retention terms and shall be provided with appropriate funding, as determined by the
Committee, for payment of compensation to such consultants, outside counsel, and other advisors, as well as for ordinary administrative expenses that the Committee deems appropriate in carrying out its duties.<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:11pt; font-family:arial" ALIGN="justify">The Committee may delegate to one or more subcommittees such duties as the Committee deems necessary and appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:arial"><B><U>Meetings</U> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:11pt; font-family:arial" ALIGN="justify">The Committee will meet as
often as it deems necessary, but not less frequently than quarterly. The Committee may request any officer or employee of the Company or the Company&#146;s outside counsel to attend a meeting of the Committee or to meet with any members of, or
consultants to, the Committee. The Committee may also meet periodically in separate executive sessions with management, and have such other direct interaction with members of management from time to time as the members of the Committee deem
appropriate. Notice of all Committee meetings will be given, and waiver thereof determined, in accordance with the notice and waiver of notice requirements applicable to the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:11pt; font-family:arial" ALIGN="justify">A majority of the members, present in person, by phone, or via other electronic media, will constitute a quorum. A majority of the
members present at a duly constituted meeting may decide any question brought before the Committee. The Committee may act by written consent to the extent permitted by and in accordance with the <FONT STYLE="white-space:nowrap">by-laws</FONT> of the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:arial"><B><U>Minutes</U> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:11pt; font-family:arial" ALIGN="justify">The Secretary
of the Company or the Chair&#146;s designate will prepare the minutes of the Committee&#146;s meetings. Minutes will be distributed to Committee members and to the Company&#146;s directors who are not Committee members. The Secretary of the Company
will maintain copies of all minutes as permanent records.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:arial"><B><U>Specific Duties</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:arial" ALIGN="justify">Acting in a manner that is consistent with the purpose and authority described above, the Committee will perform such specific duties as it deems
appropriate, including the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:arial; " ALIGN="justify"><U>Compliance</U>. Review and discuss with management the implementation and enforcement of policies, standards,
procedures, risk management programs, and compliance with applicable laws and regulations on a global basis, including pharmacy, healthcare, and retail laws and regulations to which the Company is subject. In furtherance of this responsibility, the
Committee shall periodically (and at least annually): </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:arial; " ALIGN="justify">Review with the Global Chief Compliance and Ethics Officer (a)&nbsp;the design, implementation, and effectiveness of
the Company&#146;s compliance programs and policies, (b)&nbsp;compliance matters relating to the Company&#146;s wholly owned and <FONT STYLE="white-space:nowrap">non-wholly</FONT> owned businesses, and (c)&nbsp;the adequacy of resources for the
Company&#146;s compliance programs and related initiatives. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:arial; " ALIGN="justify">Review with the Chief Controlled Substance Compliance Officer (a)&nbsp;the design, implementation, and effectiveness
of the Company&#146;s controlled substance compliance program and policies, and (b)&nbsp;the adequacy of resources for the Company&#146;s controlled substance compliance program and related initiatives. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 33
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:arial; " ALIGN="justify">Review with management the enforcement of policies, standards, procedures, and risk management programs relating to
compliance with applicable laws and regulations, including pharmacy, healthcare, and retail laws and regulations to which the Company is subject, and any agreements with any federal, state, local, or foreign government body relating to legal or
regulatory compliance. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:arial; " ALIGN="justify">Review with management (a)&nbsp;key compliance risks and issues, including those identified and monitored through the
Company&#146;s risk assessment processes, (b)&nbsp;results of compliance assessments, and (c)&nbsp;management&#146;s business judgments regarding, and plans to respond to, identified compliance matters, including in consultation with the Board as
appropriate. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:arial; " ALIGN="justify"><U>Patient Safety and Clinical Quality</U>. Review and discuss with management the implementation and administration
of programs and strategies related to advancing the Company&#146;s patient safety and clinical quality initiatives on a global basis. In furtherance of this responsibility, the Committee shall periodically (and at least annually):
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:arial; " ALIGN="justify">Review with the head of Patient Safety for Pharmacy the Company&#146;s practices, policies, and initiatives related to
advancing patient safety and clinical quality, including with regard to pharmacy dispensing and other pharmacy services. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:arial; " ALIGN="justify">Review with the Chief Medical Officer and/or senior medical staff the Company&#146;s practices, policies, and
initiatives related to advancing the quality performance of the Company&#146;s healthcare services, including with regard to the Company&#146;s medical clinic, primary care, and <FONT STYLE="white-space:nowrap">in-home</FONT> care operations.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:arial; " ALIGN="justify">Review with management (a)&nbsp;key risks and issues relating to patient safety and clinical quality, including those
identified and monitored through the Company&#146;s risk assessment process, and (b)&nbsp;management&#146;s business judgments regarding, and plans to respond to, identified matters relating to patient safety and clinical quality, including in
consultation with the Board as appropriate. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:arial; " ALIGN="left"><U>Team Member Safety</U>. Review and discuss with management the implementation and administration of programs and
strategies related to the safety of the Company&#146;s employees on a global basis. In furtherance of this responsibility, the Committee shall periodically (and at least annually): </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:arial; " ALIGN="justify">Review with management (a)&nbsp;key risks and issues relating to team member safety, including those identified and
monitored through the Company&#146;s risk assessment process, and (b)&nbsp;management&#146;s business judgments regarding, and plans to respond to, identified matters relating to team member safety, including in consultation with the Board as
appropriate. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:arial; " ALIGN="left"><U>Technology</U>. Review and discuss with management the design, implementation, effectiveness, and adequacy of
resources for the Company&#146;s technology-related projects and strategies that are related to or may impact compliance, safety, or quality matters. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:arial; " ALIGN="justify"><U>Global Chief Legal Officer</U>. Review with the Global Chief Legal Officer (a)&nbsp;significant litigation,
(b)&nbsp;government or regulatory matters, and (c)&nbsp;privileged compliance assessments and legal reviews that are related to compliance, safety, or quality issues. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 34
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:arial; " ALIGN="justify"><U>Ethics</U>. Review with the Global Chief Compliance and Ethics Officer the administration of the Company&#146;s
Code of Conduct and Ethics, and any significant changes to the Company&#146;s ethics program. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:arial; " ALIGN="justify"><U>Complaint Procedures</U>. Review and monitor the procedures for the receipt, retention, and treatment of complaints
regarding compliance, safety, or quality matters, as well as for confidential, anonymous submission by Company employees of concerns regarding such matters. Review periodically with management these procedures and any significant complaints
received. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:arial; " ALIGN="justify"><U>Coordination with the Audit Committee</U>. Consult with the Audit Committee as appropriate regarding matters
relevant to each Committee&#146;s respective responsibilities. In furtherance of coordination: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:arial; " ALIGN="justify">The Committee shall meet in joint session with the Audit Committee at least annually, and may meet in joint session
more frequently. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:arial; " ALIGN="justify">Any member of the Committee may attend any regular meeting of the Audit Committee, and any member of the Audit
Committee may attend any regular meeting of the Committee, as is available to all Board members. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:arial; " ALIGN="justify">The Committees shall coordinate on matters that are relevant to both Committees&#146; responsibilities, including
(a)&nbsp;the Company&#146;s annual compliance assessment plans and the annual audit plans of the Company&#146;s internal audit function, to the extent the annual audit plans involve matters relating to compliance, safety, or quality, (b)&nbsp;the
Company&#146;s technology-related projects and strategies, and (c)&nbsp;significant complaints and anonymous submissions regarding compliance, safety, or quality matters. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:arial; " ALIGN="justify">The Committee does not bear any of the duties or responsibilities of the Company&#146;s Audit Committee, as set forth
in the Audit Committee Charter promulgated by the Board from time to time or as required by law. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:arial; " ALIGN="justify"><U>Committee Reports to the Board</U>. Report to the Board regarding the activities of the Committee on a regular
basis and as otherwise requested by the Chair of the Board, and determine when matters should be referred to the Board for further consideration. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:arial; " ALIGN="justify"><U>Annual Performance Evaluation</U>. At least annually, evaluate the Committee&#146;s performance and report to the
Board regarding the Committee&#146;s self-evaluation. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:arial; " ALIGN="justify"><U>Charter Review</U>. At least annually, review this Charter and recommend any proposed changes to the Board for
approval. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:arial; " ALIGN="justify"><U>Other Duties</U>. Perform such other duties and responsibilities as may be assigned to the Committee by applicable
law or regulation (whether in a domestic or foreign jurisdiction), by the Company&#146;s <FONT STYLE="white-space:nowrap">by-laws,</FONT> or by the Board. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:arial"><I>Effective as of [month ##, ####]. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 35
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:55pt; font-family:Times New Roman" ALIGN="center">EXHIBIT 2 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 36
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g821017sp40.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Walgreens U.S. Retail Pharmacy </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Governance, Risk, and Compliance Committee Charter </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>I.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>Purpose </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:12pt; font-family:Times New Roman">The U.S. Retail Pharmacy Governance, Risk, and Compliance Committee (the &#147;Retail Pharmacy GRC&#148;) is a standing subcommittee of the
WBA Executive Governance, Risk, and Compliance Committee (the &#147;Executive GRC&#148;) and oversees key compliance and safety matters relating to the Company&#146;s pharmacy and retail operations. It focuses on: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Identifying and evaluating key risks relating to the Company&#146;s pharmacy and retail operations.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Monitoring the Company&#146;s compliance, safety, and quality matters relating to its pharmacy and retail
operations, including controlled substances dispensing, patient and team member safety, and billing compliance. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Escalating significant risks and matters, as well as key metrics, to the Executive GRC and, as appropriate, the
Board of Directors. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Recommending, and coordinating the implementation of, continuous improvements to the compliance and ethics
programs and internal controls relating to the Company&#146;s pharmacy and retail operations. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Providing team members with appropriate resources and infrastructure relating to risks and matters overseen by
the Retail Pharmacy GRC. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>II.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>Membership, Structure&nbsp;&amp; Organization </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>Retail Pharmacy GRC Members </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:12pt; font-family:Times New Roman">The Committee shall be led by two or more <FONT STYLE="white-space:nowrap">co-chairs,</FONT> and shall be comprised of a total of
approximately 8&#150;10 senior leaders across functions at the Company, including the Compliance, Quality/Patient Safety Organization, Human Resources, Internal Audit, Finance, Legal, Pharmacy Operations, and Retail Operations functions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:12pt; font-family:Times New Roman">The Retail Pharmacy GRC has the authority to retain outside advisors, including legal counsel or other compliance experts, as it deems
appropriate. The Company will provide funding for such advisors. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>Meeting Frequency </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:12pt; font-family:Times New Roman">The Retail Pharmacy GRC will meet at least quarterly each year, with additional meetings as needed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 37
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g821017sp40.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>Agenda and Meeting Minutes </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:12pt; font-family:Times New Roman">The Vice President and US Compliance Officer (or their delegate) shall be responsible for documentation of each Retail Pharmacy GRC meeting
via the preparation and retention of agendas, meeting materials, and meeting minutes. The agenda and meeting materials for each meeting will be distributed to members sufficiently in advance of each meeting to permit meaningful review. Minutes shall
include specific descriptions of the Retail Pharmacy GRC&#146;s discussion, consideration, and business decisions regarding risks and matters within the scope of its oversight responsibilities, including compliance, safety, and quality risks and
matters. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>III.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>Specific Responsibilities </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>Identify and monitor key compliance, safety, and quality risks relating to the Company&#146;s pharmacy and
retail operations, including by: </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">Overseeing regular assessments of the overall effectiveness of compliance and ethics programs relating to the
Company&#146;s pharmacy and retail operations. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">Reviewing compliance metrics, including metrics regarding complaints raised through the Company&#146;s
reporting mechanisms, compliance assessment results, employee training results, approved exceptions, monitoring reports, audit results, and corrective actions. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">Reviewing data and analytics pertaining to compliance with laws, regulations, and policies applicable to the
Company&#146;s pharmacy operations, including laws, regulations, and policies relating to controlled substances, prescription dispensing, government billing and reimbursement, anti-kickback laws, Stark Law compliance, and other matters as determined
by the Retail Pharmacy GRC. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">Reviewing data and analytics pertaining to compliance with laws, regulations, and related policies applicable
to the Company&#146;s retail operations, including laws, regulations, and policies relating to employee and customer safety, anti-money-laundering, pricing, <FONT STYLE="white-space:nowrap">age-restricted</FONT> product compliance, tobacco and
alcohol sales, food safety, and other matters as determined by the Retail Pharmacy GRC. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">Overseeing the Company&#146;s compliance with requirements relating to its pharmacy and retail operations set
forth in agreements with government agencies. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">f.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">Evaluating the effectiveness and impact of compliance-related employee training programs.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">g.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">Evaluating results of employee culture surveys related to values, ethics, and compliance.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 38
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g821017sp40.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">h.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">Reviewing external environment developments, such as industry enforcement actions and legislative and
regulatory updates, to analyze compliance needs, trends, and developments in key risk areas. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>Escalate key compliance, safety, and quality matters relating to the Company&#146;s pharmacy and retail
operations, including by: </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">Providing regular reports and recommendations to the Executive GRC. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">Coordinating with Legal, Compliance, Internal Audit, and other functions within the Company regarding key and
emerging compliance and safety risks. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>Recommend and coordinate enhancements to the compliance and ethics programs and internal controls for the
Company&#146;s pharmacy and retail operations in response to key identified risks, including by: </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">Recommending, reviewing, and approving annual compliance program priorities and goals. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">Recommending and providing appropriate resources and infrastructure to support the Company&#146;s compliance
and ethics programs and internal controls. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">Recommending enhancements relating to the Company&#146;s compliance with laws, regulations, and policies, as
well as with government agreements. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">Recommending enhancements to compliance monitoring plans, employee training, employee communications,
educational initiatives, and related controls. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 39
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:50pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 40
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES DISTRICT COURT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>NORTHERN DISTRICT OF ILLINOIS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>EASTERN DIVISION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="19" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="19" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">VLADIMIR GUSINSKY REVOCABLE TRUST, Derivatively on Behalf of WALGREENS BOOTS ALLIANCE, INC.,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Case No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">23-cv-15654</FONT></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; font-size:12pt; font-family:Times New Roman">Plaintiff,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>EXHIBIT B &#150; [PROPOSED]</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman"><B>ORDER
PRELIMINARILY</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; font-size:12pt; font-family:Times New Roman">v.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>APPROVING SETTLEMENT</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt"><FONT STYLE="font-size:12pt">STEFANO PESSINA, JOSE E. ALMEIDA, JANICE M. BABIAK, DAVID J. BRAILER, WILLIAM C. FOOTE, GINGER L. GRAHAM, JOHN A. LEDERER, DOMINIC MURPHY, LEONARD
D. SCHAEFFER, NANCY M. SCHLICHTING, and JAMES A. SKINNER,</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; font-size:12pt; font-family:Times New Roman">Defendants,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; font-size:12pt; font-family:Times New Roman">and</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt"><FONT STYLE="font-size:12pt">WALGREENS BOOTS ALLIANCE, INC., a Delaware Corporation,</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:14pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; font-size:12pt; font-family:Times New Roman">Nominal
Defendant.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #cdd4e9">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #cdd4e9">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, the above-referenced derivative action captioned <I>Vladimir Gusinsky Revocable Trust
v. Pessina et al.</I>,<I> </I>Case No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">23-cv-15654</FONT></FONT> (the &#147;Action&#148;), is pending before this Court; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, Plaintiff Vladimir Gusinsky Revocable Trust<I> </I>has moved for an order: (i)&nbsp;preliminarily approving the
proposed Settlement of the Action, in accordance with the Stipulation and Agreement of Settlement dated April&nbsp;10, 2024 (the &#147;Stipulation&#148;), which, together with the exhibits attached thereto, sets forth the terms and conditions for
the proposed Settlement and dismissal with prejudice of the Action, upon the terms and conditions set forth therein; and (ii) approving the form and content of notice of the pendency of the Action and proposed Settlement to Walgreens Shareholders;
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 41
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, unless otherwise defined herein, all capitalized terms contained herein shall have the same meanings as set forth in
the Stipulation; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, the Court (i)&nbsp;has read and considered the Stipulation and the exhibits attached
thereto, (ii)&nbsp;has found upon a preliminary evaluation that the proposed Settlement falls within the range of preliminary approval criteria, including because it confers benefits on Walgreens Boots Alliance, Inc. (&#147;Walgreens&#148;) and its
shareholders and appears to be the product of serious, informed negotiations overseen by an experienced mediator, and (iii)&nbsp;has found upon a preliminary evaluation that Walgreens Shareholders should be apprised of the Settlement through the
proposed form of notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">NOW THEREFORE, IT IS HEREBY ORDERED: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1.&#8195; This Court has jurisdiction over the subject matter of the Action, and the Parties to the Stipulation agreed to
submit to the jurisdiction of the Court for purposes of implementing and enforcing the Settlement embodied in the Stipulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.&#8195; The Court does hereby preliminarily approve, subject to further consideration at the Settlement Hearing described
below, the Settlement as set forth in the Stipulation as fair, reasonable, and adequate, including the terms and conditions for settlement and dismissal with prejudice of the Action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">3.&#8195; The Settlement Hearing shall be held before the Court on <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>, 2024 at
<U>&#8195;&#8195;&#8195;</U> <U>&#8195;</U>.m. to determine: (i)&nbsp;whether the terms and conditions of the Settlement set forth in the Stipulation are fair, reasonable, and adequate to Walgreens and Walgreens Shareholders and should be finally
approved by the Court; (ii)&nbsp;whether an Order and Final Judgment approving the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 42
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Settlement, substantially in the form attached to the Stipulation as Exhibit E, should be entered; (iii)&nbsp;whether to approve the
agreed-upon amount of attorneys&#146; fees and expenses (&#147;Fee and Expense Amount&#148;); and (iv)&nbsp;such other matters as the Court may deem appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.&#8195; The Court approves, as to form and content, the Notice, attached as Exhibit C to the Stipulation, and the Summary
Notice, attached as Exhibit D to the Stipulation, and finds that the posting of the Notice and publication of the Summary Notice in the manner and form set forth in paragraphs 5&#150;6 of this Order meet the requirements of Fed. R. Civ. P. 23.1 and
due process, and constitute due and sufficient notice of all matters relating the Settlement to all Persons entitled to such notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.&#8195; No later than ten (10)&nbsp;business days following entry of this Order, Walgreens shall cause the Summary Notice,
substantially in the form attached to the Stipulation as Exhibit D, to be published one time in <I>Investor&#146;s Business Daily</I> or a similar online publication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">6.&#8195; No later than ten (10)&nbsp;business days following entry of this Order, Walgreens shall cause the Stipulation and
the Notice to be included in a Form <FONT STYLE="white-space:nowrap">8-K</FONT> furnished to the Securities and Exchange Commission, and Walgreens shall post a link to the Stipulation and the Notice on the &#147;Investor Relations&#148; page of
Walgreens&#146; website, and shall maintain that link through the date of the hearing for the Court to determine whether to finally approve the Settlement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">7.&#8195; No later than seven (7)&nbsp;calendar days prior to the Settlement Hearing, Walgreens shall file with the Court and
serve on Plaintiff&#146;s Counsel proof, by affidavit or declaration, of compliance with the notice procedures set forth in this Order. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">8.&#8195; Any and all costs of Notice shall be paid by Walgreens, regardless of whether the Court finally approves the
Settlement or the Effective Date fails to occur, and in no event shall Plaintiff or Plaintiff&#146;s Counsel be responsible for the payment of costs associated with the Notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 43
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">9.&#8195; All papers in support of the Settlement and the Fee and Expense Amount shall be filed with the Court and served no
later than <FONT STYLE="white-space:nowrap">twenty-one</FONT> (21)&nbsp;calendar days prior to the Settlement Hearing and any reply papers shall be filed with the Court no later than seven (7)&nbsp;calendar days prior to the Settlement Hearing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">10.&#8195; Any Walgreens Shareholder who continues to own Walgreens common stock through the date of the Settlement Hearing
may file a written objection to the Settlement and/or to the payment of the Fee and Expense Amount and appear and show cause, if he, she or it has any cause, why the Settlement and/or the Fee and Expense Amount should not be approved; provided,
however, that, unless otherwise directed by the Court for good cause shown, no such person or entity shall be heard or entitled to contest the approval of the terms and conditions of the Settlement and/or the payment of the Fee and Expense Amount to
Plaintiff&#146;s Counsel unless that person or entity: (i)&nbsp;files notice of an intention to appear that includes proof of current ownership of Walgreens common stock; (ii)&nbsp;files papers in support of the objection with the Clerk of the Court
by at least fourteen (14)&nbsp;calendar days prior to the hearing; and (iii)&nbsp;ensures such notice and papers have been served on and received by counsel as identified in the Notice by at least fourteen (14)&nbsp;calendar days prior to the
Settlement Hearing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">11.&#8195; Any objection: (a)&nbsp;must state the name, address, and telephone number of the person
or entity objecting and, if represented by counsel, the name, address and telephone number of his, her, or its counsel; (b)&nbsp;must be signed by the shareholder; (c)&nbsp;must contain a written, specific statement of the shareholder&#146;s
objection or objections, and the specific reasons for each objection, including any legal and evidentiary support the shareholder wishes to bring to the Court&#146;s attention; (d)&nbsp;must state that the objection is being filed with respect to
&#147;<I>Vladimir Gusinsky Revocable Trust v. Pessina et al.</I>,<I> </I>Case No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">23-cv-15654&#148;;</FONT></FONT> (e) must include documentation
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 44
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">sufficient to prove that the shareholder held shares of Walgreens common stock as of the close of business on the date of the Stipulation and
continues to hold such stock as of the date the objection is made; and (f)&nbsp;must state the dates when the shareholder acquired Walgreens shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">12.&#8195; Any Walgreens Shareholder who wishes to be heard orally at the hearing in opposition to the approval of the
Settlement must also file a notice of appearance with the Clerk of the Court and serve the notice on counsel as identified in the Notice so that it is received no later than fourteen (14)&nbsp;calendar days prior to the Settlement Hearing.
Shareholders who intend to object and desire to present evidence at the Settlement Hearing must include in their written objection or notice of appearance the identity of any witnesses they may call to testify and exhibits they intend to introduce
into evidence at the hearing. Any person appearing at the Settlement Hearing must present at the hearing documentation sufficient to prove that the shareholder continues to hold shares of Walgreens common stock as of the date of the hearing. Such
persons may be heard orally at the discretion of the Court. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">13.&#8195; Unless otherwise ordered by the Court, any
Walgreens Shareholder who does not make his, her, or its objection in the manner provided herein shall be deemed to have waived his, her, or its right to object and shall forever be barred from raising any objection to the Settlement and/or the Fee
and Expense Amount, or any other matter related to the Settlement, in the Action or in any other action or proceeding, and shall otherwise be bound by the Order and Final Judgment to be entered and the Releases to be given. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">14.&#8195; All Walgreens Shareholders shall be bound by all orders, determinations, and judgments in the Action concerning the
Settlement, whether favorable or unfavorable to Walgreens Shareholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 45
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">15.&#8195; All proceedings in the Action, other than those relating to the Settlement itself, are hereby stayed until further
Order of the Court. Pending final determination of whether the Settlement should be approved, Plaintiff and all other Walgreens Shareholders are hereby barred and enjoined from commencing or prosecuting, derivatively on behalf of Walgreens, any of
the Released Claims against any of the Released Persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">16.&#8195; The Court may adjourn the date of the Settlement
Hearing or modify any other dates set forth herein without further notice to Walgreens Shareholders and retains jurisdiction to consider all further applications arising out of or connected with the Settlement. The Court may approve the Settlement
and any of its terms, with such modifications as may be agreed to by the Parties, if appropriate, without further notice to Walgreens Shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">17.&#8195; Neither the Stipulation nor the Settlement, nor any act performed or document executed pursuant to or in
furtherance of the Stipulation or the Settlement: (i)&nbsp;is or may be deemed to be or may be offered, attempted to be offered, or used in any way by any Party or any other Person as a presumption, a concession, an admission, or evidence of any
fault, wrongdoing, or liability of any Party or Released Person, or of the validity of any Released Claim; or (ii)&nbsp;is intended by the Parties to be offered or received as evidence or used by any Person in any action or proceeding, whether
civil, criminal, or administrative, other than to enforce the terms therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>IT IS SO ORDERED. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">DATED: <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>, 2024 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="right"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="right">Honorable Matthew F. Kennelly&#8195; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 46
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:50pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT C </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 47
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES DISTRICT COURT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>NORTHERN DISTRICT OF ILLINOIS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>EASTERN DIVISION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="19" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="19" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">VLADIMIR GUSINSKY REVOCABLE TRUST, Derivatively on Behalf of WALGREENS BOOTS ALLIANCE, INC.,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Case No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">23-cv-15654</FONT></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; font-size:12pt; font-family:Times New Roman">Plaintiff,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>EXHIBIT C &#150; NOTICE OF</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>PENDENCY
AND PROPOSED</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman"><B>SETTLEMENT OF</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; font-size:12pt; font-family:Times New Roman">v.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>SHAREHOLDER DERIVATIVE</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>ACTION AND
OF</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman"><B>SETTLEMENT HEARING</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">STEFANO PESSINA, JOSE E. ALMEIDA, JANICE M. BABIAK, DAVID J. BRAILER, WILLIAM C. FOOTE, GINGER L. GRAHAM, JOHN A. LEDERER, DOMINIC MURPHY, LEONARD D. SCHAEFFER, NANCY M.
SCHLICHTING, and JAMES A. SKINNER,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; font-size:12pt; font-family:Times New Roman">Defendants,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; font-size:12pt; font-family:Times New Roman">and</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">WALGREENS BOOTS ALLIANCE, INC., a</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman">Delaware Corporation,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:14pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; font-size:12pt; font-family:Times New Roman">Nominal
Defendant.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #cdd4e9">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #cdd4e9">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF <U> </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>SHAREHOLDER DERIVATIVE ACTION AND OF SETTLEMENT HEARING</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>TO: ALL PERSONS WHO OWNED SHARES OF THE COMMON STOCK OF WALGREENS BOOTS ALLIANCE, INC. (&#147;WALGREENS&#148; OR THE &#147;COMPANY&#148;)
AS OF APRIL&nbsp;10, 2024 (&#147;WALGREENS SHAREHOLDERS&#148;). </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY.</B> This
Notice relates to a proposed settlement (the &#147;Settlement&#148;) of the above-captioned shareholder derivative action brought in the United States District Court for the Northern District of Illinois (the &#147;Court&#148;). Your rights will be
affected by the legal proceedings in the Action. If the Court approves the Settlement, you will be forever barred from pursuing the Plaintiff&#146;s Released Claims (defined below) against the Defendants&#146; Released Persons (defined below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>THIS ACTION IS NOT A &#147;CLASS ACTION.&#148; THUS, THERE IS NO COMMON FUND UPON WHICH YOU CAN MAKE A CLAIM FOR A MONETARY PAYMENT.
</B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 48
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">As more fully described below, Plaintiff Vladimir Gusinsky Revocable Trust (&#147;Plaintiff&#148;) alleges in the Action that the Individual
Defendants breached their fiduciary duties to the Company by failing to adequately oversee opioids-related matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the
Settlement, Walgreens&#146;s current Board of Directors has acknowledged, in an exercise of its independent business judgment, that the Settlement confers substantial benefits to Walgreens and Walgreens Shareholders, and that the initiation,
prosecution, and settlement of the Action caused: (1)&nbsp;Walgreens&#146;s receipt of a $36,000,000.00 cash payment from its and/or the Individual Defendants&#146; directors and officers insurance carriers (the &#147;D&amp;O Insurers&#148;); and
(2)&nbsp;the adoption and/or implementation of corporate governance reforms (the &#147;Reforms&#148;), attached as Exhibit A to the Stipulation and Agreement of Settlement, dated April&nbsp;10, 2024 (the &#147;Stipulation&#148;), which shall remain
in effect for no less than five years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>Please note that there is no proof of claim form for shareholders to submit in connection with
this Settlement, and shareholders are not required to take any action in response to this Notice. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Also, please note that this Notice
is not an expression of any opinion by the Court with respect to the truth of the allegations in the Action or the merits of the claims or defenses asserted by or against any Party. It is solely to notify you of the pendency of the Action and the
terms of the proposed Settlement, and your rights related thereto. Capitalized terms not otherwise defined herein shall have the definitions set forth in the Stipulation. A copy of the Stipulation may be found on Walgreens&#146;s website at
http://investor.walgreensbootsalliance.com. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt" BGCOLOR="#cdd4e9">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt" BGCOLOR="#d1d1d1">&nbsp;</TD></TR>
<TR BGCOLOR="#cdd4e9" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="padding-bottom:2pt ;BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt; padding-right:2pt" BGCOLOR="#d1d1d1"><B>&#8194;WHAT IS THE PURPOSE OF THIS
NOTICE?</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman">1.&#8195; The purpose of this Notice is to explain the Action, the terms of the proposed Settlement, and how
the proposed Settlement affects Walgreens shareholders&#146; legal rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2.&#8195; In a derivative action, one or more
people who are current shareholders of a corporation sue on behalf of and for the benefit of the corporation, seeking to enforce the corporation&#146;s legal rights. In this case, Plaintiff filed suit on behalf of Walgreens asserting claims against
defendants Stefano Pessina, Jos&eacute; E. Almeida, Janice M. Babiak, David J. Brailer, William C. Foote, Ginger L. Graham, John A. Lederer, Dominic Murphy, Leonard D. Schaeffer, Nancy M. Schlichting, and James A. Skinner (collectively, the
&#147;Individual Defendants&#148; and together with nominal defendant Walgreens, the &#147;Defendants&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">3.&#8195;
The Court will hold a hearing (the &#147;Settlement Hearing&#148;) on <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>, 2024, at <U>&#8195;</U>:<U>&#8195;</U> <U>&#8195;</U>.m., at the United&nbsp;States District Court for the Northern District of
Illinois, 219 South Dearborn St., Chicago, IL 60604, at which the Court will: (a)&nbsp;determine whether the Settlement should be approved by the Court as fair, reasonable, and adequate; (b)&nbsp;determine whether the Court should enter the Judgment
dismissing the Action with prejudice pursuant to the Stipulation; (c)&nbsp;determine whether to approve the <FONT STYLE="white-space:nowrap">agreed-to</FONT> amount of attorneys&#146; fees and expenses to be paid to Plaintiff&#146;s Counsel;
(d)&nbsp;hear and determine any objections to the Settlement or to the fee and service awards; and (e)&nbsp;rule on such other matters as the Court may deem appropriate. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 49
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt" BGCOLOR="#cdd4e9">
<TD HEIGHT="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt" BGCOLOR="#d1d1d1">&nbsp;</TD></TR>
<TR BGCOLOR="#cdd4e9" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="padding-bottom:10pt ;BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt; padding-right:2pt" BGCOLOR="#d1d1d1"><B>&#8194;WHAT IS THIS CASE ABOUT? WHAT HAS HAPPENED
SO FAR?</B></TD></TR>
</TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">THE FOLLOWING DESCRIPTION OF THE ACTION AND THE SETTLEMENT HAS BEEN PREPARED BY COUNSEL FOR THE PARTIES. THE
COURT HAS MADE NO FINDINGS WITH RESPECT TO SUCH MATTERS, AND THIS NOTICE IS NOT AN EXPRESSION OR STATEMENT BY THE COURT OF FINDINGS OF FACT, OR AN AGREEMENT BY THE DEFENDANTS THAT ANY ALLEGATION IS CORRECT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4.&#8195; The above-captioned action (&#147;Action&#148;) is a shareholder derivative action brought for the benefit of
Walgreens. The Action alleges that certain current and former officers and directors of Walgreens breached their fiduciary duties to the Company by failing to adequately oversee opioids-related matters, including Walgreens&#146;s compliance with the
Controlled Substances Act (&#147;CSA&#148;). </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5.&#8195; Specifically, the Action alleges that the Board failed to
adequately oversee the Company&#146;s compliance with a 2013 settlement agreement with the Drug Enforcement Administration and with the CSA, which harmed the Company by exposing it to liability, including in expansive multi-district litigation and
other opioids-related litigation and proceedings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">6.&#8195; On September&nbsp;23, 2022, Plaintiff filed a shareholder
derivative action on behalf of Walgreens in the United States District Court for the Northern District of Ohio (the &#147;N.D. Ohio Action&#148;), asserting claims for breach of fiduciary duty, unjust enrichment, and violations of Section&nbsp;14(a)
of the Securities Exchange Act of 1934. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">7.&#8195; One year later, on September&nbsp;22, 2023, the court in that case
ruled that the Northern District of Ohio was an improper venue for the litigation, and thus dismissed the N.D. Ohio Action without prejudice for refiling in a proper venue. Plaintiff selected the Northern District of Illinois as the venue for the
refiling of its claims. Accordingly, it filed the Complaint in the above-captioned action on November&nbsp;4, 2023, raising the same allegations and claims as it had previously asserted in the N.D. Ohio Action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">8.&#8195; On September&nbsp;21, 2023, Plaintiff served a settlement demand on the Individual Defendants. The demand called for
a material monetary payment to be made to the Company by the D&amp;O Insurers, as well as corporate governance reforms to be implemented at the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">9.&#8195; To facilitate their settlement discussions, the Parties retained the Hon. Layn R. Phillips (Ret.) of Phillips ADR
Enterprises, an experienced and respected mediator. Under the guidance of Judge Phillips and Michelle Yoshida, Esq., also of Phillips ADR Enterprises, the Parties exchanged counteroffers in January 2024, and convened for a <FONT
STYLE="white-space:nowrap">two-day,</FONT> <FONT STYLE="white-space:nowrap">in-person</FONT> mediation on February&nbsp;10 and 11, 2024, in New York City. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 50
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">10.&#8195; Although no settlement was reached by the end of the <FONT STYLE="white-space:nowrap">in-person</FONT> mediation,
settlement negotiations continued under Judge Phillips&#146;s supervision. Ultimately, the Parties agreed to the Settlement and executed a term sheet on February&nbsp;23, 2024. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt" BGCOLOR="#cdd4e9">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt" BGCOLOR="#d1d1d1">&nbsp;</TD></TR>
<TR BGCOLOR="#cdd4e9" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="padding-bottom:10pt ;BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt; padding-right:2pt" BGCOLOR="#d1d1d1"><B>&#8194;WHAT ARE THE TERMS OF THE
SETTLEMENT?</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">11.&#8195; In consideration for the full and final release, settlement, and discharge of any
and all Released Claims and the dismissal with prejudice of the Action, Walgreens will receive a monetary payment from the D&amp;O Insurers of $36,000,000.00. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">12.&#8195; Walgreens and its Board will also adopt, implement, and/or initiate corporate governance changes (the
&#147;Reforms&#148;) for a period of not less than five years. The Reforms include, among other things: </P> <P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">The creation of a Compliance, Safety, and Quality Committee of the Board, which shall be dedicated to the
oversight of compliance, safety, and quality risks; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">The appointment of two new independent directors to the Board; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">The creation of the U.S. Retail Pharmacy Governance, Risk, and Compliance Committee, a management-level
committee charged with overseeing key compliance and safety matters relating to the Company&#146;s pharmacy and retail operations; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Changes to the responsibilities of the Chief Controlled Substance Compliance Officer; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Changes to the responsibilities of the Controlled Substance Compliance Committee. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt" BGCOLOR="#cdd4e9">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt" BGCOLOR="#d1d1d1">&nbsp;</TD></TR>
<TR BGCOLOR="#cdd4e9" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt; padding-right:2pt" BGCOLOR="#d1d1d1"><B>&#8194;WHAT ARE THE PARTIES&#146; REASONS FOR THE
SETTLEMENT?</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">13.&#8195; Plaintiff and Plaintiff&#146;s Counsel believed at all times and continue to
believe that the claims asserted in the Action have merit. Plaintiff and Plaintiff&#146;s Counsel also recognize the substantial time, expense, and uncertainty inherent in the continued prosecution of the claims through trial and any subsequent
appeal, including problems of proof, overcoming the available defenses, the difficulties of proving and measuring damages, and the challenges of collecting on any damages awarded at trial. Based on their thorough investigation and evaluation,
Plaintiff and Plaintiff&#146;s Counsel have determined that the Settlement set forth in this Stipulation is appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">14.&#8195; Plaintiff&#146;s Counsel&#146;s conclusion is based on their extensive and thorough investigation and evaluation of
information, which included, <I>inter alia</I>: (i)&nbsp;reviewing Walgreens<B> </B>press releases, public statements, SEC filings, and securities analysts&#146; reports and advisories about the Company; (ii)&nbsp;reviewing media reports about the
Company; (iii)&nbsp;researching the applicable law </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 51
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">with respect to the claims alleged in the Action and potential defenses thereto; (iv)&nbsp;preparation and filing of the Action as well as
litigation of the N.D. Ohio Action; (v)&nbsp;reviewing and analyzing relevant pleadings, exhibits, and other documents from the national opioids multi-district litigation captioned <I>In re National Prescription Opiate Litigation</I>, No. <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1:17-md-2804</FONT></FONT> (N.D. Ohio); (vi) reviewing the Company&#146;s existing corporate governance policies and preparing a settlement demand detailing proposed corporate governance
reforms to strengthen the Company&#146;s governance; (vii)&nbsp;participating in mediation sessions and extensive settlement discussions with Defendants&#146; Counsel; and (viii)&nbsp;negotiating the term sheet executed by the Parties on
February&nbsp;23, 2024, and the Stipulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">15. &#8195;Plaintiff&#146;s Counsel&#146;s assessment of the facts and legal
issues material to their recommendation in favor of the Settlement was honed and refined over the course of months of substantive written and verbal exchanges with counsel for Defendants and the Mediator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">16. &#8195;Based on Plaintiff&#146;s Counsel&#146;s thorough review and analysis of the relevant facts, allegations, defenses,
and controlling legal principles, Plaintiff and Plaintiff&#146;s Counsel have concluded that the Settlement set forth in the Stipulation is fair, reasonable, and adequate, and that the Settlement confers substantial benefits upon and is in the best
interests of Walgreens and its shareholders, including through the substantial financial component to be paid to the Company and the adoption and/or implementation of the Reforms. Accordingly, Plaintiff has agreed to settle the Action upon the terms
set forth in the Stipulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">17. &#8195;The Individual Defendants have denied and continue to deny each and all of the
claims alleged by Plaintiff in this Action. In particular, the Individual Defendants have expressly denied and continue to deny each and all charges of wrongdoing or liability against them relating to opioids, arising out of any of the conduct,
statements, acts, inaction, or omissions alleged in the Action, or arising out of any claim related to opioids that could have been alleged in the Action. Without limiting the foregoing, the Individual Defendants have denied, and continue to deny,
among other things, that they breached their fiduciary duties or any other duty owed to Walgreens or its shareholders, or that they or the Company committed or engaged in any violation of law or improper action. The Individual Defendants have
further asserted, and continue to assert, that at all relevant times, they acted in good faith and in a manner they reasonably believed to be in the best interests of Walgreens and its shareholders. In addition, the Individual Defendants maintain
that they have meritorious defenses to all claims alleged in the Action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">18. &#8195;Nonetheless, Defendants have
concluded that further litigation could cause burden, inconvenience, expense, uncertainty, and distraction, and that it is desirable and beneficial to finally put to rest and terminate all of the claims that have been, or could have been, asserted
in the Action. Defendants have therefore determined that the Settlement confers a substantial benefit upon Walgreens and its shareholders, and the Settlement, and each of its terms, is in all respects fair, reasonable, and in the best interests of
Walgreens and its shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">19. &#8195;Walgreens&#146;s current Board of Directors acknowledges, in an exercise of
its independent business judgment, that the initiation, prosecution, and settlement of the Action was the cause of consideration for this Settlement, and that the Settlement is fair, reasonable, and adequate, and confers substantial benefits to
Walgreens and its shareholders. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 52
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt; padding-right:2pt" BGCOLOR="#d1d1d1"><B>WHAT WILL HAPPEN IF THE SETTLEMENT IS APPROVED? WHAT CLAIMS WILL THE SETTLEMENT RELEASE?</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">20. &#8195;At the Settlement Hearing, the Parties shall jointly request that the Court enter
the Judgment finally approving the Settlement. Pursuant to the Judgment, upon the Effective Date of the Settlement (as defined in the Stipulation), the Action will be dismissed with prejudice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">21. &#8195;The Settlement is conditioned upon the occurrence of certain events, which include, among other things, entry of an
order by the Court approving the Settlement and dismissing the Action with prejudice. The Settlement will not become effective until such an order has been entered and become final and <FONT STYLE="white-space:nowrap">non-appealable</FONT> (the
&#147;Effective Date&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">22. &#8195;Upon the Effective Date, the Releasing Parties shall be deemed to have fully,
finally, and forever released, relinquished, and discharged the Released Claims (including Unknown Claims), including against the Released Persons, and any and all claims arising out of, relating to, or in connection with the defense, settlement, or
resolution of the Action against the Released Persons. In addition, upon the Effective Date, each of the Defendants shall be deemed to have fully, finally, and forever released, relinquished, and discharged Plaintiff and Plaintiff&#146;s Counsel
from all claims (including Unknown Claims), arising out of, relating to, or in connection with the institution, prosecution, assertion, settlement, or resolution of the Action or the Released Claims. Nothing in these releases, however, shall in any
way impair or restrict the rights of any Party to enforce the Settlement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt; padding-right:2pt" BGCOLOR="#d1d1d1"><B>HOW WILL PLAINTIFF&#146;S COUNSEL BE PAID?</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">23. &#8195;After negotiating the substantive terms of the Settlement, the Parties commenced
negotiations regarding the attorneys&#146; fees and expenses to be paid to Plaintiff&#146;s Counsel. In recognition of Plaintiff&#146;s Counsel&#146;s role in prosecuting and settling the Action and the substantial benefits conferred upon the
Company and its shareholders as a result of the Settlement, and subject to Court approval, Walgreens agrees that Plaintiff&#146;s Counsel&#146;s should receive a fee and expense award of $8,000,000.00 (the &#147;Fee and Expense Amount&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">24. &#8195;Plaintiff&#146;s Counsel may also apply to the Court for a service award of up to $2,500 for Plaintiff, only to be
paid upon Court approval, and to be paid from the Fee and Expense Amount in recognition of Plaintiff&#146;s participation and effort in the prosecution of the Action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">25. &#8195;To date, Plaintiff&#146;s Counsel have neither received any payment for their services in conducting the Action,
nor been reimbursed for their <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 53
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt; padding-right:2pt" BGCOLOR="#d1d1d1"><B>WHEN AND WHERE WILL THE SETTLEMENT HEARING BE HELD? DO I HAVE THE RIGHT TO APPEAR AT THE SETTLEMENT HEARING?</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">26. &#8195;The Court will consider the Settlement and all matters related to the Settlement at
the Settlement Hearing. The Settlement Hearing will be held before The Honorable Matthew F. Kennelly, on <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>, 2024 at <U>&#8195;</U>:<U>&#8195;</U> <U>&#8194;</U>.m., at the United States District Court for the
Northern District of Illinois, 219 South Dearborn St., Chicago, IL 60604, at which the Court will: (a)&nbsp;determine whether the Settlement should be approved by the Court as fair, reasonable, and adequate; (b)&nbsp;determine whether the Court
should enter the Judgment dismissing the Action with prejudice pursuant to the Stipulation; (c)&nbsp;determine whether to approve the <FONT STYLE="white-space:nowrap">agreed-to</FONT> amount of attorneys&#146; fees and expenses to be paid to
Plaintiff&#146;s Counsel; (d)&nbsp;hear and determine any objections to the Settlement or to the fee and service awards; and (e)&nbsp;rule on such other matters as the Court may deem appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">27. &#8195;Any Walgreens Shareholder (<I>i.e.</I>, any person or entity who owned Walgreens common stock as of April&nbsp;10,
2024, and continues to own Walgreens common stock through <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>, 2024, the date of the Settlement Hearing) may object to the terms and conditions of the Settlement and/or to the payment of the Fee and Expense
Amount. Objections must be in writing and must be filed, together with copies of all other papers and briefs supporting the objection, with the Clerk of the Court at the address set forth below on or before
<U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>, 2024. Objections must also be served on Plaintiff&#146;s Counsel and Defendants&#146; Counsel (by first-class U.S. mail or express service) at the addresses set forth below so that the objection is
<B><I>received</I></B><B> </B>on or before <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>, 2024. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="bottom" ALIGN="center"><B><U>Clerk of the Court</U></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Representative</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>Plaintiff&#146;s Counsel</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Representative</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>Defendants&#146; Counsel</U></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="bottom" ALIGN="center">United States District Court</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Matthew T. Hurst</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">John M. Skakun III</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="bottom" ALIGN="center">Northern District of Illinois</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Heffner Hurst</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Sidley Austin LLP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="bottom" ALIGN="center">219 South Dearborn St.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">30 North LaSalle Street</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">One South Dearborn Street</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="bottom" ALIGN="center">Chicago, IL 60604</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Suite 1210</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Chicago, IL 60603</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Chicago, IL 60602</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">28. &#8195;Any objection: (a)&nbsp;must state the name, address, and telephone
number of the person or entity objecting and, if represented by counsel, the name, address and telephone number of his, her, or its counsel; (b)&nbsp;must be signed by the shareholder; (c)&nbsp;must contain a written, specific statement of the
shareholder&#146;s objection or objections, and the specific reasons for each objection, including any legal and evidentiary support the shareholder wishes to bring to the Court&#146;s attention; (d)&nbsp;must state that the objection is being filed
with respect to &#147;<I>Vladimir Gusinsky Revocable Trust v. Pessina</I>, Case No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">23-cv-15654&#148;;</FONT></FONT> (e) must include documentation sufficient to prove that the
shareholder held shares of Walgreens common stock as of the close of business on<U>&#8195;&#8195;&#8195;&#8195;</U> <U>&#8195;</U>, 2024 and the date the objection is made; and (f)&nbsp;must state the dates when the shareholder acquired Walgreens
shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">29. &#8195;You may file a written objection without having to appear at the Settlement Hearing. You may not,
however, appear at the Settlement Hearing to present your objection unless you first filed and served a written objection in accordance with the procedures described above, unless the Court orders otherwise. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 54
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">30. &#8195;If you wish to be heard orally at the hearing in opposition to the approval of the Settlement, and if you file and
serve a timely written objection as described above, you must also file a notice of appearance with the Clerk of the Court and serve it on Plaintiff&#146;s Counsel and Defendants&#146; Counsel at the addresses set forth above so that it is
<B><I>received</I></B> on or before <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>, 2024. Shareholders who intend to object and desire to present evidence at the Settlement Hearing must include in their written objection or notice of appearance the
identity of any witnesses they may call to testify and exhibits they intend to introduce into evidence at the hearing. Any person appearing at the Settlement Hearing must present at the hearing documentation sufficient to prove that the shareholder
continues to hold shares of Walgreens common stock as of the date of the hearing. Such persons may be heard orally at the discretion of the Court. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">31. &#8195;You are not required to hire an attorney to represent you in making written objections or in appearing at the
Settlement Hearing. However, if you decide to hire an attorney, it will be at your own expense, and that attorney must file a notice of appearance with the Court and serve it on Plaintiff&#146;s Counsel and Defendants&#146; Counsel at the addresses
set forth above so that the notice is <B><I>received</I></B><I> </I>on or before <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">32. &#8195;Unless the Court otherwise directs, any person or entity who fails to object in the manner prescribed above shall
be deemed to have waived his, her, or its right to object and shall forever be barred from raising any objection to the Settlement and/or the Fee and Expense Amount, or any other matter related to the Settlement, in the Action or in any other action
or proceeding, and shall otherwise be bound by the Order and Final Judgment to be entered by the Court and the Releases to be given. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt; padding-right:2pt" BGCOLOR="#d1d1d1"><B>WHOM SHOULD I CONTACT IF I HAVE QUESTIONS?</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">33. &#8195;This Notice does not purport to be a comprehensive description of the Action, the
allegations related thereto, the terms of the Settlement, or the Settlement Hearing. For a more detailed statement of the matters involved in the Action, you may inspect the pleadings, the Stipulation, the Orders entered by the Court, and other
papers filed in the Action at the Office of the Clerk, United States District Court for the Northern District of Illinois, during regular business hours of each business day. You may also view a copy of the Stipulation at
http://investor.walgreensbootsalliance.com. If you have questions regarding the Settlement, you may write or call the following counsel for Plaintiff: Matthew T. Hurst, Esq., Heffner Hurst, 30 N. LaSalle St., Suite 1210, Chicago, IL 60602 (312) <FONT
STYLE="white-space:nowrap">346-3466</FONT> or <U>mhurst@heffnerhurst.com</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PLEASE DO NOT CONTACT THE COURT OR WALGREENS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REGARDING THIS NOTICE. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 55
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="59%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-size:12pt">DATED: <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>, 2024</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">&#8195;&#8195;&#8195;&#8195;&#8195;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">BY ORDER OF THE UNITED STATES</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">DISTRICT COURT
FOR THE NORTHERN</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman">DISTRICT OF ILLINOIS</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 56
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:50pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT D </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 57
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES DISTRICT COURT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>NORTHERN DISTRICT OF ILLINOIS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>EASTERN DIVISION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">VLADIMIR GUSINSKY REVOCABLE TRUST, Derivatively on Behalf of WALGREENS BOOTS ALLIANCE, INC.,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#8195;Case No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">23-cv-15654</FONT></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; font-size:12pt; font-family:Times New Roman">&#8195;&#8195;&#8195;&#8195;&#8195;Plaintiff,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>&#8195;EXHIBIT D &#150; SUMMARY</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>&#8195;NOTICE</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; font-size:12pt; font-family:Times New Roman">v.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">STEFANO PESSINA, JOSE E. ALMEIDA, JANICE M. BABIAK, DAVID J. BRAILER, WILLIAM C. FOOTE, GINGER L. GRAHAM, JOHN A. LEDERER, DOMINIC MURPHY, LEONARD D. SCHAEFFER, NANCY M.
SCHLICHTING, and JAMES A. SKINNER,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7.00em; font-size:12pt; font-family:Times New Roman">&#8195;&#8195;&#8195;&#8195;&#8195;Defendants,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:7.00em; font-size:12pt; font-family:Times New Roman">and</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">WALGREENS BOOTS ALLIANCE, INC., a Delaware Corporation,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="padding-bottom:12pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; font-size:12pt; font-family:Times New Roman">&#8195;&#8195;&#8195;&#8195;&#8195;Nominal&nbsp;Defendant.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #cdd4e9">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #cdd4e9">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SUMMARY NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>SHAREHOLDER DERIVATIVE ACTION</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>TO: ALL PERSONS WHO OWNED SHARES OF THE COMMON STOCK OF WALGREENS BOOTS ALLIANCE, INC. (&#147;WALGREENS&#148; OR THE &#147;COMPANY&#148;)
AS OF APRIL&nbsp;10, 2024 (&#147;WALGREENS SHAREHOLDERS&#148;). </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>PLEASE READ THIS SUMMARY NOTICE CAREFULLY, YOUR RIGHTS WILL BE
AFFECTED BY PROCEEDINGS IN THE LITIGATION. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">YOU ARE HEREBY NOTIFIED, pursuant to Rule 23.1 of the Federal Rules of
Civil Procedure and an Order of the United States District Court for the Northern District of Illinois (the &#147;Court&#148;), of (i)&nbsp;the pendency of the above-captioned shareholder derivative action (the &#147;Action&#148;), which was brought
on behalf of and for the benefit of nominal defendant Walgreens; and (ii)&nbsp;a proposed settlement of the Actions (the &#147;Settlement&#148;), subject to Court approval, on the terms and conditions set forth in a Stipulation and Agreement of
Settlement (the &#147;Stipulation&#148;) filed with the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 58
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Court and available for review as indicated below. On <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>, 2024, at <U>&#8195;&#8195;&#8195;</U>
<U>&#8195;</U>.m., a hearing (the &#147;Settlement Hearing&#148;) will be held before the Honorable Matthew F. Kennelly, at the U.S. District Court for the Northern District of Illinois, 219 South Dearborn St., Chicago, IL 60604, to:
(a)&nbsp;determine whether the Settlement should be approved by the Court as fair, reasonable, and adequate; (b)&nbsp;determine whether the Court should enter the Judgment dismissing the Action with prejudice pursuant to the Stipulation;
(c)&nbsp;determine whether to approve the <FONT STYLE="white-space:nowrap">agreed-to</FONT> amount of attorneys&#146; fees and expenses to be paid to Plaintiff&#146;s Counsel; (d)&nbsp;hear and determine any objections to the Settlement or to the
fee and service awards; and (e)&nbsp;rule on such other matters as the Court may deem appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">This<B> </B>is a
summary notice only. A more detailed Notice of Pendency and Proposed Settlement of Shareholder Derivative Action and of Settlement Hearing (the &#147;Notice&#148;) that provides additional information concerning the Action, the terms of the proposed
Settlement, and Walgreens Shareholders&#146; legal rights with respect to the proposed Settlement is being furnished to the Securities and Exchange Commission. You may also obtain a copy of the Notice, as well as a copy of the Stipulation, from
Walgreens&#146;s website, http://investor.walgreensbootsalliance.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">If you owned shares of Walgreens common stock as of
April&nbsp;10, 2024 and continue to own such shares through <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>, 2024 (the date of the Settlement Hearing), you may, if you wish to do so, comment to the Court on the proposed Settlement and/or the amount of
attorneys&#146; fees and service awards. Any objections to the proposed Settlement and/or the attorneys&#146; fees and service awards must be filed with the Court and delivered to counsel for Plaintiff and Defendants such that they are received by
no later than <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>, 2024, in accordance with the instructions set forth in the Notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>PLEASE DO
NOT CONTACT THE COURT, THE CLERK&#146;S OFFICE, OR WALGREENS REGARDING THIS NOTICE OR THE PROPOSED SETTLEMENT</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">All questions about
this notice or the proposed Settlement should be directed to the following counsel for Plaintiff: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">Matthew T. Hurst, Esq. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">Heffner Hurst </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">30 N. LaSalle St.,
Suite 1210 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">Chicago IL 60602 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">(312) <FONT STYLE="white-space:nowrap">346-3466</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><U>mhurst@heffnerhurst.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="right">By
Order of the Court </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 59
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:50pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT E </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 60
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES DISTRICT COURT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>NORTHERN DISTRICT OF ILLINOIS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>EASTERN DIVISION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">VLADIMIR GUSINSKY REVOCABLE TRUST, Derivatively on Behalf of WALGREENS BOOTS ALLIANCE, INC.,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#8195;Case No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">23-cv-15654</FONT></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; font-size:12pt; font-family:Times New Roman">&#8195;&#8195;&#8195;&#8195;&#8195;Plaintiff,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>&#8195;EXHIBIT E &#150; [PROPOSED]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>&#8195;ORDER&nbsp;&amp; FINAL JUDGMENT</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; font-size:12pt; font-family:Times New Roman">v.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">STEFANO PESSINA, JOSE E. ALMEIDA, JANICE M. BABIAK, DAVID J. BRAILER, WILLIAM C. FOOTE, GINGER L. GRAHAM, JOHN A. LEDERER, DOMINIC MURPHY, LEONARD D. SCHAEFFER, NANCY M.
SCHLICHTING, and JAMES A. SKINNER,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7.00em; font-size:12pt; font-family:Times New Roman">&#8195;&#8195;&#8195;&#8195;&#8195;Defendants,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:7.00em; font-size:12pt; font-family:Times New Roman">and</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">WALGREENS BOOTS ALLIANCE, INC., a Delaware Corporation,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="padding-bottom:12pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; font-size:12pt; font-family:Times New Roman">&#8195;&#8195;&#8195;&#8195;&#8195;Nominal&nbsp;Defendant.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #cdd4e9">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #cdd4e9">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:40pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">This matter came before the Court for hearing pursuant to the Court&#146;s Order Preliminarily
Approving Settlement, dated <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>, 2024 (the &#147;Preliminary Approval Order&#148;), and on Plaintiff&#146;s motion for final approval of the settlement of the Action as set forth in the Stipulation and
Agreement of Settlement dated April&nbsp;10, 2024 (the &#147;Stipulation&#148;). Due and adequate notice having been given to Walgreens Shareholders as required in said Preliminary Approval Order, the Court having reviewed and considered all
relevant documents, evidence, objections (if any), and arguments presented in support of or against the Settlement and otherwise being fully informed in the premises, and good cause appearing therefore, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 61
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">IT IS HEREBY ORDERED, ADJUDGED, AND DECREED that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1. &#8195;This Order and Final Judgment (&#147;Judgment&#148;) incorporates by reference the definitions in the Stipulation,
and unless otherwise defined herein, all capitalized terms used herein shall have the same meanings as set forth in the Stipulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2. &#8195;The Court has jurisdiction to enter this Order and Final Judgment. The Court has jurisdiction over the subject
matter of the Action, including all matters necessary to effectuate the Settlement, and the Parties to the Stipulation have consented to the jurisdiction of the Court for purposes of implementing and enforcing the Settlement embodied in the
Stipulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">3. &#8195;The Court finds that the Settlement set forth in the Stipulation is fair, reasonable, and
adequate, and in the best interests of Walgreens and Walgreens Shareholders, and pursuant to Fed. R. Civ. P. 23.1, the Court hereby finally approves the Settlement in all respects, finds that the Settlement set forth in the Stipulation confers
substantial benefits upon and is in the best interests of Walgreens and Walgreens Shareholders, and orders the Parties to perform its terms to the extent the Parties have not already done so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4. &#8195;The Action and all claims contained therein, as well as all of the Released Claims (including Unknown Claims), are
hereby ordered as compromised, settled, released, and discharged and are dismissed on the merits and with prejudice by virtue of the proceedings herein and this Order and Final Judgment, and as set forth in the Stipulation. As among Plaintiff,
Walgreens, and the Individual Defendants, the Parties are to bear their own costs, except as otherwise provided in the Stipulation, the Preliminary Approval Order, and this Order and Final Judgment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 62
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5. &#8195;Upon the Effective Date of the Settlement, Plaintiff, all other Walgreens Shareholders, Plaintiff&#146;s Counsel, and
Walgreens shall be deemed to have, and by operation of law and of the Judgment shall have, fully, finally, and forever released, relinquished, and discharged their right to assert any and all of the Released Claims (including Unknown Claims),
including against the Released Persons, as well as any and all claims arising out of, relating to, or in connection with the defense, settlement, or resolution of the Action, including against the Released Persons, and shall forever be barred and
enjoined from instituting, commencing, or prosecuting derivatively on behalf of the Company any and all of the Released Claims, including against the Released Persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">6. &#8195;Upon the Effective Date of the Settlement, Defendants shall be deemed to have, and by operation of law and of the
Judgment shall have, fully, finally, and forever released, relinquished, and discharged Plaintiff and Plaintiff&#146;s Counsel from all claims (including Unknown Claims), arising out of, relating to, or in connection with the institution,
prosecution, assertion, settlement, or resolution of the Action or the Released Claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">7. &#8195;Notwithstanding
paragraphs 5 and 6 above, nothing in this Order and Final Judgment shall in any way impair or restrict the rights of any Party to enforce the terms of the Stipulation or this Order and Final Judgment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">8. &#8195;The Court finds that the notice to Walgreens Shareholders (a)&nbsp;was provided pursuant to and in the form and
manner directed by the Preliminary Approval Order; (b)&nbsp;meets the requirements of Fed. R. Civ. P. 23.1 and due process; and (c)&nbsp;constitutes due and sufficient notice of all matters relating to the Settlement to all Persons entitled to such
notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">9. &#8195;Pursuant to and in compliance with Fed. R. Civ. P. 23.1 and due process, the Court hereby finds that
the notice provided advised Persons in interest of the terms of the Settlement and the Fee and Expense Amount and of their right to object thereto, and a full and fair opportunity was accorded to all Persons entitled to be heard with respect to the
foregoing matters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 63
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">10. &#8195;This Court finds that the Action has been properly maintained as a derivative action according to the provisions of
Fed. R. Civ. P. 23.1, and the Court finds that throughout the course of the Action, the Parties and their counsel at all times complied with the requirements of Fed. R. Civ. P. 11. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">11. &#8195;The Court hereby approves the Fee and Expense Amount, which sum the Court finds to be fair and reasonable. No other
fees, costs, or expenses may be awarded to Plaintiff&#146;s Counsel in connection with the Settlement. The Court also hereby approves payment of the Service Award, which shall be funded from the Fee and Expense Amount. The Fee and Expense Amount
shall be paid in accordance with the terms of the Stipulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">12. &#8195;No proceedings or court order with respect to
the Fee and Expense Amount or Service Award shall in any way disturb or affect this Order and Final Judgment (including precluding this Order and Final Judgment from being final or otherwise being entitled to preclusive effect), and any such
proceedings or court order shall be considered separate from this Order and Final Judgment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">13. &#8195;Neither the
Stipulation (whether or not consummated), including the exhibits thereto, the negotiations leading to the execution of the Stipulation, nor any proceedings taken pursuant to or in connection with the Stipulation and/or approval of the Settlement
(including any arguments proffered in connection therewith): (i) shall be offered against any of the Released Persons as evidence of, or construed as, or deemed to be evidence of any presumption, concession, or admission by any of the Released
Persons with respect to the truth of any fact alleged by Plaintiff or the validity of any claim that was or could have been asserted or the deficiency of any defense </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 64
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">that has been or could have been asserted in the Action or in any other litigation or proceeding, or of any liability, negligence, fault, or
other wrongdoing of any kind of any of the Released Persons or in any way referred to for any other reason as against any of the Released Persons, in any civil, criminal, or administrative action or proceeding, other than such proceedings as may be
necessary to effectuate the Settlement; or (ii)&nbsp;shall be offered against any of the Releasing Parties as evidence of, or construed as, or deemed to be evidence of any presumption, concession, or admission by any of the Releasing Parties that
any of Plaintiff&#146;s claims are without merit, that any of the Defendants had meritorious defenses, or that damages recoverable under the Complaint would not have exceeded the Settlement consideration or with respect to any liability, negligence,
fault, or wrongdoing of any kind, or in any way referred to for any other reason as against any of the Releasing Parties, in any civil, criminal, or administrative action or proceeding, other than such proceedings as may be necessary to effectuate
the Settlement; provided, however, that the Parties, the Released Persons, and their respective counsel may file the Stipulation and/or this Order and Final Judgment, and file or reference acts performed or documents executed pursuant to or in
furtherance of the Stipulation and/or the Judgment: (i)&nbsp;in any action that may be brought against them in order to support a defense or counterclaim based on principles of res judicata, collateral estoppel, full faith and credit, release,
good-faith settlement, judgment bar or reduction, or any other theory of claim preclusion or issue preclusion or similar defense or counterclaim; (ii)&nbsp;in furtherance of the Settlement contemplated in the Stipulation; and (iii)&nbsp;in any
action to enforce the Settlement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">14. &#8195;Without affecting the finality of this Order and Final Judgment in any way,
the Court hereby retains continuing jurisdiction over: (a)&nbsp;implementation of the Settlement; (b)&nbsp;the Parties for the purpose of construing, enforcing, and administering the Stipulation and this Order and Final Judgment; and (c)&nbsp;any
other matters related to the foregoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#0000ff"> Case: 1:23-cv-15654 Document #: 21-1 Filed: 04/10/24 Page
 65
 of 65 PageID #:124 </FONT></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">15. &#8195;Without further approval from the Court, the Parties are hereby authorized to agree to and adopt such amendments or
modifications of the Stipulation to effectuate the Settlement that: (a)&nbsp;are not materially inconsistent with this Order and Final Judgment; and (b)&nbsp;do not materially limit the rights of Walgreens Shareholders in connection with the
Settlement. Without further order of the Court, the Parties may agree to reasonable extensions of time to carry out any provisions of the Settlement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">16. &#8195;This Order and Final Judgment is a final, appealable judgment and should be entered by the Clerk of the Court
forthwith in accordance with Fed. R. Civ. P. 58. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">IT IS SO ORDERED. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">DATED: <U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>, 2024 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:12pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#8195;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Honorable Matthew F. Kennelly</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d821017dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES DISTRICT COURT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>NORTHERN DISTRICT OF ILLINOIS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>EASTERN DIVISION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="51%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">VLADIMIR GUSINSKY REVOCABLE TRUST, Derivatively on Behalf of WALGREENS BOOTS ALLIANCE, INC.,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#8195;Case No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">23-cv-15654</FONT></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; font-size:12pt; font-family:Times New Roman">&#8195;&#8195;&#8195;&#8195;&#8195;Plaintiff,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>&#8195;NOTICE OF PENDENCY AND</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>&#8195;PROPOSED SETTLEMENT OF</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; font-size:12pt; font-family:Times New Roman">v.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>&#8195;SHAREHOLDER DERIVATIVE</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>&#8195;ACTION AND OF</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">STEFANO PESSINA, JOSE E. ALMEIDA, JANICE M. BABIAK, DAVID J. BRAILER, WILLIAM C. FOOTE, GINGER L. GRAHAM, JOHN A. LEDERER, DOMINIC MURPHY, LEONARD D. SCHAEFFER, NANCY M.
SCHLICHTING, and JAMES A. SKINNER,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>&#8195;SETTLEMENT HEARING</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7.00em; font-size:12pt; font-family:Times New Roman">&#8195;&#8195;&#8195;&#8195;&#8195;Defendants,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:7.00em; font-size:12pt; font-family:Times New Roman">and</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">WALGREENS BOOTS ALLIANCE, INC., a Delaware Corporation,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" STYLE="padding-bottom:12pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; font-size:12pt; font-family:Times New Roman">&#8195;&#8195;&#8195;&#8195;&#8195;Nominal&nbsp;Defendant.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>SHAREHOLDER DERIVATIVE ACTION AND OF SETTLEMENT HEARING</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>TO: ALL PERSONS WHO OWNED SHARES OF THE COMMON STOCK OF WALGREENS BOOTS ALLIANCE, INC. (&#147;WALGREENS&#148; OR THE &#147;COMPANY&#148;)
AS OF APRIL&nbsp;10, 2024 (&#147;WALGREENS SHAREHOLDERS&#148;). </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY.</B> This
Notice relates to a proposed settlement (the &#147;Settlement&#148;) of the above-captioned shareholder derivative action brought in the United States District Court for the Northern District of Illinois (the &#147;Court&#148;). Your rights will be
affected by the legal proceedings in the Action. If the Court approves the Settlement, you will be forever barred from pursuing the Plaintiff&#146;s Released Claims (defined below) against the Defendants&#146; Released Persons (defined below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>THIS ACTION IS NOT A &#147;CLASS ACTION.&#148; THUS, THERE IS NO COMMON FUND UPON WHICH YOU CAN MAKE A CLAIM FOR A MONETARY PAYMENT.
</B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">As more fully described below, Plaintiff Vladimir Gusinsky Revocable Trust
(&#147;Plaintiff&#148;) alleges in the Action that the Individual Defendants breached their fiduciary duties to the Company by failing to adequately oversee opioids-related matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the Settlement, Walgreens&#146;s current Board of Directors has acknowledged, in an exercise of its independent business judgment,
that the Settlement confers substantial benefits to Walgreens and Walgreens Shareholders, and that the initiation, prosecution, and settlement of the Action caused: (1)&nbsp;Walgreens&#146;s receipt of a $36,000,000.00 cash payment from its and/or
the Individual Defendants&#146; directors and officers insurance carriers (the &#147;D&amp;O Insurers&#148;); and (2)&nbsp;the adoption and/or implementation of corporate governance reforms (the &#147;Reforms&#148;), attached as Exhibit A to the
Stipulation and Agreement of Settlement, dated April&nbsp;10, 2024 (the &#147;Stipulation&#148;), which shall remain in effect for no less than five years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>Please note that there is no proof of claim form for shareholders to submit in connection with this Settlement, and shareholders are not
required to take any action in response to this Notice.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Also, please note that this Notice is not an expression of any opinion by the
Court with respect to the truth of the allegations in the Action or the merits of the claims or defenses asserted by or against any Party. It is solely to notify you of the pendency of the Action and the terms of the proposed Settlement, and your
rights related thereto. Capitalized terms not otherwise defined herein shall have the definitions set forth in the Stipulation. A copy of the Stipulation may be found on Walgreens&#146;s website at http://investor.walgreensbootsalliance.com. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:#d1d1d1;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; font-size:12pt; font-family:Times New Roman"><B>&#8194;WHAT IS THE PURPOSE OF THIS NOTICE? </B></P></div>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">1. &#8195;&#8195;The purpose of this Notice is to explain the Action, the terms of the proposed Settlement, and how the
proposed Settlement affects Walgreens shareholders&#146; legal rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">2. &#8195;&#8195;In a derivative action, one or
more people who are current shareholders of a corporation sue on behalf of and for the benefit of the corporation, seeking to enforce the corporation&#146;s legal rights. In this case, Plaintiff filed suit on behalf of Walgreens asserting claims
against defendants Stefano Pessina, Jos&eacute; E. Almeida, Janice M. Babiak, David J. Brailer, William C. Foote, Ginger L. Graham, John A. Lederer, Dominic Murphy, Leonard D. Schaeffer, Nancy M. Schlichting, and James A. Skinner (collectively, the
&#147;Individual Defendants&#148; and together with nominal defendant Walgreens, the &#147;Defendants&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">3.
&#8195;&#8195;The Court will hold a hearing (the &#147;Settlement Hearing&#148;) on June&nbsp;18, 2024, at 8:50 a.m., at the United States District Court for the Northern District of Illinois, 219 South Dearborn St., Chicago, IL 60604, at which the
Court will: (a)&nbsp;determine whether the Settlement should be approved by the Court as fair, reasonable, and adequate; (b)&nbsp;determine whether the Court should enter the Judgment dismissing the Action with prejudice pursuant to the Stipulation;
(c)&nbsp;determine whether to approve the <FONT STYLE="white-space:nowrap">agreed-to</FONT> amount of attorneys&#146; fees and expenses to be paid to Plaintiff&#146;s Counsel; (d)&nbsp;hear and determine any objections to the Settlement or to the
fee and service awards; and (e)&nbsp;rule on such other matters as the Court may deem appropriate. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:#d1d1d1;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; font-size:12pt; font-family:Times New Roman"><B>&#8194;WHAT IS THIS CASE ABOUT? WHAT HAS HAPPENED SO FAR? </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-bottom:0pt; font-size:6pt; font-family:Times New Roman"><B>&#8195;</B></P></div> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">THE
FOLLOWING DESCRIPTION OF THE ACTION AND THE SETTLEMENT HAS BEEN PREPARED BY COUNSEL FOR THE PARTIES. THE COURT HAS MADE NO FINDINGS WITH RESPECT TO SUCH MATTERS, AND THIS NOTICE IS NOT AN EXPRESSION OR STATEMENT BY THE COURT OF FINDINGS OF FACT, OR
AN AGREEMENT BY THE DEFENDANTS THAT ANY ALLEGATION IS CORRECT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">4. &#8195;&#8195;The above-captioned action
(&#147;Action&#148;) is a shareholder derivative action brought for the benefit of Walgreens. The Action alleges that certain current and former officers and directors of Walgreens breached their fiduciary duties to the Company by failing to
adequately oversee opioids-related matters, including Walgreens&#146;s compliance with the Controlled Substances Act (&#147;CSA&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">5. &#8195;&#8195;Specifically, the Action alleges that the Board failed to adequately oversee the Company&#146;s compliance
with a 2013 settlement agreement with the Drug Enforcement Administration and with the CSA, which harmed the Company by exposing it to liability, including in expansive multi-district litigation and other opioids-related litigation and proceedings.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">6. &#8195;&#8195;On September&nbsp;23, 2022, Plaintiff filed a shareholder derivative action on behalf of Walgreens in
the United States District Court for the Northern District of Ohio (the &#147;N.D. Ohio Action&#148;), asserting claims for breach of fiduciary duty, unjust enrichment, and violations of Section&nbsp;14(a) of the Securities Exchange Act of 1934.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">7. &#8195;&#8195;One year later, on September&nbsp;22, 2023, the court in that case ruled that the Northern District of
Ohio was an improper venue for the litigation, and thus dismissed the N.D. Ohio Action without prejudice for refiling in a proper venue. Plaintiff selected the Northern District of Illinois as the venue for the refiling of its claims. Accordingly,
it filed the Complaint in the above-captioned action on November&nbsp;4, 2023, raising the same allegations and claims as it had previously asserted in the N.D. Ohio Action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">8. &#8195;&#8195;On September&nbsp;21, 2023, Plaintiff served a settlement demand on the Individual Defendants. The demand
called for a material monetary payment to be made to the Company by the D&amp;O Insurers, as well as corporate governance reforms to be implemented at the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">9. &#8195;&#8195;To facilitate their settlement discussions, the Parties retained the Hon. Layn R. Phillips (Ret.) of Phillips
ADR Enterprises, an experienced and respected mediator. Under the guidance of Judge Phillips and Michelle Yoshida, Esq., also of Phillips ADR Enterprises, the Parties exchanged counteroffers in January 2024, and convened for a <FONT
STYLE="white-space:nowrap">two-day,</FONT> <FONT STYLE="white-space:nowrap">in-person</FONT> mediation on February&nbsp;10 and 11, 2024, in New York City. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">10. &#8195;&#8199;Although no settlement was reached by the end of the <FONT STYLE="white-space:nowrap">in-person</FONT>
mediation, settlement negotiations continued under Judge Phillips&#146;s supervision. Ultimately, the Parties agreed to the Settlement and executed a term sheet on February&nbsp;23, 2024. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:#d1d1d1;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; font-size:12pt; font-family:Times New Roman"><B>&#8194;WHAT ARE THE TERMS OF THE SETTLEMENT? </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-bottom:0pt; font-size:6pt; font-family:Times New Roman"><B>&#8195; </B></P></div>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">11. &#8195;&#8199;In consideration for the full and final release, settlement, and discharge of any and all Released Claims
and the dismissal with prejudice of the Action, Walgreens will receive a monetary payment from the D&amp;O Insurers of $36,000,000.00. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">12. &#8195;&#8199;Walgreens and its Board will also adopt, implement, and/or initiate corporate governance changes (the
&#147;Reforms&#148;) for a period of not less than five years. The Reforms include, among other things: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">The creation of a Compliance, Safety, and Quality Committee of the Board, which shall be dedicated to the
oversight of compliance, safety, and quality risks; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">The appointment of two new independent directors to the Board; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">The creation of the U.S. Retail Pharmacy Governance, Risk, and Compliance Committee, a management-level
committee charged with overseeing key compliance and safety matters relating to the Company&#146;s pharmacy and retail operations; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Changes to the responsibilities of the Chief Controlled Substance Compliance Officer; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:12pt">Changes to the responsibilities of the Controlled Substance Compliance Committee. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:#d1d1d1;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; font-size:12pt; font-family:Times New Roman"><B>&#8194;WHAT ARE THE PARTIES&#146; REASONS FOR THE SETTLEMENT? </B></P></div>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">13. &#8195;&#8199;Plaintiff and Plaintiff&#146;s Counsel believed at all times and continue to believe that the claims
asserted in the Action have merit. Plaintiff and Plaintiff&#146;s Counsel also recognize the substantial time, expense, and uncertainty inherent in the continued prosecution of the claims through trial and any subsequent appeal, including problems
of proof, overcoming the available defenses, the difficulties of proving and measuring damages, and the challenges of collecting on any damages awarded at trial. Based on their thorough investigation and evaluation, Plaintiff and Plaintiff&#146;s
Counsel have determined that the Settlement set forth in this Stipulation is appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">14.
&#8194;&#8199;Plaintiff&#146;s Counsel&#146;s conclusion is based on their extensive and thorough investigation and evaluation of information, which included, <I>inter alia</I>: (i)&nbsp;reviewing Walgreens press releases, public statements, SEC
filings, and securities analysts&#146; reports and advisories about the Company; (ii)&nbsp;reviewing media reports about the Company; (iii)&nbsp;researching the applicable law with respect to the claims alleged in the Action and potential defenses
thereto; (iv)&nbsp;preparation and filing of the Action as well as litigation of the N.D. Ohio Action; (v)&nbsp;reviewing and analyzing relevant pleadings, exhibits, and other documents from the national opioids multi-district litigation
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
captioned <I>In re National Prescription Opiate Litigation</I>, No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1:17-md-2804</FONT></FONT> (N.D. Ohio); (vi) reviewing the
Company&#146;s existing corporate governance policies and preparing a settlement demand detailing proposed corporate governance reforms to strengthen the Company&#146;s governance; (vii)&nbsp;participating in mediation sessions and extensive
settlement discussions with Defendants&#146; Counsel; and (viii)&nbsp;negotiating the term sheet executed by the Parties on February 23, 2024, and the Stipulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">15. &#8195;&#8199;Plaintiff&#146;s Counsel&#146;s assessment of the facts and legal issues material to their recommendation in
favor of the Settlement was honed and refined over the course of months of substantive written and verbal exchanges with counsel for Defendants and the Mediator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">16. &#8195;&#8199;Based on Plaintiff&#146;s Counsel&#146;s thorough review and analysis of the relevant facts, allegations,
defenses, and controlling legal principles, Plaintiff and Plaintiff&#146;s Counsel have concluded that the Settlement set forth in the Stipulation is fair, reasonable, and adequate, and that the Settlement confers substantial benefits upon and is in
the best interests of Walgreens and its shareholders, including through the substantial financial component to be paid to the Company and the adoption and/or implementation of the Reforms. Accordingly, Plaintiff has agreed to settle the Action upon
the terms set forth in the Stipulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">17. &#8195;&#8199;The Individual Defendants have denied and continue to deny each
and all of the claims alleged by Plaintiff in this Action. In particular, the Individual Defendants have expressly denied and continue to deny each and all charges of wrongdoing or liability against them relating to opioids, arising out of any of
the conduct, statements, acts, inaction, or omissions alleged in the Action, or arising out of any claim related to opioids that could have been alleged in the Action. Without limiting the foregoing, the Individual Defendants have denied, and
continue to deny, among other things, that they breached their fiduciary duties or any other duty owed to Walgreens or its shareholders, or that they or the Company committed or engaged in any violation of law or improper action. The Individual
Defendants have further asserted, and continue to assert, that at all relevant times, they acted in good faith and in a manner they reasonably believed to be in the best interests of Walgreens and its shareholders. In addition, the Individual
Defendants maintain that they have meritorious defenses to all claims alleged in the Action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">18.
&#8195;&#8199;Nonetheless, Defendants have concluded that further litigation could cause burden, inconvenience, expense, uncertainty, and distraction, and that it is desirable and beneficial to finally put to rest and terminate all of the claims
that have been, or could have been, asserted in the Action. Defendants have therefore determined that the Settlement confers a substantial benefit upon Walgreens and its shareholders, and the Settlement, and each of its terms, is in all respects
fair, reasonable, and in the best interests of Walgreens and its shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">19. &#8195;&#8199;Walgreens&#146;s current
Board of Directors acknowledges, in an exercise of its independent business judgment, that the initiation, prosecution, and settlement of the Action was the cause of consideration for this Settlement, and that the Settlement is fair, reasonable, and
adequate, and confers substantial benefits to Walgreens and its shareholders. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:#d1d1d1;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; margin-left:1%; font-size:12pt; font-family:Times New Roman"><B>WHAT WILL HAPPEN IF THE SETTLEMENT IS APPROVED? WHAT CLAIMS WILL THE SETTLEMENT RELEASE? </B></P></div>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">20. &#8195;&#8199;At the Settlement Hearing, the Parties shall jointly request that the Court enter the Judgment finally
approving the Settlement. Pursuant to the Judgment, upon the Effective Date of the Settlement (as defined in the Stipulation), the Action will be dismissed with prejudice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">21. &#8195;&#8199;The Settlement is conditioned upon the occurrence of certain events, which include, among other things,
entry of an order by the Court approving the Settlement and dismissing the Action with prejudice. The Settlement will not become effective until such an order has been entered and become final and
<FONT STYLE="white-space:nowrap">non-appealable</FONT> (the &#147;Effective Date&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">22. &#8195;&#8199;Upon the
Effective Date, the Releasing Parties shall be deemed to have fully, finally, and forever released, relinquished, and discharged the Released Claims (including Unknown Claims), including against the Released Persons, and any and all claims arising
out of, relating to, or in connection with the defense, settlement, or resolution of the Action against the Released Persons. In addition, upon the Effective Date, each of the Defendants shall be deemed to have fully, finally, and forever released,
relinquished, and discharged Plaintiff and Plaintiff&#146;s Counsel from all claims (including Unknown Claims), arising out of, relating to, or in connection with the institution, prosecution, assertion, settlement, or resolution of the Action or
the Released Claims. Nothing in these releases, however, shall in any way impair or restrict the rights of any Party to enforce the Settlement. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:#d1d1d1;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; font-size:12pt; font-family:Times New Roman"><B>&#8194;HOW WILL PLAINTIFF&#146;S COUNSEL BE PAID? </B></P></div>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">23. &#8195;&#8199;After negotiating the substantive terms of the Settlement, the Parties commenced negotiations regarding the
attorneys&#146; fees and expenses to be paid to Plaintiff&#146;s Counsel. In recognition of Plaintiff&#146;s Counsel&#146;s role in prosecuting and settling the Action and the substantial benefits conferred upon the Company and its shareholders as a
result of the Settlement, and subject to Court approval, Walgreens agrees that Plaintiff&#146;s Counsel&#146;s should receive a fee and expense award of $8,000,000.00 (the &#147;Fee and Expense Amount&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">24. &#8195;&#8199;Plaintiff&#146;s Counsel may also apply to the Court for a service award of up to $2,500 for Plaintiff, only
to be paid upon Court approval, and to be paid from the Fee and Expense Amount in recognition of Plaintiff&#146;s participation and effort in the prosecution of the Action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">25. &#8195;&#8199;To date, Plaintiff&#146;s Counsel have neither received any payment for their services in conducting the
Action, nor been reimbursed for their <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:#d1d1d1;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; margin-left:1%; font-size:12pt; font-family:Times New Roman"><B>WHEN AND WHERE WILL THE SETTLEMENT HEARING BE HELD? DO I HAVE THE RIGHT TO APPEAR AT THE SETTLEMENT HEARING? </B></P></div>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">26. &#8195;&#8199;The Court will consider the Settlement and all matters related to the Settlement at the Settlement Hearing.
The Settlement Hearing will be held before The Honorable Matthew F. Kennelly, on June&nbsp;18, 2024, at 8:50 a.m., at the United States District Court for the Northern </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
District of Illinois, 219 South Dearborn St., Chicago, IL 60604, at which the Court will: (a)&nbsp;determine whether the Settlement should be approved by the Court as fair, reasonable, and
adequate; (b)&nbsp;determine whether the Court should enter the Judgment dismissing the Action with prejudice pursuant to the Stipulation; (c)&nbsp;determine whether to approve the <FONT STYLE="white-space:nowrap">agreed-to</FONT> amount of
attorneys&#146; fees and expenses to be paid to Plaintiff&#146;s Counsel; (d)&nbsp;hear and determine any objections to the Settlement or to the fee and service awards; and (e)&nbsp;rule on such other matters as the Court may deem appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">27. &#8195;&#8199;Any Walgreens Shareholder (<I>i.e.</I>, any person or entity who owned Walgreens common stock as of
April&nbsp;10, 2024, and continues to own Walgreens common stock through June&nbsp;18, 2024, the date of the Settlement Hearing) may object to the terms and conditions of the Settlement and/or to the payment of the Fee and Expense Amount. Objections
must be in writing and must be filed, together with copies of all other papers and briefs supporting the objection, with the Clerk of the Court at the address set forth below on or before June&nbsp;4, 2024. Objections must also be served on
Plaintiff&#146;s Counsel and Defendants&#146; Counsel (by first-class U.S. mail or express service) at the addresses set forth below so that the objection is <B><I>received</I></B><B> </B>on or before June&nbsp;4, 2024. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="bottom" ALIGN="center"><B><U>Clerk of the Court</U></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Representative</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>Plaintiff&#146;s&nbsp;Counsel</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Representative</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>Defendants&#146;&nbsp;Counsel</U></B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="19"></TD>
<TD HEIGHT="19" COLSPAN="2"></TD>
<TD HEIGHT="19" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="bottom" ALIGN="center">United States District Court</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Matthew T. Hurst</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">John M. Skakun III</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="bottom" ALIGN="center">Northern District of Illinois</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Heffner Hurst</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Sidley Austin LLP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="bottom" ALIGN="center">219 South Dearborn St.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">30 North LaSalle Street</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">One South Dearborn Street</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="bottom" ALIGN="center">Chicago, IL 60604</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Suite 1210</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Chicago, IL 60603</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Chicago, IL 60602</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">28. &#8195;&#8199;Any objection: (a)&nbsp;must state the name, address, and telephone number
of the person or entity objecting and, if represented by counsel, the name, address and telephone number of his, her, or its counsel; (b)&nbsp;must be signed by the shareholder; (c)&nbsp;must contain a written, specific statement of the
shareholder&#146;s objection or objections, and the specific reasons for each objection, including any legal and evidentiary support the shareholder wishes to bring to the Court&#146;s attention; (d)&nbsp;must state that the objection is being filed
with respect to &#147;<I>Vladimir Gusinsky Revocable Trust v. Pessina</I>, Case No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">23-cv-15654&#148;;</FONT></FONT> (e) must include documentation sufficient to prove that the
shareholder held shares of Walgreens common stock as of the close of business on April&nbsp;10, 2024 and the date the objection is made; and (f)&nbsp;must state the dates when the shareholder acquired Walgreens shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">29. &#8195;&#8199;You may file a written objection without having to appear at the Settlement Hearing. You may not, however,
appear at the Settlement Hearing to present your objection unless you first filed and served a written objection in accordance with the procedures described above, unless the Court orders otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">30. &#8195;&#8199;If you wish to be heard orally at the hearing in opposition to the approval of the Settlement, and if you
file and serve a timely written objection as described above, you must also file a notice of appearance with the Clerk of the Court and serve it on Plaintiff&#146;s Counsel and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
Defendants&#146; Counsel at the addresses set forth above so that it is <B><I>received</I></B> on or before June&nbsp;4, 2024. Shareholders who intend to object and desire to present evidence at
the Settlement Hearing must include in their written objection or notice of appearance the identity of any witnesses they may call to testify and exhibits they intend to introduce into evidence at the hearing. Any person appearing at the Settlement
Hearing must present at the hearing documentation sufficient to prove that the shareholder continues to hold shares of Walgreens common stock as of the date of the hearing. Such persons may be heard orally at the discretion of the Court. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">31. &#8195;&#8199;You are not required to hire an attorney to represent you in making written objections or in appearing at
the Settlement Hearing. However, if you decide to hire an attorney, it will be at your own expense, and that attorney must file a notice of appearance with the Court and serve it on Plaintiff&#146;s Counsel and Defendants&#146; Counsel at the
addresses set forth above so that the notice is <B><I>received</I></B><I> </I>on or before June&nbsp;4, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">32.
&#8195;&#8199;Unless the Court otherwise directs, any person or entity who fails to object in the manner prescribed above shall be deemed to have waived his, her, or its right to object and shall forever be barred from raising any objection to the
Settlement and/or the Fee and Expense Amount, or any other matter related to the Settlement, in the Action or in any other action or proceeding, and shall otherwise be bound by the Order and Final Judgment to be entered by the Court and the Releases
to be given. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:#d1d1d1;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; font-size:12pt; font-family:Times New Roman"><B>&#8194;WHOM SHOULD I CONTACT IF I HAVE QUESTIONS? </B></P></div>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">33. &#8195;&#8199;This Notice does not purport to be a comprehensive description of the Action, the allegations related
thereto, the terms of the Settlement, or the Settlement Hearing. For a more detailed statement of the matters involved in the Action, you may inspect the pleadings, the Stipulation, the Orders entered by the Court, and other papers filed in the
Action at the Office of the Clerk, United States District Court for the Northern District of Illinois, during regular business hours of each business day. You may also view a copy of the Stipulation at http://investor.walgreensbootsalliance.com. If
you have questions regarding the Settlement, you may write or call the following counsel for Plaintiff: Matthew T. Hurst, Esq., Heffner Hurst, 30 N. LaSalle St., Suite 1210, Chicago, IL 60602 (312) <FONT STYLE="white-space:nowrap">346-3466</FONT> or
<FONT STYLE="font-family:Times New Roman; font-size:12pt" COLOR="#467886"><U>mhurst@heffnerhurst.com</U></FONT><FONT STYLE="font-family:Times New Roman">. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PLEASE DO NOT CONTACT THE COURT OR WALGREENS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REGARDING THIS NOTICE. </B></P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8196;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">BY ORDER OF THE UNITED STATES</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">DISTRICT&nbsp;COURT&nbsp;FOR&nbsp;THE&nbsp;NORTHERN</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">DISTRICT OF ILLINOIS</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>wba-20240501.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 5/2/2024 12:40:54 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2023"
  xmlns:wba="http://walgreensbootsalliance.com/20240501"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://walgreensbootsalliance.com/20240501"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" namespace="http://xbrl.sec.gov/naics/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" namespace="http://fasb.org/us-types/2023" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="wba-20240501_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="wba-20240501_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="wba-20240501_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://walgreensbootsalliance.com//20240501/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="wba_DocumentAndEntityInformationTable" name="DocumentAndEntityInformationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="wba_DocumentAndEntityInformationLineItems" name="DocumentAndEntityInformationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="wba_M3.600WalgreensBootsAllianceInc.NotesDue2025Member" name="M3.600WalgreensBootsAllianceInc.NotesDue2025Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="wba_M2.125WalgreensBootsAllianceInc.NotesDue2026Member" name="M2.125WalgreensBootsAllianceInc.NotesDue2026Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>wba-20240501_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 5/2/2024 12:40:57 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef roleURI="http://walgreensbootsalliance.com//20240501/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="wba-20240501.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://walgreensbootsalliance.com//20240501/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="wba-20240501.xsd#wba_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="wba_DocumentAndEntityInformationTable" />
    <link:loc xlink:href="wba-20240501.xsd#wba_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="wba_DocumentAndEntityInformationLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="wba-20240501.xsd#wba_M3.600WalgreensBootsAllianceInc.NotesDue2025Member" xlink:type="locator" xlink:label="wba_M3.600WalgreensBootsAllianceInc.NotesDue2025Member" />
    <link:loc xlink:href="wba-20240501.xsd#wba_M2.125WalgreensBootsAllianceInc.NotesDue2026Member" xlink:type="locator" xlink:label="wba_M2.125WalgreensBootsAllianceInc.NotesDue2026Member" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="wba_DocumentAndEntityInformationTable" order="1" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="wba_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="23.0001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="24" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="wba_M3.600WalgreensBootsAllianceInc.NotesDue2025Member" order="25" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="wba_M2.125WalgreensBootsAllianceInc.NotesDue2026Member" order="26" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="28.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="29.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="33.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="34.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="35.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="36.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="37.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="38.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="39.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="40.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="41.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="42.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="43.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="44.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="45.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="46.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="47.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="48.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="49.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="50.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="51.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="52.001" priority="2" use="optional" />
  </link:definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>wba-20240501_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 5/2/2024 12:40:54 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="wba-20240501.xsd#wba_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="wba_DocumentAndEntityInformationTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wba_DocumentAndEntityInformationTable" xlink:to="wba_DocumentAndEntityInformationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="wba_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="wba_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Table]</link:label>
    <link:loc xlink:href="wba-20240501.xsd#wba_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="wba_DocumentAndEntityInformationLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="wba_DocumentAndEntityInformationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="wba_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="wba_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
    <link:loc xlink:href="wba-20240501.xsd#wba_M3.600WalgreensBootsAllianceInc.NotesDue2025Member" xlink:type="locator" xlink:label="wba_M3.600WalgreensBootsAllianceInc.NotesDue2025Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wba_M3.600WalgreensBootsAllianceInc.NotesDue2025Member" xlink:to="wba_M3.600WalgreensBootsAllianceInc.NotesDue2025Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="wba_M3.600WalgreensBootsAllianceInc.NotesDue2025Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">M 3.600 Walgreens Boots Alliance Inc . Notes Due 2025 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="wba_M3.600WalgreensBootsAllianceInc.NotesDue2025Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">M 3.600 Walgreens Boots Alliance Inc . Notes Due 2025 [Member]</link:label>
    <link:loc xlink:href="wba-20240501.xsd#wba_M2.125WalgreensBootsAllianceInc.NotesDue2026Member" xlink:type="locator" xlink:label="wba_M2.125WalgreensBootsAllianceInc.NotesDue2026Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wba_M2.125WalgreensBootsAllianceInc.NotesDue2026Member" xlink:to="wba_M2.125WalgreensBootsAllianceInc.NotesDue2026Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="wba_M2.125WalgreensBootsAllianceInc.NotesDue2026Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">M 2.125 Walgreens Boots Alliance Inc . Notes Due 2026 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="wba_M2.125WalgreensBootsAllianceInc.NotesDue2026Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">M 2.125 Walgreens Boots Alliance Inc . Notes Due 2026 [Member]</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>wba-20240501_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 5/2/2024 12:40:55 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://walgreensbootsalliance.com//20240501/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="wba-20240501.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://walgreensbootsalliance.com//20240501/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="wba-20240501.xsd#wba_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="wba_DocumentAndEntityInformationTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="wba_DocumentAndEntityInformationTable" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="wba-20240501.xsd#wba_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="wba_DocumentAndEntityInformationLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationTable" xlink:to="wba_DocumentAndEntityInformationLineItems" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="wba-20240501.xsd#wba_M3.600WalgreensBootsAllianceInc.NotesDue2025Member" xlink:type="locator" xlink:label="wba_M3.600WalgreensBootsAllianceInc.NotesDue2025Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="wba_M3.600WalgreensBootsAllianceInc.NotesDue2025Member" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="wba-20240501.xsd#wba_M2.125WalgreensBootsAllianceInc.NotesDue2026Member" xlink:type="locator" xlink:label="wba_M2.125WalgreensBootsAllianceInc.NotesDue2026Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="wba_M2.125WalgreensBootsAllianceInc.NotesDue2026Member" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="47.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="48.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="49.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="50.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="51.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wba_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="52.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g821017sp40.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g821017sp40.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1$$17AI9@  34T *@    @ !0$2  ,
M   !  $   $[  (    /   (5H=I  0    !   (9IR=  $    >   0WNH<
M  <   @,    2@     <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M     $1E97!T:2!":&%K=6YI    !9 #  (    4   0M) $  (    4   0
MR)*1  (    #,#0  )*2  (    #,#0  .H<  <   @,   (J      <Z@
M  @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !$ $,# 2(
M A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1
M @$# P($ P4%! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152
MT? D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D
M969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0
M'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%
M! 0  0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D
M-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T
M=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$
M/P#T[_@I#_P42^.'P@_;I^)/AGPS\2=>T?0='U"&*SLH([<QVZFT@<@%HR?O
M,QY/>O$O^'K7[1G_ $5SQ-_WZM?_ (U5G_@J]:3:C_P4M^*UO;JK7%QK%M%$
MK,%#,UG;  D\ 9(Y/ K[Z_9V_8T_8=\'_#VPT#6O&?PG\>>*HX@NIZC=^,H?
M-NKC'[PQ1I<*(XPV0JJ,A0-S,<L?CXT\16KS4*EDF]V^^R/] :V/X3X<X8RO
M$X[*HXBI5HTG^[P].<OX<'*4VTK:M:MWDWUU:_/S_AZU^T9_T5OQ-_WYM?\
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M^PZ>C"W-QY4+SR?O)BD:[8XW;YF&=N!DX%?1O_#FO]IH_P#-*[K_ ,'NE_\
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JY4G=?UL:5*LYQA&;;4597>RNW9=E=MV[MOJ.HHHIF84444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140427771670032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wba_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001618921<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  01,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">WALGREENS BOOTS ALLIANCE, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-1758322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">108 Wilmot Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Deerfield<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">60015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(847)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">315-2500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wba_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">WBA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=wba_M3.600WalgreensBootsAllianceInc.NotesDue2025Member', window );">M 3.600 Walgreens Boots Alliance Inc . Notes Due 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wba_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">3.600% Walgreens Boots Alliance, Inc. notes due 2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">WBA25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=wba_M2.125WalgreensBootsAllianceInc.NotesDue2026Member', window );">M 2.125 Walgreens Boots Alliance Inc . Notes Due 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wba_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">2.125% Walgreens Boots Alliance, Inc. notes due 2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">WBA26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wba_DocumentAndEntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wba_DocumentAndEntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=wba_M3.600WalgreensBootsAllianceInc.NotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=wba_M3.600WalgreensBootsAllianceInc.NotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=wba_M2.125WalgreensBootsAllianceInc.NotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=wba_M2.125WalgreensBootsAllianceInc.NotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MC*LR$%P#TOX\:+8:%PB/[Q4MUSN%Z)&]D&$$N2?F(MQ-VG$^AV2]=>ZW&NV
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MP"*,*W(_GQ^)'Z[G(J-%VZ=XC_Z";*CU&LA<@ Y9)V#1]>E)77^0<+6P\?P
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M)#M<<@9K9WL!?#^',+V>V+WQ_*^-SC]02P,$%     @ $HBA6)^@&_"Q @
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M\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @
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M&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ $HBA6 =!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    "  2B*%8N_'GUNT    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    "  2B*%8F5R<(Q &  "<)P  $P
M        @ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( !*(
MH5C&<L"=,04  .88   8              " @0P(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    "  2B*%8GZ ;\+$"  #B#   #0
M        @ %S#0  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( !*(H5B7BKL<
MP    !,"   +              "  4\0  !?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( !*(H5@<.&7J/P$  #P"   /              "  3@1  !X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    "  2B*%8)!Z;HJT   #X 0  &@
M    @ &D$@  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M"  2B*%899!YDAD!  #/ P  $P              @ &)$P  6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     "0 ) #X"  #3%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>4</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>3</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d821017d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://walgreensbootsalliance.com//20240501/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="d821017d8k.htm">d821017d8k.htm</File>
    <File>wba-20240501.xsd</File>
    <File>wba-20240501_def.xml</File>
    <File>wba-20240501_lab.xml</File>
    <File>wba-20240501_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="28">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d821017d8k.htm": {
   "nsprefix": "wba",
   "nsuri": "http://walgreensbootsalliance.com/20240501",
   "dts": {
    "inline": {
     "local": [
      "d821017d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "wba-20240501.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "wba-20240501_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "wba-20240501_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "wba-20240501_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 2,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 4,
   "entityCount": 1,
   "segmentCount": 3,
   "elementCount": 30,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 28
   },
   "report": {
    "R1": {
     "role": "http://walgreensbootsalliance.com//20240501/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2024-05-01_to_2024-05-01",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d821017d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2024-05-01_to_2024-05-01",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d821017d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://walgreensbootsalliance.com//20240501/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://walgreensbootsalliance.com//20240501/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://walgreensbootsalliance.com//20240501/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://walgreensbootsalliance.com//20240501/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "wba_DocumentAndEntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://walgreensbootsalliance.com/20240501",
     "localname": "DocumentAndEntityInformationLineItems",
     "presentation": [
      "http://walgreensbootsalliance.com//20240501/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Line Items]",
        "terseLabel": "Document And Entity Information [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "wba_DocumentAndEntityInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://walgreensbootsalliance.com/20240501",
     "localname": "DocumentAndEntityInformationTable",
     "presentation": [
      "http://walgreensbootsalliance.com//20240501/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Table]",
        "terseLabel": "Document And Entity Information [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://walgreensbootsalliance.com//20240501/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://walgreensbootsalliance.com//20240501/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://walgreensbootsalliance.com//20240501/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://walgreensbootsalliance.com//20240501/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://walgreensbootsalliance.com//20240501/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://walgreensbootsalliance.com//20240501/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://walgreensbootsalliance.com//20240501/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://walgreensbootsalliance.com//20240501/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://walgreensbootsalliance.com//20240501/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://walgreensbootsalliance.com//20240501/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://walgreensbootsalliance.com//20240501/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://walgreensbootsalliance.com//20240501/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://walgreensbootsalliance.com//20240501/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "wba_M2.125WalgreensBootsAllianceInc.NotesDue2026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://walgreensbootsalliance.com/20240501",
     "localname": "M2.125WalgreensBootsAllianceInc.NotesDue2026Member",
     "presentation": [
      "http://walgreensbootsalliance.com//20240501/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "M 2.125 Walgreens Boots Alliance Inc . Notes Due 2026 [Member]",
        "terseLabel": "M 2.125 Walgreens Boots Alliance Inc . Notes Due 2026 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "wba_M3.600WalgreensBootsAllianceInc.NotesDue2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://walgreensbootsalliance.com/20240501",
     "localname": "M3.600WalgreensBootsAllianceInc.NotesDue2025Member",
     "presentation": [
      "http://walgreensbootsalliance.com//20240501/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "M 3.600 Walgreens Boots Alliance Inc . Notes Due 2025 [Member]",
        "terseLabel": "M 3.600 Walgreens Boots Alliance Inc . Notes Due 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://walgreensbootsalliance.com//20240501/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://walgreensbootsalliance.com//20240501/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://walgreensbootsalliance.com//20240501/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://walgreensbootsalliance.com//20240501/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://walgreensbootsalliance.com//20240501/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://walgreensbootsalliance.com//20240501/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://walgreensbootsalliance.com//20240501/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://walgreensbootsalliance.com//20240501/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001193125-24-127601-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-127601-xbrl.zip
M4$L#!!0    ( !*(H5C$A-N&G!$   5X   .    9#@R,3 Q-V0X:RYH=&WM
M/6MSXCBVW_,K5,SV3E(5P#:0!))FBR9T#SMY%<EL3^V7*6&+H&UC>R3QNK_^
MGB/;8-X0"$PRZ:KNMJW7T=%YZTA<_6O0<4F/"<E][_//9L;XF3#/]AWN/7_^
MN?)8K==__E?YZ*JMH!I4]63)8?QSJJU44,IF!TWA9B2S,\]^+PL%6<NP<JFH
M8E>FU3!@<E2[164SXXOG;%PR4=WS/:_;&57N]_L9W3TV<)3(8HLL5$I#+2:X
M';<;N-S[,=&LG].-S&*QF-6E<=69FJ,!+,/(9;&X226+J_>;=%R;NL^",4\V
M?5])ZKJ<>C;+V'X')Y$W"H8Y DCR>># $&;V]]N;1[O-.C3-/:FPBQ&VE%@(
M6C$+I7%%+OV\99XOF4=48]1@L*BN"74]F#7[_4OC9EQ=S:\_KII5@GJRY8L.
M54 WV%,A;5AIZRS121KH8J*CF$Y6]7.1SHUQ"8/S95.=PB*6.E/T&54^RX:%
M"?)\IC282YU8D"3.Q>2%C)%"!F'4@?\45RXK7Z1_O<J&CT=7':8HP>9I]F>7
M]SZGJKZGF*?23T#0*6*';Y]3B@U45G>7A5;9L$-"R%73=X;E*X?WB%1#EWU.
M.5P&+ATBQ[!4F5SQ00EK,Q$]<\=A7O@,5>Y"=B$>[6!;QDN5#O,<^*N^NO0Y
M@F"@&JP%Q5VAE^(/).JT :MA_J'\Q%N*<.=SB@]Z:>LBERJWJ"O9579BI)F1
ML<4O&J@_8/@_:AZ@9EB%\05UZY[#!K^R82H!WX(*F\%9-H#?SLR+HF7.PI>=
M0I-@+29 [C$)[R@&2E)S*8SUFE)&CX1R[7-*\D[@CKZU!4X2Y$\Z%BZ9@73B
M4BILX2,AK!XC&TUV8H+Z7?I=$;YJ'BM%V-6+M09VXV9,K]7HE3OXH<69(!J#
M;*X$J-9_G5R?Z<8(]=S^ UA WQF] O,+=4T5*X]ABUN.R\:P.@OJQB6C84?C
M9">P\S)L_1%)E/2C@D&0\:HNE?*^]:A\^T=EP.6H1M7O='Q/?[]EG283>\!T
MA"[VC)!%[PZ,-PA<;G,5PD$<#L7:2DA%P)863B=5CJO,S.<J.[?[,:;'</R]
M* "9_3:7.3.,[[&I\05-C4ID:M0].W/G*R:ONPPZ+KQI\H#)EC:?[ ?M+*,=
M*V-:A;70>?;V:6?CR;X#VLE.Z>ULTN[+@GT(_R6L1&R5IBY_]DHVS"5<[T1Y
MGSNJ7;K(%+AWF:CKLI:Z[%#QS+TT/I<([2H__B+X<SOZA-T%<6=HT:?;3)?F
M,D8PZD+Y02GQVO25\CLE"[XT?0&@QU_,8$"D[W*'_&3H/ZGR/W\RSXS+JVR0
M'"C1;1XZ(9/]XDBD!1A+2_Y_K&1>C-Y;M,/=8>D)2$V2.]8G#;]#O4M=U@_A
M;OJN<SD':[_=U9]JU^3QJ?)4>UP,CK$G<!YKU=\:]:=Z[9%4[JY)[??J+Y6[
M;S52O;^]K3\^UN_OMH+1V@6,WZEL<^]9^=XIN<Y4,\0R"OGB8KC,?2'OZWWC
M=K%C=.W;710""<]L<[\H9UZD0@]PTNO8;O8[618@G$;M[HDT:@_WC:?#D\E#
M5\@N]111/GED-B*8F#GB"V(6CIV3PP/HMXAJ,X2M*[CBT+XVL-O4>V:D8BL"
MQ68QE_\+K"SJ$ 2GP0)?*'(<OS,*.H1)15@/:A*ABYES4EK-! ]:$=5"_;0Q
M-X1!'>0(57)0ET/SMD.'0X"(>4EN*:;*MW1(S%."[7?*-59^%[A=C*HP4-%@
MSUQB)$O=0<G+Y88%.N][Y>9;HU:[>R1?[N^?0,+?W-0K=]7:*:G?53-S AE;
M<(BQ"^0<UP84. %Q@O0F1K@@5!(9,!M-08=PCW E"? .D)^8YNPIH)::#O!E
MPC0XNE*TZ3)B,]>5 ;4Q<)TR4OH]H(X3OT=#15:'[;LN#20KQ0_+,9% &ZJA
MT'0R#>-39,64C C*DA';1@"7T/\ZDP97+O\)HS+)@AX3BMO4C5 ;3G2Z4M3:
M6J]U#.),[60W5]D(1!&7!O29I9N"T1\8GP93OD1[/MAD:V/'U,LS,2))4 T)
MR29&EK8LR=0$8-E3Y2M82F^"/!)T",7+.1)< %^ I-.LIUV)JM_UE!A6?6<K
M488Q;33O%0N$W\-A)V2998(D9B[M@XR;%60X)<2YL\[JCTA\NOH!T/F5NPS*
MT&5\N7"ST%DTT[FS\T+Q'>'FB0[JD<=K:V1LC:A<JIP_3YOGA0M VC),O0+[
M7NR&>U^JDG9BXA]KAD<CT@?;39#_@>DF':ZMRXWTI?D*P(&*Y$GAI#7A8>C^
ML(N$@6$N,>A#4+P<?&%"MOW;+D>]\4AJG<#UAQ@J._!:3 I4,KTT6N[!/VCV
MO54K4D.XC1E9,'9B".8OWK4A6'$<P:2,_KOA'C.WT,SY5-DT+LAW[G9\!5.F
MSK1Z/EWE*T:05.'Q7CSY?6\+< IH;#(!_I7[8D"TKKP7#V#-<IU&\7JV\1DP
MMNMRS^?R'=E_$1X??)BY^U\>O,C#&"/I/%4^ S.Y\#;MOA6H/(Z0A8&"0 "]
M\8"ZA V8W56\A_$#D/E,GOR5R>$8UIC@(I_,+,D<E;1A*' G$9EQ..J?/UU8
MYOFE!#RX+&C['B.>UJ6G:(2Z7=1J!%Q5"O0*-+-89*"XJD"]+8G[ M!WD3\_
MF0UC)7'>;W/%TJB$&53J"QHL8<(;'Y;O :>VM=]53)5S9B%M%0QC(?=M$^?=
MR>+>@>*I!+B#B:2V3?AO-W;C5Y#_X&.%X3^AU0&\TI#/@<Q:) R7 T^B?B$N
ME7$4>DEX?Q?H3)6K;6;_T/%[&H!* HF#?F'3'Y F<_T^ H>%.(75%*@W=#05
MD!9WD7&X!"Y2S'-@<LJ'^76ZKJ(>\[O2'1()A"=;0SU"U,!O NY"DS;:5TA$
M2[O0#R#.&\9E+3 I_3ZV0W7*T5.2I5>(F^[4HAV9L6/3=M:&GK*QUU)EJ7G&
MJ_7I<JX$7R0LO@NN8,'0]>QZD7<AMS9YFK[O-BDLE@+22@B4G-["+I[G\Y>S
M\F2%9IOV",GDTI*M9<W4AG^J'.$&D)%$#@D2.W2-+I!+WBI$M#JU,8;[8<?F
M.:E^;1 K9V2@XB8N6_Z#?E?2[Z.O,U=@W%N09"#.W-<C7O,M$>\8,=!UB)E9
MRETIXLT\39M6+.7'1#ZQY1N3^,K>K+R1"7L\29@/']RP,VYX$ PE.28UZYP-
MU,3BOM5Z@1&X-E=8;XDK5I(H8#!M)U 8D_XJ'; &)SEIZ[AYLEM>"OO\X*9]
M<%-=RBX3>^&IW =/K<53.9;.']N[Y:FHS[5Y:N<^6L* #)TA)L"="N;EA2'S
MD_42LE[#3WHS.P/YW#8))N9N$DQ"(/X:D<JI1..,@:)A(M=X6E3&4YS#-@?=
M&'O"(X5A6I_=)C:FQN]GP_*E*#SPMN:3H,B?!]_0?!QVH.A8[FE[^8VNUEV4
M0ZB)FT5B_>!K!ZH'Y ! --9/DVKR?>V;1IIU:%I-+6TVM/NV.NJ8, KSJ7)8
M3G2%4_(/(V.8)*""]*C;?1_9=9%X"J7#@1!=2)6_?ZF\"W3&I!M;A"_(QMX.
MJ],N#\JPF7WPW!GH)3!A[ZATZ)\A>9-;*GXP16YNJGO>^'W_XN:%YVH3"W:>
M*NOVG\BH!Z*[('$?IP1[(1YV0YPNPY,,2[?PWPQ/O;*(VGYQ+K3\>B?8WH\$
M>RG2UQ-OQ0_QMG?QMOG1[_&"Y8U46;??3+R=O0N&VX=XVVIQS%"\O0]L[U&\
MO0#I:XFWO+6=>-M'3+7N.1AG9J0Y)+;.@8$>?X 7R_1YB*G$$RX)+":@$@=]
M)L_"[ZLVAJL#3$:AP/"LQ;WP"%^8 6 4YH1AQ]'7'#E&:CN_U%D <66N#_\%
M>/@/$X76C'E;S?1H0W:]T._J3F/H,/X]TW\"S,PKIWLE.$_?JI JUQ8LPHH4
MU+C9-]VJ&C9ZM?V:_++]FM=-Z*JWEI JYC3.I7L^DVO5!JIF+K,54#4H-=QE
MZ$JF:P'"HHPNO)F.ZYV'\$8.1) >RQWBX'T.0^/B>  ?E C6XQ+: :^ D,$$
M!&K;>.@0*^,==0X5C@QSN9Q%6QRY8SK:XD@2=X:,,+ZS?8U]W=T1WDP2W4]R
M=#2?/%AGACKP4\+^:S+ /]A_;I\.92H\^7QTU1Z9BK;O^J+T4U'_N8QG$PR2
MNZU9#<#R*U)V>T/*T?16\I?[QG6MD:[>W]Q4'AYKI?CA+[V5/'\OF>A'()_9
MC=$Y-D&R6./2879T!JZDMS*1"H'%0:ECVK)A7IYG\)8<+9LSL^9.<O!#[0XO
M"Q_/P<J2:3?8<]<-4T._7I-K+FW7EUT\1!S.GVRR,WNV"UE;05D%,BW,9G5"
MB)AS2O! EM_3-E/(Y&9>W]R0.]5B*^B"88;)_+)-!6L#5O"")Y"@O>ASERLR
M2RSZN<05(,].E?_C@EG>X8)\ZTH@SQ]#TF ]7Z<\DR?1E8KT,N2!22BD!"PO
MZL84<@K 9=;()U^Y.YY+V[VT63@KY$>T%YH)QW>9ZPRINV[FA/3QC@-%AV$&
M,.B)#DQ.8X$*;:' 5[QO"B17^-D'D)O<!:6-8EXR!3XA&K$9<N^12B"X&^'4
M"&_#6(+3%G=A6$HZOB8;U$ZP8"Z@S:-B&*8\]T -P3@T,1+!&Z3<'FHE[!I
MB7*29T X3X( JDPHHF4DCNH1+8$2(P(116/&72=GE[SH1;6I6@ J]GFZR@U%
M@U4I:N,%0P0,6@9]4C0&VX!:J%XL9DR T,$'ZQ3G&Z!^[3$7; 3\GCB "SV
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MAJPAW2*3<<P%MGCI:5K"=SS&^G!-I^<;TVF=3:>=[8WM= MUUJ15U$"2>$;
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MA"AQ4I8/YC+[HW\*<6#3V-G%B0 GT-H:4&3!D6)):0%RA:6%J?!XA#JC+,G
M"B7)E:Y1]ELWX97U29E$GX4\4).<*0WO]=#Y5DIR'9;A2F-.-6?E(B83$F,1
MKL/S#;!;T31I0C\"*P29>T,7M4B\\ S/WQQ987I)F2V%NA +=XL.O D^BF)D
M\WR<I%&^"#RGIPO1LWEFROM;0!D1/<QSUL5)>B.?8M6A&-"]M(%4&19EG[D&
MQ72!Q"ERBBU+K*!F10/*MK,(>G;2,+^2?G*=O[3XW =<#?MT8YJMM6GV_(<V
MS>Y9W#SS]6 7"K^)R]%3=8ME+\6R-7%$AIC=9?5 BJQ9L\,6Z2]-1.+D0WZ-
MH  0D!,G"F+]A\TF, V5 R^!D#]S)B1F& [JW+4>[L?$+^OU$*-6K@R;H*85
M9G]!EPXX);.8?M1LF$Q-MA)BEU)RDRT@)BP:=L;"B-6K@(-7N.).9V P?A&'
M(,>BO-9\Q<^P]-$PJO-E6_A*O]\9@B98^R:K+]Q\)/I)6=;<VF'XN$A.EI*H
ML2,]K=!*AH4?R;TYZ0 ,44N99:M6MEC565A=WE_2<S/)-K,:<P%F)7:)F*3/
M+(W9H7)=W+^DX#"P,>'K7FK@?-P2>;N^:E=9L)-?VMITSJ0KIUA;H!AY.H8H
M80P+)6I+-4.2P(M7DMXRI_OWKUG:;STWS-&E&2#SX8(]BU!&,03.;?<WDR!T
MYC.\[K]V@R>45&32%@I!:S]^)[JE:N,3;/B.'66)=?X0KROR7";.PNV.4Z,)
MC6V\$<\VXPXA-A2UC)>=,RN=$##+J)C$;O+4/4JGXD9Z>;/19EJN::D:E&+/
M6NBH$GI862Y7$\RF C)XX"S)(@.IY_= ,HD%%+LHIME[*V8+PTO5X (2'2]*
MP7*T78U)V6P4%]\$3\3XM/&334[IO>:4/EG?G-(SYSWU<"$/_01XR9A<TX31
M)ZT=IQT6^NZ(*[LL@6\(=UGJ.E1*0F=_M*A(#]A,?+8Q$]?:3'RQ,1-OS@AL
MJM_'E<VQEG497MK^:E6?#1/V"]!N !W^SSE5,):P>(?>&QT"[R.GQQ>[-#PN
MJ/C8H"'+BT^P(2S/EUAHCBV\/(UHAB;GQK, EC4,)A:)FD497)A\T*4^F*!&
M51N]KQCO]]>7G[A4NAM1246)(Z2H.]"'6DD>-TP19EO+[>]R"KKKUD>2STJ;
MZI4J88=O+D/"'ZZC"XL9G=81_CI0@<W?.DXPBGYA@A6\R:ZFJ]F(IF#.I#)-
M1L D0YZ;UHD/A+N^8#$;NNT'K+9[,!MEVV"C8-^K@OUT?17L Q=5!DIPVNDK
M83N,]ILYM^0!!ZI=).-<?!YKK(0_]97P,D.M;8UC96V-AL[-X6T^H<-O<]#.
M%&669HG?.0+N\A'J<94*SEO%)?K &2("\2=/8_9J'>;1+\VC/H=H^136)"%A
M8*>12[6Z!%=)L4%R),>4ZTUMI\8A_PR4\7@MPNQ/G4+;'2U#\60<?/3)]]%;
M5"YCP(.)=<[H;9UJ![NP]#02\\&V3^1*=QDT7ARE](*]0,UCRG\=&"U%Q+[1
MJZ?S?,[0$52@@"ZW-#*.:/$5&PVD3E!^YUW8\W;!A/XY:E.C/=8R.]M-F3@;
MJU\UET590?%P&4O<GU:V@FYWD1-T?TJZ"66L$/76IJ?DG!(%7!-XEBO\]_/D
MROJZGX*(R"06X"5*S<G'B1N'IH48-SZ4S'3H*Z2:FP1H=R0Q9='@Z)%+NKPV
MKY3M>, Y]33.[.$Z7IYO'"_K['C9W?ZA'2]?Q!&E+\NR))IEHB4V,+VH_@=>
M2EA-YMB(#=0*%V@V0+Z70#XJ%2I^&!L9%>+KC*)TRGWQ\MATN\,8H8_0%11M
M;QOX=N#;"Y/%)/#5H<WF=J".]1%;7@67L5U7?H9"$<'!$$?'IL*AQ=]L5!N&
MF&I&Z=43<@R?]&6O%<L?\S3*AA'OC\/K]LKY2L5AC+AT?9@Y"T2^B!0W8R_D
M0-+(E@Y=8"MQ:8ERZ-4#S_B!R34;N3-^0 8,EX!N70-%[H?Q\_%M<,B7;AFL
M%=]-H$*K:O4D[&\RA)=3"<Q/NP8-/'46RT5X\<H1>^35M')_XOK\Y?W6;H!)
MS %G,#]K[>/_/%$<]7M<"GN:G%OV9R2IB8/6-33V=8A"!@2UDBDJ!0XR)RGE
M]!KMJMF0]C)2YCCR)+_)0N&Z2B_1(/ P<&<I(J%8L'=,>N0?J$BXR+5P\DQ_
MAE&9?L$N,E2<95"<HC@#J5Z-J)^5),PFBBE%-,.=HU0;<1,YU)] 6LD$1.N,
MP!LY?-_:I<1;!<#,:*.R7.97K[6QM[BK=R&T7WNW% BKSK?EE[ (?3QNP;GC
MPTQ&>N!=7D_+!6#CE41(J3;?B@K-JJZ%#>*Y*R6)O9#N@!4[.HU-@LKR3)Y*
M-H'B<G'BZ;8R*<REKWERA0EPQ%%R,@.+[&2'WH(I*(\D)V&:#*WL"ORT=?3M
MF'S^D4L7^H*1&W[E03!<I' US&/DZCUL0KDG2*QGII T9'.1F@TA=)."7'>Y
MS2IB!&^JERJZ$T@HD%&&D_.<"@_27GFQL5?6VE[9>5CVRB9J\<N;U\_6-VKQ
M(<J(>\8ZF6>(26]D]IH&()X5 Q"B"?B>+@\KA41>Q#6"TJ4UEUH]"SZI:UQ0
MI(Q:-Q2#K218-^@GJ#J#T69V+Y;B75+#-]/FD!SKM>UUJP*(,YT3UQ;R(DF&
ML%JH%9FNBI@#.>"6<-G8%+J"^DRR]F:O60/=YUD1P<GH>+1E0]DD%V$1Q;L&
MC*D4I,:U'D;9C!!]:Y1)D]G .:;>&_!Y(-DC]#Y*%)Y5J%0PALG=65%!Q4JH
MF 0V=LRPSR8CA>&UPLR0U%2GD8LVTWL#G(.^\/41RMK@$?N 3V72]]3@*W@%
MHW2 9H<TU&P0$07T"XY]E$:7R02X@'1/Q-)(@CNG)4%OS@0T-&Z@(57:[MU%
M.&8/GT@@J=',XHC&/,UL!IYK0$1S9%C50B6W\R$@=?NE=D7SPN^Q4=-B0^WL
MF(R99L-@?G.-'#J-W+-X'M4>5 2T3=0F_J80[!UXLNO7L&Q>E&/".^^FY;G4
MS0Q#80MT3+ PM3IE =AF"Q<[HN)DW<Q,Z9],#R:6&>\7UJ2 ^76!.+^D@L.,
M1YJ(,Z3Y8?VI=P+\9*G"9E9SFPA<=RFAL,.+F.V$6YGR=)">)W;N5V-DR)0,
MG64,L(*&2*KCBWS,Y' %$AJ=,MIPK](JPDJY@D0YKFAJRUE9@U249RZ^=#L,
M9P'R,VV8V63U"B^*EE6S4=ZABM,HB@>$3V5AZ[W =0[[,7IE';2!&B=7:-D%
M3 %>870^7M)234J;+(*Q(:8%E2LP'B&& \5K(&FZQ-D07+K65R$[VB=FDM-#
M3'T+)2NQ-VGMTH^>.7N^4Y]KIO^"A<BR"38_CPWO,Y#;&6/THPL)7>I6"M 9
MN$J3^&*(0I[*6EPAK9>7-X7=O-3E]$ I!:-#'WA>,W3UYKP1B8BNC-\JP4B.
MI?-)=7"%]HJ"XX6Y20$PJL2V'ZJ)O+N],9'7VD3>?5@F\K<,Z8DJ8[RDM2&\
MHB++K%K\XQX$/BLD-9D!II6-R+ Z_ZWD$DLCF[+FC.\#VTR:PX<LWX@;<45B
M6:TNO5#XVR@$C2-P;)$9F.69HG+SE<3U6,3X"G8%F!5^FE)/[@KSHX&1)*IS
M0)?6 '-N7(X/2S:C/!7N+8$ZU+GN:^(':#&EL(:40F)#%8&L+[+IR^0S<710
M/5)A[39"AOY]%/TQQX)<S)9\Z[+D@@I<'6Q]J($B'G; $A VWG>O"RE\0X2&
M#,/STY>D%XW6%;A6J#BIE/V:VKL!6@6P)BGU6)I8<G+8'D$EU+($1M;);0,C
M58>@!?JG \UT.A#UAJQMN\?!2D:O<F&N4DAF=92P%!=W*32%H+L9-952V0=6
MD"SYI27$'[$$,%U5]<9:D]N^4([EPKGR.B^5Z@KNSQ+6*5=E+ZV#]F9QN=IL
M!HX8UY5KAX<Z Y$I"AGAMGAMH"D :7I!)RD#(F>Y!$3\7%<;;"QN6_EM]MG*
M67'>[6+Y<.Z53TU2K*VEU_12F[5M<@?\DU4=!J'"&;K$DUU Q'7V,G6,L01$
M@Y'LQ&P^(R H89H3'I=X%-:IXOJ90S\Z+Y_5*>;M(1@UA<%D*E--A<U4'TU1
M8)/]B'1"<V3=&B27AH4:,3JNEYF7&' C3[!>VYWMV@L$,2M),UB:+9(..LM;
M5AWBSFYKX/][MG2YRP5;PQ0="\"%_^1\T_["7\>U<&8^]P*YJ49A 0\VZ0Q7
MH UC+Q*=B=1$F#0^4TZU* &=^SI.P>2OB#\XE&194E>LDOVO5P^&K4_@\V2<
M.FV1FJGI:8*Z/"P)J0D4^K?,X.&&/'=W-O;<6MMS>S^T/7?/?.=%P>'DI0\R
M&Y" @R1AU_,/560?GKBJXT6H2?9!&@H;$:.)F(.\;&SP[R@QU&#0D6\K45FR
M#I)^9]N//=FYUR+6IMI5Q9#:AR+U J,/&+_(),O.ZCQ4-(K*70(&14H:L90@
M2K]WS!G45 6U%BNQLU0*&] ELSS5?JQ>BHY+./545VX+XE'/6LRX$'<LJ!U&
M566W+$C."2A6&=OO7-S V8"YGN+><A!=M#[/LTI"GE)/+9K^#-N,<T9=P2GB
M5?H&-D$1>P+GHF(7+:_'%B0&:$_0;?B@6R->8![%V.=8\@Q36)US@/X""Q@3
MB -QMZ>P.LX8"SBT(/%SO^#-#Q59_75@4K3%)AY$*3![G#PLGR3ANL(L?\FO
M0K&=",P1F12B4Z^!/K?CJH/JK.%4?-T9.ZQ&DX@1J?#<2_KS8&$-0I<I69?F
M:\Z9N8+I34Z=,NA:JY]A6K'JRS":K,4IV_>J#FNKQT):0W&KP)Q94/S'&H>U
M$3\Z/830/)D4,N)#25ZT78G1;89.B3RW>;MX8UP J"V38S&+PQZ'4D+%>A#H
MDRH^F-7U)8AJ1#22D83]L6Z2K%/<#>G'8YR"F+(\G<EZ\87^98%8)\V&26.H
M="U= CS%)X,-4?XNJM;*?X\U7&[Q6Q.T+SD 6%T:</ED%&..@9"/])8DX[Z<
MK%P(H#MHC[J\ &>U![+T\ =>A&GI,Y S:*[!BH!@H/2(Z1SCPYK@D)%M\HW.
MN4F?@=D#)Z*L&M4/X\_I?)8/%H&$XWW+\%)[<5RCNHAZ2 (&DV>I(1SL8V*=
MW,S4/6^G3B_P2<@$DTF$-8"9^)N3]"*,8:<>LN6XN[$<U]IRW-]8CK=@?M;_
MUJ:H&*,MFHB/P3VI:!J4FH(:C@.]%?04$+?D&T8MM._G=<S\ZA@#,%2.:NAK
M0Y,A"#0L4"P9INY!$ASC-@TIQ@#+3:WH-YEJ 0XR-\@O+)ZD;]R-IEK"=Z\F
M/I@9EU81\33Y,:SR>)TJ:?1K(2"?7R\@#4BQ!YR$_LQFPP$+!U:W%X D4VD:
MF'Q7+,\:)V@YVS6Q"2:]7$K)NQ,P/Y+(B5 #UD.](CPP8+,'(HKKR+@P?"[N
MXF;Q%,$8UH2J^*T<C1'O?CZ6\"M&%YL-VW/Z4G,ZGB7LT@2LI7?!=892^P3C
M-%>86L,O#P<,QDDTT%O): N&5 H"@.X<#Z+99$U\Z#LO?,M\K$-.>!/W"=H+
M%)2V'15-R':$FWB)^51T'C$>XT>@IEJT?:)-UGUXQ==BUKO6%_5)J,(4QU4+
MPKP6BKXA3KC DK<N3G\#/LY)ZXX140M![+2:IJ#(X]N$E7H,JQ;U]OLSH]WE
MKBIQ>A@N@S-(8G(J3).4DVXQ20+]=0&Z-4SD%=@NJ.>#/$WB:* XO@NBH:6L
M-U5N0U1YL!VSQ.-D-;""7!P*9NP%)QP8H< UT-XHX.(+3E*H%+N1F FGIM6H
M"XY^;SK=]?4%R;$ON#B<9;\Z@:.^*2WE\5]*THE$MJ4,'BS.<02<<9:I]N$9
M(O*E()3[G)D$;RB$P0/$8)G'KG&0@..XRZ7YCUAVP?5,-D[B+2YRQ"-EN*<K
M/%B/_2GT$O:;6:>:\MD+H &HV[@"%2?YRGZFFNJ4<;%Q0K/A.NN5</JQ8GD:
M64]+80"%.E=DZ<+.Z;UV: Q28$97!6I7>MI/AI'+I"J/UHSM 5N=>QNK<ZVM
MSB<;J_,67*H"T%F7F4IL7-0\'QFBINM$9&K&6 (G:8U<IAZ 1KZ6S4ALJ! -
M2%<"??@RP@1/<EBRCVWA96HM#]&8#B);[*=V3^*?_TA@C";/U/\1'6E)^AFU
M+TS/QW]S/5@3F=(]AH-^?MSI]=2G]YVSSLG;HHN3].E!2$IYG9_ U\BL3W\X
M1_7<.?MM[Y4'S*'W-QQZK3GTTX?%H5T1?;FVO5S[7MAEKT;^?HOO2UN$U,-U
M]:_E#U<:CS7W5$)N?S'5[CQ5-V1S(5]VIYO,U_O/S?=4N.[&9]9A2=6_NMTZ
MO"X-CNKWL8H/:*X-/'W".[BS':C=[=U]?Z"E^<A>5Q$&"H^^GP?0DA27PYN7
M-ZWWG>Z[]^>PR'O%5WO?X[D$<H3G[][BFIH1?,4-^>7-Z_/W'?6IT^UUSM11
M^Y-ZVSW[T%*GK8,*+,-WVI8WKWO=PZ/.[ZK]L7<.0A;.M!W9WVZ[/K[^.?M9
M_1KBO;!-;T$52Q-1$9?_L[_BMR>P]!_789]Y:O].*1U$G;7 ;@6E+[UV<M5Y
M?-L]^7J:T^O2/JM'&+*F%(U?NJ]!^06=<J 0"^J7G[NO'W_E<KG7Z"CYI*,,
MC(&C\ K&E$X#811?4W]\_3:9I^H\N8+WODFCX87^VA/=W=Y6;T#A4N_#M(\]
M?5,J?NK-(S"(]K>WO_)\/V'>QP&88.-DG P^:S":3ML*3O'N\Z\]\T=/=[8?
M7^_AV]U]LK6]N_W44PF_YJC^&!'Y_\\5$=\DO$(<T]8@F2[71=>JT!1EV/O.
MV[?'(&+??SSKG1OXH*](1!_ 4AS#Q_.6>J]'HUBG7WN2_AOG:99_Y0GN;:MC
MPO8\"GM89VK.Y\[NSO;7GNK!& CR(@E<B/+I]M/MW:\\XW,]T;-Q$H-I]VAO
M9]><TV9CQ4G=VW^Z!?\]K3?>[GN$TS&3VO_(OV.D W-0O^:&3.E-M:_]]OQA
MY_;\H?O:S_NT*8HHUBW,V'?5SKXBT50T/O7H.&FII[O/GN_O/'W\E4GVUV0<
MHX;5^QQ^GL?-1K?;->]_\>SIWE=__P%FID>Q5NV6^H3Y__SRO=W]YT_WOO;+
M3^"]O62.[9X/->DZ\=>>KN6<1\0S]]:09SY_LK?U;!O5O&_!,S]G1/3_ T;)
M1"^^!;/\(R-:+[WQ*TYQ(#3>N@("7S'1+^+/-Q[_%[-G!U!4X,_B33- D _2
M-?]DXYI?:]?\LX?EFE\:C[M^M9]LWY9XP<CJ_._[[IONN6I;@-8-':\E'3__
M(>CX:[#@6BK^=A( 7O_+Q]<')V>G)V?M\TZS\>[DM\[9<?OXH*/..F]/SC[T
MT,UZS<AVE@WM2P+NKS]R?[4P%LP&^'V44NJ?[0 W(, +T&@G!,S N;"!:5\2
MPY?Y0CUZL2WHQ::'291AC9MDIW/"&\(&8CXI]S$TJ51^QU?7?>5-DN29:D\F
M$3X$=-MXT%*/\'I,^GKV2AJMX(?GKQXS@&R.MV'G 6I\F>H!UB"I1WP#_2*7
M4W-CKW;/9%)R79_4\6&IV3"98;<:DPMFF_M8:$RJ,K>](VW%M21IX]";C<$X
MC"\T]PX(,;L\2FB(F!D\8?#1,%9/U +,A<Q[&M5\6K#.H6T!YR_9JGZOV[<]
MV#\,<OIJ</3N^H*C(Y^ "9KT1*9F('6*4.@"E[@Y3/I781P8N.#A2?HP#AM3
MFPX(19@/;2\<Z5S:5O]_<\9SLK,)I';/2Y8:8G\/VPE0X1G*J"2&$NS=<S/W
MW&;C3WEP&F6?39WL%,XUY@0A'X()SC3-4@T-4V"L4'_\=-2Y='P<IEA[8Z$&
M@%=TI!1Z1U+_H\S-8W,$[W $U_L,MF<S3)>;"O1 >\AEUZ#0=3UJLB)FG<[E
M)X/=C26\C']@I,9QPFUJ)*'YG151_IG,R^>"ET+MJAA>4GN8X#CF439:6#QH
M=]6 VON 88\]@ JMPSCSVLIPK#3J+[!DB8]F6-R!Y>\.<RGWQD%F$;[QUS">
MA^E"<F$X%<9(>!FJ@4&Q\.:K<QV_SDYA28#,$Y<.YVCG]7+#5,I,96?O[BU1
M=EKKQVK>6D4OC$6A!#$8#CYSKRFI)(UR@[*=ZLM(7P4W/<JNK(?2>D-JMT5H
MYO(D:HT;<F?$(17*>U P5.#/J+?T:9[!G+'+B#= $(X#D;A4@H@/S1[S^957
M>/6MV(XS)EZ$>OI%$DXRQ3B/S#GL*#*LP\RP,<6T#_)_',U,]W;F2U>14S>H
MMFH8D9[ !;X7R"'20.E\'$<#3)YN-O1?J'1K4AVH41Q<+J@'?.ZK/'MS\N[I
MY.VNX<D[(;E$1VNB?<+#>DVAR<A!A-Y%;IK2820^Z:,CE&^;??YA>G[P0;=-
MT/&B402'-L+S-IPSQD;,@Z!..UPQ*-@81D"3ZNJF4KA,]&D:WX;B[T>!76\-
MUK<B/X0QS!I);>M(7^J)1\&!.@.KB;FB,]S6U^(T[75+-N?'5J^ESK#&<*).
MP7R;AH/%+6;)(JOX[)7V8+-A#,+=C4%X/^?IM_4^3G!'"OH:['Z/(1:8?H24
M;G%,-K2PLK/AT^L(I;V^='(@?EZ0M@?C2(_4-52C3D:C:*"Q.ULV0P@34O2Q
MK&V-.*YS1[,F(KB4I0%;'UXX'#K_G6G10?W1;K,B+RO6^.;8_&CF+S8X^'-.
MHG6"QNV,.DO:EA&B>]_N(*7Z C1<$SMQ=S4;M;>=ILE%&DY-A.B@=W!JXDFB
M!$PR1DDRHQ+"OK&/>ZFR_0 363:@Y>L=_W_QL.+_&[:\EKZ1=AQ3AXO@#NS7
M0@!G7J]'=HH@)M$ENP@]_#U]&2%^-0:^31"@*A)*3!V8M-^"2EBS\KK"%-_L
M;C=-F6I"#RY<7T!Q\T&#!FX1,KL(+BA)OB..+J#KR&(PY[:;:K-1>JF=O^OB
MLW'.?'4#XLV#,""*^DO]L7.N_L/YCV0VW'C>&S/AQS<3D)BF2993OT!REJ-\
MHI8'6.#"0@)9Z2STNGK=_.@0"38;T901W/2$8/RH(4"(2/84(K@WM7]#J3^P
MYH0>Z3('+PA\U%W4+)E$ ^*(Z&'^ I)EY-A+O?B;VZ4;2/2UMDOWMA^67?HE
M]15/;DN[)BU]QV@R&P)>/P+>^2$(^"YK'>):U]4S7).G[U4*??6A4'3NAF)/
M'7 LMQ"O6WK@KQ_E3OTH95BG#"=[D]J.FX I/O_OF[R[ J'H$IV+51'DD:B6
M1N!5=Z["P!8_.L.TFB@;Z^'M=)+2<_E+\V1I!\3->V0^V# :VP7Z6>*/=J0,
MI<[),TGZP#H(?IW;Z*3Z L$BDW112"]W67#21QT]2-277G(+L"]..,G'@S"5
ME+*4DP\(<]][LBDD<:W'3)9!E)F<GT ]VET^Z'!XB8,RB; S>*;)&<IU.)4L
M.3\C7CW:6_HXF';I>29; F]TDS+]$19*LNN_&'W]CM3;C=$W$/ENO1FB%BUQ
M*+@FZ3 !V#973$#>-R$T@_<JW" P&R,_(Y2[S=KR>HBX]Q)VO;+0]?1S92R%
M$42YT?,E">L\L1TJ$9J(,/)SKU\87 W$5!Y:J5\(#8G:6FIN?ZZ%TJ;82"NE
MA+9F0RJUJ'!HD,QL/OBJA2P-_D[;?V-&B30JH>(OXLSWQ"W=<G.J*;MRN6)+
MC?25ZVV,_0Z\FA*"[)<#:<'%+57!*^!'G4O/#B]%WLM#=[U:CL-L&/ZI>GDR
M^*P^A.EGG7O@YP4>@44S%TF*E7JJ/O>^I=I8:Q;B-&*]=(R%U$67H"C7$>4&
MDLWK)P+#]1[KH :%S$)U@3N7SLB"4J>$<2$^LF/ 4F5G><]-!F_[4E).,&V0
MZ2&+UTDV<<UM4AB@TTLRJ ?S-(5)8\DC+T,;1$%>-IV_$VDNFP5%'R03U+D4
M6$Q2YR"@4;@6(19\Z/L;9;92K(56AQM/-AO#*!N P/,>)$SM9 5MT5GJ+QUE
M2.PX F;\9>/U*[N0D<.Q@JO\<RA+2*)=NL@A)R<4:5_VFXY+S<87# 8;57!!
M*<-.<P-(Z_(I\G58G4N@>.D#9"H_ QNX@M%BS>@J<I8]XBXK\".U_9 !((U,
ML(^P$Q=#?J TIG'A*YFVQY;PK'H9^38CXIY:*=[Q3!S*1%S7);-6(?=>&H 6
MEEH>;6>828^:X@2;C6K-096 R3=<%.9?4SBV;?MJI(I#ELMK)RE-Q^U"LVTI
M @GE#%Q*B49!#8ZEQQ!56\-^L L>.0PH9Q?< ;6LG= 9]Q4Z3RWBK<;.6519
M7>N'?<>&@ ENNQ N+' '=*5!9D+:0?':(^K<9'_C+VW"<>G[&T;-R98@X^Q4
M='NVDNC$G5J#@Y[9;'2],'?E 5UI!,8BRXSC Y75VF&K'6Y61J<DTW%$!YLO
MF5&#T%A3WR"CV$KG]DMN9D2YY&EI&[UV:!H[EF6EW[^KS+R62*DU#6IY\PGV
M3L-VH?,<XQ:NJ[1;,;"?HHP*#[,2?\!>#P54 3%0FXT,^V1[0K-HS);L$EUN
M[8<GH,1@$(EA:ZQ1K7KYO'5M_ @7N$_'S.$U_:6H/:HB)]GV]BMVWNT^_>_[
M<25M+^-IO8\U3JYG3V![07SF2(5;Y#I\2?&;G5]^AAM>JRXWRLBC?*)=]_JA
MM>1,CC[_&5]@<RPF1[G42=C<&%[Q@&MZ@=V@' #)"X36;!A+Y!&6LJU)/XAK
MR'V3H?<P',F[?Q='\DW9,^>&V/(;PP8SOSL+,DO"B]&<CH7M%[5-*$&O";%4
MVR3='G2KHI*F[_-E./O<2R?,?%68=3I/KPA(!L_"A;&"T4;5<6:SS*2IWNTD
M![WV2F-Z,:O5"::G8:V?USP;Q2V6K<89Z:IA6534"AMR2YFV=R@V9'U!D21-
M<3VD,%IEQKU$_9*\-HG9O#\P%V:\O"9_J%[<QAKU/%H\+)EVZW$WE>/&6OD'
MK='RR]; N5^R4,C%A"5JR0@39&#=HKR\6('J X58_*$1&D+L\R"_B<W!+)],
M-JCAVLPT[625$FM-0:]-%EJ7%?RD-M^R=$SHD&,^SY#Z+M+25DW;A*P$FA\?
MZ7CAV<'8R8J[;,EA5-B;J_"$NNE0BC\]DX&9!.X*3E.&*45(HTX!AL/(_4GI
M_5-;5\G'G&UHUT-93!&JC1<3G.]SMKM[!'69M,U1Z5\A^:6F/FYJLU&@^>,$
M5"B&W )2\)T>3*[6B+V Z<0\;.E%AD/6<*-CB$%-"V+NA\9O\6YF-*NH[,OT
M&IM52Y"_ R-JPW/_8,V_Z!8,;-8R3)FMH #E <'<4H^TRR@T]I!KUTHY8X%S
M$]O^;G_.DW0^;:G*"ZV+P;X0 4S8-^2>,+2'@)GE ,\*DCL=/22D/B$Y8&_R
M$;L[KR/S 7<KE;0Y?)67HUT7?6!8A]K]O[:707^!K9XSTZ;43+U@#7XM?\F'
M*(857 ?&W--H\(74Y;B>*:+#T[#$H>;FO\+&):.1B92G5.$ YE9SNEM*)F^/
M^1"UB:@_ET!.U0LJS<]K6+2#V+D:)[:3=>4)3&QVJB7VC\$GE$F(O<Y6]BSB
MB2!_,O,"1H>D%\9(A.)!*"HM7XM8>@)Q*!G47SDOH,J/!KGTGPQ1%,0<6<K)
MC*T6$-AVXZ3J6!\&$,X ]A@+T_O)I2Z'#)F:V*7 TLG@.GJJE5$1"N+$=X;G
M?D[W*G"BW6^3S$H+6E[S;Y["^MW3J>L)S4M-M:162)-!.D? !''/#LDY-<\J
M>@V'*@WZI6MI+)V:;1*!I+0&+N 88'E/,M##>8K?(S:?_]P95UYF@<7K$Z>H
ML=6,VE";4(&C,-D<_1".B4^I7R5'HZ6Z,9B-*2H #E(M*KFFN6BJZI@N:):/
MZ/2:@&8HY5:/7]XJ9?QO=<J>WSU//%RG(RCGS;+SFX<A@&B\E![6%(+2P0R*
M44."&$I&B/I5S1=P[S('D7&Q[#E^U)?W>9>:G!*_**[FX: M$%[P%;I4\*DW
MZFW/=UF%D6XV2$E:V,2C@;<('"P:D,(!AS"9 S_*!(RE6FJW;,;&HR1XOK!N
MMRS!VQS$FQW$_CH?Q-M5N=[M+)9M $>9J\M*A5Q+YY..0_^FQ^%+WGF;$_)@
M B6;DI'U#I3L/:Q R=^5J0_6E:F7+)@;F"O*MU:([RVQ6'SUQT]:O)'E\M7M
M%'X )=Q83 'G+!_I(9@O$YHWFO>39("?0$@@TP+N(3@(-.%^,EP4=#W*FR<G
M>VW:_$9O^AI';/@ CIA5B#YKGR \0'[L!:*SHC\)'5D>UBI>-DU R4A2RC]D
MI.(Z79Y.9HAF069.YD"L!*L2P3&>3SB9VH?HL#>5+0HW&PM&7H9I]8!(!$5X
M$O*!9!_ D.)-WHRJII._ %[*D8L,^>FPI<C.YG#=R0?W#0K%;^6#*^7X$2+I
M!'1KS+Z3BJ@O=<[Y601)3'9'P>:E7_0%>GZ-<D_)EU@7Y*#3BD@U,NK,C7I@
M1FW:;W@&0M5!=QO_624M^D;N,]3D-R?D;^4_NT'>;"TQ4S!^@/*B:%#[%.Q.
MABF9(YWM^G-P@^I!/-"8V6,J!Z2\S/R*M18XO W/_YLZHLH)VU(-5<K5!AU^
M5.M16D;?V)>ECL!+K-_P\U(6<LV+O)HO0[,KJ+_F 68J?(;0!HNF&$-VIM"U
MOF/8A7$RU<9Q3(-)8.AL+K4V4N'O:O<7C)*R)5*P:V_)U,ER@;-T ].E3.]+
M+)>2._=KV")UL9M;SCN*779=O<523;_<'+Q;&RQ[:W"V!)#PX^MS1!CXP 6=
MK%W=KW&B2K9)LU%OG%#I.I-IO2@RV:??Q?180NI+< G_5K3^(YH>=Q(R=5@=
MJ[UAS<8#E"FKI[GQ>7T3$;*_!B?'$R&#<9Q,DHO;B8YE<?5"3%VB'2[TC:&)
M:V+?N1W/EA$P0'$8.ZEXQR@5$PT*3Q)1">P"AX49U3YFA2%WAUMA3LB&D.](
MR$_6@)!]Y^WR6O ";=<G>!6N=Y(#R9R:K /A8W4[%_<'S8;EW5Y,CB!4;.S-
M1A4*H0Q@GI?11%\4(Q!>Z(,NYV >%^C74_HUM,TR[N&G@NQM4D'6.A5D?Y,*
MLB;<^.F:<6-.D;T!YUV=6LO9<V6KM*HY8!QZ2-;C@6FI:Q_FTBY\=KX:#%KS
M,,3\W>@(=Z3*9VM&E41L6.Z$W:4DHZBB^8IEQT4]]C*KLB+4?33+ U??+@ K
MV._2KT6G%V64D",]3FZFD59*T,$L&[%I%U+->A(OIMB9))OWI0LTE@2:?"//
MVS(BR#303_P^+51E9)5?F7?!E5*C\F>%I:@]3X49PQ)=ZEMVL]V<&WMNGJ_=
MN6$8A*)CH(2]QP?I@'T(2Z\JN:(]PA2:1/*9Z,N0"V"I!WJEIA*='FQIUL!/
M53V* V_XFU*>']X?>%[C*R80@2A6?U [;H$*6$&D94<R\WCT+M0^"?V!8*$Y
MK(8-Z_OA\P/:%N&B!D\6J_H%,R->B%\@+:-GE*C.*:K%Q])E?N'BS9[N/S<C
MW!Z_90X>"@'B-+7B&XK]P:/Q!<9H&GQ9X:@Q/&?B!K[3R0IC&( GC#.6QA4)
M[ 45FHU"/589/9V[1=4ZPB3 89 +Y=*0#@S_5!]KC S*(E]J@.2"$IC&DF=&
M\64RN:ROIERMO >%BJ]*6O3-'=LEAV&]BBV,HFH(^(K^E_F_-P'2'Z<TH*@0
M#1,X^P@7TM=A*DA1'-9AQ(DR%'BDEQVVJOP"6@3M"(S6?(P9;;6ZE0#[XP&8
MSB>,8U] FZZ"+<&0PLR@%QGX_8W NJ-U^6*=:).],D(:9])5UL>C,OX9:B6X
MI'DLL7,&,8YJH'@X[T34I&:#,D^8A6:<WWN%S20$.\UO;QY&5@D3?'T*C7K]
M'+03F=DXF4^&".Q#P*:IRXX1LL92+C9,&4!F*)F0&T*^*X;+]II1,O=G5J=>
M=F[G,IS,+2:XURW!69::+RD!A=F,8>]A7'#HG81FH^XH5)Z1Z<EH2]N1; CN
MK@2W=JA!(DO9C;N4P@3KW>^K([0DO1-(#4"G7))A:+H8&['L2S* @(XV%'17
M"EJWFK<3DD<.8:UEN%<!+'-%FVB0H>B/Z)/U!M9*H>&IR%]$++3%U\T&*&]>
MM@0ZXAZ9SA"$MC9,IHBD./"+G_^8IU$VC,B:>QQX33I\A?2FV(>!Q;)):YI%
MW+Q#]Y= W'5?=TRZ%.DA(_5_IG#96/WC'P'\]X]__%\<3??UPT(YW]]D;*QU
MQL:3AY6QL?3@7;_:=^_WNONC]WM]V"3\]-N3\+6W520K+C)L3/?#.]4[._C7
M3Q?/=W>V=YYEL_WMUA^S"[SA_%\_'9V\.V&.0N^[%P[_!9O[]+8GIM!L]F.K
MAW8ZP:/8$M\O;S9[ET&Y=E^!.HNRSVRW>ZE&56]4#1KQM]=@*UWLBT/XYKKL
M_MT=H+ +W18OZE=6=Z_K25]-?']CNO_:7?]RE4^^PC>\?/'?MQH@.VAKC\\M
M"-EKT%MYRMF!:=6+CB]&5N)<(-?1P0*!?WK35AV+JG^W$7CWNW=3.3UVG,3@
M4PF.AH(@7$1V0RC+0G-<067RBHM5%_W0@WE&96<O*Z#VF\.]L[/J=.^M/-W_
M_,>+I\]>U-VW4[JOY@VKN4#AUUNSA!NN]>LNETHM#,R#<8[!1U<N]F44N);E
M[1LB7",B_,"9IDMP?>KBMTAII0!N@4JQKU -638;CB[]FK\ZK-',0T );M32
MO!]-)L6 \UJZ!S>DOT:DW\D&H9"MG^+@RG3KDJ&1,T]UGE)2O_#D@J:!=P:E
M#-/ CY. CG/H6H)OB'1#I*N(],R$1VS9M<LD%IY=0E' 3E?(5*-XCHDY\"OV
MQN/*/B'8DM++E2;4D,&AP-DL)F'07ZP,;RA]0^FK*/V4VC$2?3DAGUG87"];
MWU1P,YF.TC#+T_D@GYOZ5*'1"B,WEA_6JG#?@QHK=4.H7]\IL\9>F0^VP7N@
M>H:L>*K_#*>S5^HDO0CCZ#_,:V_FN]G0RXM5]+)_';WLK"^YU# 0P4/*OI)C
M[]E=''OE4I2^5A-),KM*;'/5:T/7@V1K@ EI+GA=:*B+:@4P74TZ;@@L.$<\
M\)&D;/P5 1O6DX5Z#AK#D^U7.]L&L7"BPR'UFAND"78;E83I3+FNMMQ$OMAN
M[, S3@4:]^<2U*=_6 /U?@X+ CQ?Y$>@ND;'H?S00+V-Q,M(6 R!V]83SW3%
M*<NVNZ_=H._6N_*+=[B.$%>ULS<-5EW38;>XC/U@6J]B V))&+1:(W8>3G.V
MC&I;P]D6DU0/*@T+J=VR::Y,N8B4WV&&4&G[N.&;7\8W=]>7;TI[9/66J]6\
M*-T:<,NZL^2U3C:Y;;8+,E>(+G28!J*N#H&= #,()ZZQ;HCME?705"2O03K-
MM8M1CFKN_ T2:QYV7L*S35["-7D)&[GPAB!$UU0NM"]T/ Q)QS(BPK0L7B,!
M\1LV,C]-=4:0&#3:C[W:5G ,V!&EH"*A5I7KQTY=MFFL$TW*T%".N<68(;%2
M)XQ$J#0;V'2<,4*X%[U!4;6X(*2)TYJ"LN9ZA@,' M8DRJS]FA>:5;?0;43E
M-AHM#<[\M*2=M/'A9'-<CXBJTBF]E@#%M9VC>0R"#E.+<?@&]/;X8C0W&&2N
M=36M'U9VH;JJO6;%U.9X)AU@N6)F218"MZ\F<$$R# JE,!)0,O"7V%R]7-98
M]2RAV)=:LVR0S&AJ& @CCU.$C=A7E*A>&V:S[VLV"B63&UWY'GU2:^R4LEW(
MS\J9[QL'U#=Q0#U>6](P220%V*AB8M,JGG*+F Z"XI2".CX/ZR]>KJ#&#:?R
M S)/[DZ-WP#EYM9D>,)A%9*,@@/BPXF*+$91B)I/N0-U?32RMI]B;;NW3=SQ
MNQ+D-\##N35!<BEB4;-R61N.9\E79< *QK=(0W)E+X=61X:(=;#\)"Q8C+)I
M%BP!$Y&.@X$%QU,YO"'F0R,_<6DCO%3_-= S8;%3EZ'%[\,+"<_ W4=I 6EJ
M2KD&*TE_HQG<%^U_ V2=+Z#]89B'@M(23A8Y,56=YD)T!3@9=EM266*Q':W?
M5=QO7GL=+Z[7$:Y[01'KIB8O$%M .3.OD"7H=Z:59$ 6"-&T/P?QA+_@Z_)H
MZW,T^-P/!Y]E/+T\3#^KH_"JH#.YQFO&Q@LS![L VI 4;6Y2"+[]N?L&R#9K
M<.XL2E/U_#4;]?KZ2@W]-J?/"BD2+?,,EJB0<0NG".22QE+F>3S4*2?J@C"E
M/ZX-)".)P$%&Z0LS-,%D$'Z$F^P?PSR!DSI(V  ))X-DG$Q@'!/D!:,D&19L
MFQ7G56V.ZW<[KGH-CZMGLZS,>S=="@GVR;3!N3;9W3N!B$;5;! <%;D^2VW7
M/;&%+M=!M*9]/7\D>ARM(3UV7/$/8006C&1*=.2.,@5[V0+Y56T*8SYO2H"^
M-C5=K#<U>9WN+94,X!O,ELWFZ:5>%#KIX8TH6[77M\ KJEE*30\PG6%WD\ZP
MYND,SS?I#'^+=(8O8;_C-62_SA9$K%_*,-7Q990FK.@-]:6>)#/2 @/)@43@
MWR&05+J 2X%[#+CO16@R8;DE5Y1-0G;Q<3S&MOJ:S\#JU%R21F;G?PI5/IAY
MAC^F.AYF!D'2#0(54U-RC(C+X48'_0;9F>L;5)3*2'VC0.+=L1*6E01O0HE_
MVU"B*P(SD42)>12Q(L6TKJN_W40]_HX1OP._*)8<*U+"X1>)E,L]G,O0E9QX
MB5RF>L%%!Y$=DN0%X8S#OU@"'T.Y%1L1^O436==7A)YYL+9>S;8&[6Z,Y')]
M/;:ZIAQ;FL'=,A\"53U)1:0H'I*TU[.;*'<CBS>RN (]D!J;1EH$4:H"1UG+
M+52$<#$>A&5G!K;W(@DGFZ2$OZ5X]DF)@XY6S[MQ:3\PJVP^8^#Y51&;9N/&
M/'0CHO^6"3(>+1:D\346["W39; XMMDPN$'58)^) VZ(\&^9+;*,"(OY(5[R
M'[4'JTD?]+["9\[C:"#D"';*<,X?@.G!Q7E$WL-2?LFUW/ !QG;V_@:QG8<<
MV7GQ]\& OPX)J0X\VL# O_'!JS=TO'9TO+_]0]#QU^# 0,4?C[OGG4-X7_N\
MTU.'W=[Y6?< M^#CV?D]H++?94C')V?G[SMGQVXT)V]5]^BH>WS2[7VG,77:
MO7,>TF_=7O?D^*OAP)<5L[+B5CC9GH)WOYIC:0$H1X&40A//=D6;J#"2/F)_
M,0H;3]4.><]<6-(+GYGO2:%QKZI95EPTN?M]I_ON_3DLQ(ORW,]/3N'*OU0&
M.OY0$1/9WGXE:[5UAK?5_3Y#0)#X@BO."SJ1&[+_4EA9V">8YJX__.+0ERC.
MZG:[\;JTKJ0]%^=\BUG]=M0^['[HGJEW'WO=X]Z_?U=GG=].#HCXSL\^]LX#
M=:C3Z)*TT,D">R*^T>-P,D(>^JE]].ZLTSGNP7*>G/> 3HZZ[>.#3J"ZQP>M
MP%^K$A7(:E;_=]4]R/?5<=*Z/EGYV@L\T6$9O_Q3OW?7D-W3+]B"%83U].$2
MUFU-,Q_AX45KFW2?6Z$\G%(16#0:!=8FN@?:*YN9]RQ;BIHCHZRI_W-Z=G)Z
MTNL<_M\:L;)Z #MW&0#M;;-Q>M8Y E9PW#[K'OU>#2#\V"2W?Q>2NVS=.ZDA
MH,HI[/]O(.%5KW-^?M3Y )JZ#9K]_5C3]KW324$ZE"D2%+NW[>,3==KI@4!L
M!^I7.(FJTP+A]J'3/<0OVL?=@X[ZT%)OVF^Z[7^#A&S_!G;$K_#%6;M[U#D+
M0)M!4?A!';346Q"-(!'?P89VSM112[T[:[]O?\ 'OS]6[98ZZL#X\:;#$SA]
MW0/UX>/9Z?O? _CA! [C8;-QV%*]@_?MSMNW>-DQB-C?\?7PW5'WX/TY/)G=
M0[^V/X#6#H_L_;M[? S7^D+MWBAT0X;?GUW=24(>ZA$FXF *X_WSK0U5?'^J
MN),0 \:QH89UI8:5HNH:\TN%8+I-PJLPQ;A8.DL$+&LC%+[9AIM1&^U\'T_Q
M=5.5W]^<G)^??%A347*<3*,XG(!J8F3*=:JP'=_2Z0V&PWW]XO;$5R*AZQ[L
M.Y=J K>%6,$2"R_7?^5 ,IB#=6LTPDHQRJ?WH/VU>P'C/O>32ZP1'.E4QP.-
M.?_&^2*%!6H0$I("_/9+]_5ODW 83:-4O4/PN^SS GNZ)PSX<)["*YJ-2^S-
MG<&OH4(HW$D+VT,'<"_UB?X6/A6_Q5^;)B&]_0)L+#B3D"I'-Z3;?#)/81WO
M LO]=?;&.A?4M2MN5A:AO*<$#8-I?V&LDA0V\Z5Z%#UF0IRE>A+A,4IA+%YV
M%F4(8H9-@F V/9WGW"O&H#+Q$@94FCP8P%-=?@/^W,NCF6F0CD9!VZ0MX/W>
MTX8426[/X.T\GIWM0.UN[^[[V^4]S.X9[/U@C&4K%]Q\W;Y9_S6.^EA>'>9Y
M.!@3$@_0<9X$6%%-Z8]R)9;X9Y)F&3/P,OW,+3[JYD[U+U$VC;(LG/ K8?W^
MF ^C@2XOS'R6Q,M? T-Q(TEU!!P=KW@418^+FZ"HG[W<G<L"QDGNO1%IEZ"P
M"R,PZ5*52>2)<HUO>V,0S.-D@CCZK[A(\R&&[?\."-,/.=RY\T.'.[\.MY_'
M$P*Z0P9Q%8& '.H1(9(PPP#->C)!.1SE0"C_03Y'C ;91.A=)[C!X_!2,\QL
M.-4&)I>P3APKBF)F?1Z_9;:T_#!_!^V$Q+(38"CAX*2:?'D&Y&6N7Y%"M?*!
MYLP" MFO>^HHF<,]Q,=#Y>3DPC9<)08OO4;J..T(%KY0&9*&\06Q;?]IS.XQ
MNS2-""BYD$:O!^$<]CY"=)MXA/5R?1T#(6!E?NPQ\C=) E^U)ZYF9=!2CUA^
MVJO\;L;PA&8C\]B_2<_684K99'UM)D;@.C#J#$:7S"G-'Z423#;6%PDEAQ%V
MLNN2A9H&]?J(6(&$:R,L. V,E+O3.M>++2#P9#X9XGAQ*4T?&=I_3^HY.#Y/
MKR'A:@5J!1SYFQ/Z\<DGA7D&G;<G9VA!GZMN3^'G-[\K,BPZA]5VT-]\E#NM
M?_[C^<Z+)Z_4N=63J6G,'W-8?E"&&$$<R($YSKS_AP8*XH+/LIYDSN5IF%+&
MO^30%HXN[CJB3 #!SOL(\RT7%=\W\M@#:KLS;I1.$!:VUZ%MFDS%TD;)\@A%
M3_O)$$M:Y,QZ [E;BYY[7?I=;^G-7(<)W(,L#,Y=G3J/];>R!;!N([B%N_)X
MV.6F8Y*W#N^!#Q J&>'F]0FY3D^2JZ!\84F$5'</3G@8I9CQ'&9)C#:*E((,
M]9]SZG):[,^T3"_'U]Q>$U^#3=LK;%K-&EMH_[$F1B8VJ-E@;!CW\;4\8]4_
MO_S\\;683R$8W<MNPLN\)^+'UK2%Q&%QSSP+\6K,%M;2K:DRV]7T '-;31!%
M$P5_6<+YN8N8X?XC= 9-%M)/ZM)AMXDA[Z2[F1)(J1.TA^E!V,1KHGZ=#R^8
MP@I6V$,UC/X.6#4/V3#:_:$-HR_BFHZ?! ;)%53-"7<"<9X1Z^6IT1LRU6%M
M7X$RY1@%;:@>OO(54<OE$B,U655DW6.+M=,I:*JD"<-;DS36BXQK?-1(2^T9
M*KTQZARB>K\5*,P.?Z_:] C1PXW/YU+&0(@N%2Q*)P>FX8):YJE"P[SO+M[V
M:W0264/N](=:1\F+Q5K$,:G=@=M$;\<.:G;4:8N]^12F!;Q^U2,.ESX"1,4P
M\XRW)"/%4"09/Y,=://^1.IBK)SC5YNKA!AA96(1)#37@@C$'CL7:3@;9^H)
MIU<]Y:>!]LP"B#K$D8GH(T;"-6^Q\=M92QU$Z$)OJ=V]U@YC"0SG9)P-=&;A
MUF*81CX' 8J_D7"T#70\GR'J&E7PE9*YE-!EIW -BGA4G/,)GS*B4M]@^J[$
M]\02WW&BL"X)%160ZT!DZM'.MIPLUY4'A!6\8 **+%=0(7!282L"3]E@O8PM
M\.K6!V2.?!E?.@S$U"9"R_"&)(:7P;3Q<;]T7W=C.$; ;4PUX1LSE<,0%@A]
M_-AI,U09J/V(>Y+$$_C=)]PUV*6GWW27BEX?]FG):>7%EAY09..%ZBWNU[6!
MI>=;_S:1)#"A8MXKL[EZ,/<*UCM_(:C_A;3/E5Y11366QXQ\!P8 &_:YEDZ$
MV<G8)9[ @L60A3K34D7*0H54-&J>6_#Z@(RZTOTLRD75YO=/,9X41N)>X6%X
M;0LP.&.XWEA,%4&/$#;OFPS*$Z&BBONBU.,N:T"0SY809*8OD22?"44.P@D&
MEE.F2,(E<'M>-N.J-#D"M<]%ID0R(D5F.KVD#;4A/7.\#Z1[+JQ;,@K(E08L
M?!A> K/ 7F]Z, E-O[%B#Q3['N'T)!N&\U17['-SB-9@'Y[;?6C'C#Q"9QG.
M!4D_H7QK'\_"B*PZN]"!H.Q,I">,;ZR*)ZA(BAFK=7Y DZ_N&.1<8*PY6:@3
MTER2 9SM0'  8&T54D@N0W(167C*TKVLZ=E'6D>X,!%1GG"89<D@HHBHW<QC
MWS/Y  W034'M>AN@>S^T 7JOO.J%XU4HN\,9*M 88!-TD:H?S CP>BO0L364
M$\,:0:%(3@R!ZS0;GI"Z5E?)K^#MBRW0)&WRR^[.742:M*- ++,9\%"9\^IQ
MQ_<F4-= /NUL%P14K1\2A ZWG8GB.0<PDBL_-(?H"B#J05L;+->OJK/'GIT+
M5B%"=07J)2K+"?GQ*2)66378JY_=<GK2904)NIB?<:9>L28=J&@$2A^Z330*
MMX@C/$@+\OO5>+%L!*M(GIPPH**8>!TZ:E\)KH\>@DT%0P":20-22NO"X!'V
MJRIY=TFH7F!?#[8#<"*@(<5BKL[(CL5YD"6[\#WNH#W8'\3$)2=%Q@:Y#<_*
M0M[0!>XMQ<UV J-;2S4(6012T\MS\5SU2"R9;^G'A%T4&X*1G:;'B V4L:9)
M2L@\36F<5S&\8AS-J+JREHQ]9SJ_="D[=!3K^,1$IY\+\3KJBH0FB XSW$OX
M2I-IN'\]WQ#+Q"90F7'!F%GY=?X*=NGP2"DAHH]O$29K6R /="3!@X$L/Z(L
M.ZP[,?-%-[WSP M*:('C?<\(],Y.@>'9W0,J"V5*4[@6R( "-6ANA%,T*H?#
MU'JB<CW1LS$Z,N(Y=G)VF6I(NLV&.X?R?)8TQ'- TL"#4.7QMR"HOFKIF\"^
M"3 >&C#?RLPS@&C[_A3@]&>@QSE.XF5#P+4#_UK)JG&<.' -I&DI_!/N/<>V
M_'/'  9E/V3.HVD?QU$QKUFVO=H/E"(CQL[@$W8[7S)]HG/*!SO+?"F%+@O.
M[$@+8%5 LX;?H%<PYKR?1\.Z[1:'J9M-A DIY!APN@ :.QQM;C;86W&3)&'U
M/7*$V6GRJIPJK!\KFK9I%EYHL?YPTR3W-\;86AMC^S^T,?9%<LF+9 #C,E[%
ML,KF*(6"OLB6ZR\HT859#R9)1LJ2]3Z+G[6@G9==R@5U']_,:D;YX4,C) L,
M<QH.M:@KHWJ92DT9T)D55^87#BA 5'(FIZ;]U_>UEG9O:"UYLLBIX.RFRPON
M9A"Y"8BS+/)MGI)*7E"D:"'#2988R\G3ADG[+?I*JZJHL[M]9RJ6O-Q &<P2
M4:YSW&>K2A9-XMNIMS5*(DS8SX+!!24UGVP7IC1IU9%%#( J*I7H":@(+\WW
M*L@]GAT([:K]"2.L75I\+*]/OF ;9('+C2>+G:\+BF,/T/["*>K,MJ&WJ;ET
ME9M2A#B#PSE"M,*?26468Z,\(]&)><0C(DUI]53-TI0(KR#QU8VY3PU?N#DK
MJHFWM%0/^$JS,9- +"[=DB,SC+)!JBNID&M@4KC\MX]E8Y[*D4JV/.K$"R]^
M5>$>E/"(+H1I^%E7U7V/UQ9B\\;'4$R,[VO*J6##GXS"JY .;>6Y:70QSDM'
M3.(\H/M@MBL\JP_J B86I\F4.H$;7?TFCAMV#C .<=$[0&.@QWC9(7[[M>(3
M S/SMCVK:+O8^T/[-06)]-#"<_-\W/[@C"@]6S9H:;H<LW+)K+%&S9E&P]AR
M^@ML3+@.<FJ_X,I=FE<N]&%7@-8&5P HP\0]?0C?/V0ULM+Z U<8Z#2V=77^
M3IF(U2B\A/.,UA!LRSQV'Y?6:SW<H-"3C1VRUG;(DQ_:#KE?5O*D&!6R_+3$
M P)AO9SV,D:;HPP;[DD$$#=Z,@HH5UHR^_]?>]_:G#:ZI?N=*OZ#:F;.KJ1*
MH6,[22?I/KV/8G!,MPT>P,FDILX'&<E&'4"T!/;V_/I9M_>B&^ [3E,SV9V
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MAH%2US'/34#:+&N=V9YJJG0V%)1KAKA^CL 1."#A(A[7DINN!.-2,(*2"T-
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ME#13S*& TR(%T-*,'$U1C@J0&QX6JZUM'RU>&<)X\I/Z?K5?+IF,ZKR%9HM
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MBS &' T"LWFEGQTG29Y!UT(47<U),E]?XE\1<O(.9'>!]?[<8DR%..S MI;
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MC/8*PA+77L=@#Q04]X/#_BH<9HM(,ADWATW8<',_C$"?\M.Y/UF)#V9S=\0
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M:-!*J@@29RVT7\];E2YD'T!1<INM2Z,(OPY',(RX#2489: 2'J>S;ZB0&N[
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M,C$P,3=D.&LN:'1M4$L! A0#%     @ $HBA6$WFKIA\I@  )5$$ !$
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M+3(P,C0P-3 Q7VQA8BYX;6Q02P$"% ,4    "  2B*%81B5CAZ@%  "U.0
M%               @ &C\0  =V)A+3(P,C0P-3 Q7W!R92YX;6Q02P4&
/  < !P"^ 0  ??<

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>d821017d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:wba="http://walgreensbootsalliance.com/20240501"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="wba-20240501.xsd" xlink:type="simple"/>
    <context id="duration_2024-05-01_to_2024-05-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001618921</identifier>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-01</endDate>
        </period>
    </context>
    <context id="duration_2024-05-01_to_2024-05-01_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001618921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-01</endDate>
        </period>
    </context>
    <context id="duration_2024-05-01_to_2024-05-01_us-gaap-StatementClassOfStockAxis_wba-M3.600WalgreensBootsAllianceInc.NotesDue2025Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001618921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">wba:M3.600WalgreensBootsAllianceInc.NotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-01</endDate>
        </period>
    </context>
    <context id="duration_2024-05-01_to_2024-05-01_us-gaap-StatementClassOfStockAxis_wba-M2.125WalgreensBootsAllianceInc.NotesDue2026Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001618921</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">wba:M2.125WalgreensBootsAllianceInc.NotesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-01</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2024-05-01_to_2024-05-01" id="ixv-283">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2024-05-01_to_2024-05-01"
      id="Hidden_dei_EntityCentralIndexKey">0001618921</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2024-05-01_to_2024-05-01" id="ixv-318">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2024-05-01_to_2024-05-01" id="ixv-319">2024-05-01</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2024-05-01_to_2024-05-01" id="ixv-320">WALGREENS BOOTS ALLIANCE, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2024-05-01_to_2024-05-01" id="ixv-321">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2024-05-01_to_2024-05-01" id="ixv-322">001-36759</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2024-05-01_to_2024-05-01" id="ixv-323">47-1758322</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2024-05-01_to_2024-05-01" id="ixv-324">108 Wilmot Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2024-05-01_to_2024-05-01" id="ixv-325">Deerfield</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2024-05-01_to_2024-05-01" id="ixv-326">IL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2024-05-01_to_2024-05-01" id="ixv-327">60015</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2024-05-01_to_2024-05-01" id="ixv-328">(847)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2024-05-01_to_2024-05-01" id="ixv-329">315-2500</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2024-05-01_to_2024-05-01" id="ixv-330">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2024-05-01_to_2024-05-01" id="ixv-331">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2024-05-01_to_2024-05-01" id="ixv-332">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2024-05-01_to_2024-05-01" id="ixv-333">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="duration_2024-05-01_to_2024-05-01_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"
      id="ixv-334">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2024-05-01_to_2024-05-01_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"
      id="ixv-335">WBA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2024-05-01_to_2024-05-01_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"
      id="ixv-336">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="duration_2024-05-01_to_2024-05-01_us-gaap-StatementClassOfStockAxis_wba-M3.600WalgreensBootsAllianceInc.NotesDue2025Member"
      id="ixv-337">3.600% Walgreens Boots Alliance, Inc. notes due 2025</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2024-05-01_to_2024-05-01_us-gaap-StatementClassOfStockAxis_wba-M3.600WalgreensBootsAllianceInc.NotesDue2025Member"
      id="ixv-338">WBA25</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2024-05-01_to_2024-05-01_us-gaap-StatementClassOfStockAxis_wba-M3.600WalgreensBootsAllianceInc.NotesDue2025Member"
      id="ixv-339">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="duration_2024-05-01_to_2024-05-01_us-gaap-StatementClassOfStockAxis_wba-M2.125WalgreensBootsAllianceInc.NotesDue2026Member"
      id="ixv-340">2.125% Walgreens Boots Alliance, Inc. notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2024-05-01_to_2024-05-01_us-gaap-StatementClassOfStockAxis_wba-M2.125WalgreensBootsAllianceInc.NotesDue2026Member"
      id="ixv-341">WBA26</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2024-05-01_to_2024-05-01_us-gaap-StatementClassOfStockAxis_wba-M2.125WalgreensBootsAllianceInc.NotesDue2026Member"
      id="ixv-342">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2024-05-01_to_2024-05-01" id="ixv-343">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
